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i 
 
Abstract 
 
Breast cancer remains a significant cause of morbidity and mortality. Assessment of the 
axillary lymph nodes is part of the staging of the disease. Advances in surgical 
management of breast cancer have seen a move towards intra-operative lymph node 
assessment that facilitates an immediate axillary clearance if it is indicated. Raman 
spectroscopy, a technique based on the inelastic scattering of light, has previously been 
shown to be capable of differentiating between normal and malignant tissue. These 
results, based on the biochemical composition of the tissue, potentially allow for this 
technique to be utilised in this clinical context. 
  
The aim of this study was to evaluate the facility of Raman spectroscopy to both assess 
axillary lymph node tissue within the theatre setting and to achieve results that were 
comparable to other intra-operative techniques within a clinically relevant time frame. 
 
Initial experiments demonstrated that these aims were feasible within the context of 
both the theatre environment and current surgical techniques. A laboratory based 
feasibility study involving 17 patients and 38 lymph node samples achieved sensivities 
and specificities of >90% in unsupervised testing .  
 
339 lymph node samples from 66 patients were subsequently assessed within the theatre 
environment. Chemometric analysis of this data demonstrated sensitivities of up to 94% 
and specificities of up to 99% in unsupervised testing. The best results were achieved 
when comparing negative nodes from N0 patients and nodes containing 
ii 
 
macrometastases. Spectral analysis revealed increased levels of lipid in the negative 
nodes and increased DNA and protein levels in the positive nodes. Further studies 
highlighted the reproducibility of these results using different equipment, users and time 
from excision. 
 
This study uses Raman spectroscopy for the first time in an operating theatre and 
demonstrates that the results obtained, in real-time, are comparable, if not superior, to 
current intra-operative techniques of lymph nodes assessment.  
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1. Breast Cancer – The clinical rationale of the project 
  
Breast cancer remains a huge problem that affects thousands of women and their 
families each year. The introduction of breast cancer screening has resulted in an earlier 
diagnosis for many women and has meant that, thankfully, the disease is increasingly 
detected before metastatic spread from the breast has occurred. Improvements and 
advances in the treatment and care that patients receive are continually being sought.  
 
In this opening chapter the clinical context in which this project is set will be discussed. 
A review of the epidemiology of breast cancer will allow an appreciation of the 
magnitude of the clinical problem. The nature of  “breast cancer”  will be defined before 
discussing the current treatment guidelines within the UK. This project aims to 
demonstrate a new and novel technique for the intra-operative assesment of axillary 
lymph nodes in breast cancer patients. Therefore the final section of the chapter will 
focus on the clinical relevance and importance of the axillary lymph nodes to emphasise 
the clinical setting in which this project is placed.  
 
1.1. Introduction and Epidemiology of Breast Cancer 
 
Breast cancer is one of the most significant causes of morbidity and mortality in the 
UK. It is the second most common cause of cancer related deaths and accounts for 1 in 
6 of all cancer deaths amongst women. 1 in 8 women will be affected by the disease in 
their lifetime (Cancer Research UK 2011). In 2008 over 47,500 patients were diagnosed 
with the disease and there are over 170,000 women who have either received or are 
2 
 
currently receiving treatment for it (National Institute for Health and Clinical 
Excellence 2009; Cancer Research UK 2011). The incidence in men remains low, with 
less than 350 new cases diagnosed in 2008, and thus reference will be made to women 
throughout this chapter. 
 
Breast cancer is the most commonly occurring cancer in women with an incidence of 
almost 150 per 100,000 persons. This rate increases with age and in those over 85 years 
old the incidence is greater than 400 per 100,000 persons (Figure 1) (National Institute 
for Health and Clinical Excellence 2009). 
 
 
 
Figure 1- Age specific incidence and incidence rates of new cases of breast cancer in the UK, 2005 
(National Institute for Health and Clinical Excellence 2009). The increase in incidence due to screening 
is clearly demonstrated. 
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The incidence of the disease has risen across all age groups in the UK over the past two 
decades (Figure 2). Evidence suggested that this rate of increase may be stabilising 
although figures released in 2011 reported that the incidence had risen by 3.8% in the 
last decade (Cancer Research UK 2011; National Institute for Health and Clinical 
Excellence 2009). 
 
Figure 2- Trend in age specific incidence rates of breast cancer in the UK (National Institute for Health 
and Clinical Excellence 2009). 
 
Whilst the incidence rate of breast cancer has been rising over the last 20 years the 
mortality rate has been consistently falling since the late 1980s (Figure 3). This may 
partly be explained by the UK national screening programme but also by increasingly 
effective treatment modalities (National Institute for Health and Clinical Excellence 
2009). 
4 
 
 
Figure 3- Age standardised rates of breast cancer mortality in the UK 1971-2005(National Institute for 
Health and Clinical Excellence 2009). 
 
These improvements are reflected in the survival rates following diagnosis. 
Examination of the relative survival rate, defined as the proportion of patients with a 
particular condition who are alive at the end of a set period when compared to similar 
people of the same age that do not have the condition, confirms this. In the 1970s the 
relative survival rate of patients five years after diagnosis was less than 60%, this 
increased to just less than 70% by the 1990s and now stands at 80% for women 
diagnosed in the period between 2001-2003 (Early Breast Cancer Trialists' 
Collaborative Group (EBCTCG) 2005;  NHS Cancer Screening Programmes and West 
Midlands Cancer Intelligence Unit 2009; West Midlands Cancer Intelligence Unit, 
2009). 
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Closer examination of these survival figures, when categorised according to the stage of 
the disease at diagnosis, reveals wide variations. Five year survival for those with stage 
I disease (tumour less than 2 cm diameter and no evidence of metastases) is greater than 
90%, but for those diagnosed with stage IV disease (evidence of distant metastases) the 
survival rate is less than 15% (Figure 4). The importance of early diagnosis can’t be 
over emphasised and in relation to prognosis diagnosis of the disease before it has 
spread beyond the breast is particularly crucial. 
 
 
Figure 4- 0-10 year relative survival rates broken down by stage at diagnosis for patients diagnosed 
between 1990-4 in the West Midlands Cancer Screening Network (West Midlands Cancer Intelligence 
Unit  2009). 
 
The appreciation of the importance of early diagnosis was one of the key influences that 
led to the introduction of the national breast screening programme in 1988 (Sant et al. 
2006 ).  Indeed it is thought that the recent improvements in survival and mortality rates 
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are partly due to advances in treatment for the disease but are largely as a result of the 
earlier diagnosis of many patients cancer. 
 
The introduction of the national breast screening programme has meant that women in 
the UK with breast cancer present to medical services in one of three ways. This may be 
either with a symptomatic lesion, such as a breast lump,  or with an asymptomatic 
change that was detected by either the screening programme or during an unrelated 
investigation. In 2006 just over 30,000 new cases presented with symptomatic changes 
and just under 16,000 patients presented via the screening programme (NHS Breast 
Screening Programme 2008). 
 
As would be anticipated patients presenting via the screening programme, with an 
asymptomatic lesion, had a lower grade of disease than those who presented with a 
symptomatic lesion. 83% of patients presenting via screening have disease classified in 
the three most favourable prognostic index groups as opposed to 51% who present 
symptomatically (Rovera et al. 2008).  By definition, this means that the percentage of 
patients who have spread of the disease from the breast will be lower in the group of 
patients presenting via screening.  
 
This “contemporary” cohort of patients that present via the screening programme have, 
on average, a lower grade of disease, which is picked up at an earlier stage, with a 
reduction in the presence of disease beyond the breast. This has encouraged the 
adoption of new techniques in the surgical management of breast cancer that reduce 
both the invasiveness of treatment and the morbidity and psychological effects of 
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surgery. Breast conserving surgery , breast reconstruction and sentinel node biopsy are 
all examples of this change. It is hoped that Raman spectroscopy can further 
compliment this by allowing for the intra-operative assessment of axillary lymph nodes. 
As will be discussed later in the chapter this in turn would allow for an immediate 
axillary clearence, if indicated, rather than a  delayed second procedure. 
 
1.2.  Anatomy, Histology and Pathology of the Human Breast and Lymph 
Nodes  
 
The diagnosis and management of breast cancer is based on an appreciation of the 
anatomy and pathology of the breast. Therefore prior to discussing the treatment of 
breast cancer and reviewing in detail the management of the axilla, the key anatomical, 
pathological and histological features of normal and malignant breast tissue will be 
reviewed.   
 
1.2.1. The human breast 
 
The adult female breast sits on the anterior wall of the thorax and its base extends from 
the second to the sixth rib in the anatomical position. The medial aspect borders the 
lateral edge of the sternum and the lateral edge extends to the mid-axillary line. The 
axillary tail (of Spence) extends into the axilla along the inferior border of pectoralis 
major (Moore 2005) (Figure 5). 
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Figure 5- The anatomy of the female breast (adapted from Ellis 2003). 
 
Histologically the breast can be viewed as a highly modified apocrine sweat gland 
which radiates towards the nipple. It is made up of 15-25 independent glandular units 
referred to as breast lobes (Wheater, Burkitt and Daniels 1995) (Figure 5, 6).  
 
The lobes are surrounded by adipose tissue and are separated from each other by fibrous 
septa. Working from proximal to distal within a lobe there are a number of continuous 
structures. At the proximal end is a collection of secretory alveoli. The inner layer of 
each alveolus is lined with luminal epithelial cells and is surrounded by both a basal 
myoepithelial layer and a basement membrane.  
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Figure 6- The components of the female breast (adapted from Wheater, Burkitt and Daniels 1995). 
 
Between 10 and 100 alveoli make up a lobule and they drain into alveolar ducts that are 
lined with epithelial cells and surrounded by a basement membrane. Lobules and the 
proximal end of the alveolar ducts are referred to as terminal ductal lobular units 
(TDLU) and is the site where the majority of breast cancers originate (Ioachim and 
Ratech 2002). A variable number of lobules are found in each lobe of the breast and the 
ducts draining each lobule will eventually coalesce to form a lactiferous duct that is 
specific for each lobe. This duct opens on to a unique point on the nipple surface 
(Raftery 2000). The branching network of lobules and the ducts they drain into are 
surrounded by collagenous stroma within which is found blood and lymphatic vessels, 
fibroblasts and adipose tissue.  
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Figure 7- The branching network of the human breast as seen after H&E staining at 60x magnification   
(adapted from Wheater, Burkitt and Daniels 1995). 
 
The fibroblasts are responsible for producing the supportive capacity of the stroma 
referred to as the extra cellular matrix. The stroma found within lobules, the intralobular 
stroma, and that found between lobules, the interlobular stroma has different 
characteristics. The intralobular stroma contains more fibroblasts and inflammatory 
cells yet the connective tissue is more loosely arranged whereas the interlobular stroma 
contains far less cells and has more closely packed collagen (Ioachim and Ratech 2002). 
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1.2.2. Histopathology of Breast Cancer   
 
Cancer is defined as a disease in which a group of abnormal cells grow uncontrollably 
by disregarding the normal rules of cell division. Cancer may be classified according to 
the cells from which the uncontrolled growth originates (Hejmadi 2010). 
 
Carcinoma, a cancer arising from epithelial cells, is the most common malignancy 
affecting the breast and can be further sub-classified into in situ or invasive carcinoma. 
Further division of the type of tumour is based on its anatomical site within the breast.  
 
1.2.2.1. Carcinoma in situ  
 
Carcinoma in situ (sometimes referred to as a “pre-malignant” condition) is 
predominantly detected as areas of micro-calcification on mammography or following 
the investigation of an invasive carcinoma. These changes can be defined as either 
ductal (DCIS) or the rarer lobular (LCIS) carcinoma in situ dependent on their position 
when viewed histologically. They are characterised by a neoplastic growth of the 
epithelium that is limited by the basement membrane. It is often associated with 
dystrophic calcification around the site and it is this that makes it visible on 
mammograms.  
 
Historically this diagnosis was rare as it seldom resulted in overt symptoms. However 
since the introduction of screening programmes its incidence has risen and it now 
accounts for 22% of all screen detected breast cancers (NHS Cancer Screening 
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Programmes and West Midlands Cancer Intelligence Unit 2009). DCIS maybe 
classified as low, medium or high grade dependent on the atypia of the cancerous cells 
and this classification is an effective method of predicting the risk of reoccurrence 
following excision (National Institute for Health and Clinical Excellence 2009). 
 
A varient of DCIS is atypical ductal hyperplasia (ADH). This is an intraductal  
epithelial proliferation that either shows some but not all of the features of DCIS or has 
features consistent with DCIS but is only present in a very small area. The presence of 
ADH is a risk factor for the development of either DCIS or invasive ductal carcinoma. 
 
As will be discussed in later sections, the assessment of the axillary lymph nodes is not 
normally indicated in DCIS. It is therefore very unlikely that many of the patients 
recruited to this study will have  this condition. 
 
1.2.2.2. Invasive Carcinoma  
 
Invasive carcinoma, in contrast to DCIS, invades into the breast stroma and spreads 
locally. It also has the potential to infiltrate the vascular and lymphatic systems and 
spread beyond the breast (Johnstone et al. 2002). Classification of invasive carcinoma 
may be according to anatomical cell origin (subtype) or histological grade. There are 16 
subtypes of invasive breast cancer although some are very rarely encountered (Raftery 
2000). These classifications are important as they help guide both initial investigations 
and subsequent treatment. 
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Invasive ductal carcinoma represents approximately 75% of all invasive carcinomas. 
Histologically it is characterised by malignant epithelial cells that originate in the 
alveolar ducts and spread within the fibrous stroma. Invasive lobular carcinoma 
accounts for between 10-15% of all cases of invasive breast cancer and arises from 
epithelium within the breast lobules. It has a tendency to multifocality with indolent and 
progressive characteristics that often result in a worse prognosis than ductal carcinoma 
(Rhakha, El-Sayed and Powe 2008). Unlike ductal carcinoma, cancer of lobular origin 
is less likely to be associated with calcification of the surrounding stroma and is 
therefore more difficult to detect on mammography (Raftery 2000).  
 
There are a variety of other types of tumour. These include mucinous carcinomas which 
account for 5% of breast cancers, medullary carcinomas that account for less than 5% of 
tumours and tubular cancers that represent between 1 and 2% of all breast tumours. 
They each have particular characteristics which are beyond the scope of this review 
(Rosen 2001). 
 
Each individual tumour can be classified histologically as well as anatomically. This 
helps predict how the tumour will progress based on the cytological and architectural 
features of the tumour cells. To maintain standardisation each tumour is categorised by 
a pathologist using a validated scoring systems such as the Nottingham Grading System 
(Elston and Ellis 1991). This grades the tumour according to the degree of tubular 
formation, the nuclear pleomorphism, and the mitotic activity into low (I), intermediate 
(II) and high (III) grade groups (Table 1). 
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Degree of Tubule  
formation within the tumour 
Majority of tumour 
Moderate Degree 
Little or None 
1 
2 
3 
Mitotic Count 0-9 Mitoses/10 high power field (hpf) 
10-19 Mitoses/10 hpf 
20 or > Mitoses/10 hpf 
1 
2 
3 
Nuclear Pleomorphism Small Regular Uniform Cells  
Moderate Nuclear Size and Variation 
Marked Nuclear Variation 
1 
2 
3 
Overall grade Low Grade (I) 
Intermediate Grade (II) 
High Grade (III) 
3-5 
6-7 
8-9 
 
Table 1: The Nottingham grading scale for breast cancer (Elston and Ellis 1991). 
 
1.2.2.3. Breast Cancer and Metastases 
 
The presence of metastases, the migration of cells from the primary tumour to other 
sites around the body, is a key indicator of the prognosis of an individual’s disease. The 
most common sites of metastasis in breast cancer are to the regional lymph nodes that 
drain the breast. If distant spread occurs then the three most common sites are to bone, 
the lungs and the liver.  The pathological grading of the tumour and the assessment of 
both the local lymph nodes and common sites of distant metastasis is used to stage each 
individual patient’s disease. It is a standardised way of documenting the extent of the 
disease spread at the time of presentation and is used to predict survival and guide 
treatment.  
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The most common staging index used across a range of malignancies is the TNM 
system. This categorises the disease based on the tumour itself (T), and the presence of 
nodal metastases (N) and distant metastases (M) (Johnson et al. 2004). Other staging 
indices which are particular to breast cancer include the widely used Nottingham 
Prognostic Index (NPI) (Tables 2, 3). There is a clear association between an increasing 
NPI score or TNM stage and worsening 5 year mortality (Figure 8). 
 
Factor  Score 
Lymph nodes No Metastases 
1-3 Positive Nodes 
>3 Positive Nodes 
1 
2 
3 
Grade  Stage I 
Stage II 
Stage III 
1 
2 
3 
Vascular Invasion No 
Yes 
0 
1 
Tumour Size 
 
Size in cm Multiplied by 0.2 
 
Table 2: The Nottingham prognostic index (NPI). A score is then calculated for each patient by adding 
the lymph node score, the grade score and the vascular invasion score and multiplying them by 0.2 of the 
tumour size.  (Sabel 2009). 
 
Examination of the 5 years survival figures plotted against the stage of the disease 
highlight the prognostic importance of metastatic spread. Patients with a T1 tumour 
have a 10% reduced 5 year survival if there are lymph node metastases present and in 
the presence of distant metastases the 5 year survival is less than 20% (Figure 8). 
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Stage Features 
Primary Tumour (T) 
 Tx 
 T0 
 Tis 
 T1 
 
 T2 
 T3 
 T4 
 
 
 Not assessed 
 No evidence of Primary Tumour 
 Carcinoma in Situ 
 Tumour < 2cm in diameter  
 ( <0.1=T1mic, <0.5cm = T1a, <1cm=T1b , rest = T1c) 
 Tumour 2-5cm in diameter 
 Tumour >5cm in diameter 
 Any size with direct spread to chest wall or skin 
 
Lymph Node Status (N) 
 Nx 
 N0 
 N1 
 N2 
 N3 
 
 
 Regional nodes cannot be assessed 
 No metastases 
 Metastases to mobile ipsilateral nodes 
 Metastases to fixed ipsilateral nodes 
 Metastases to ipsilateral internal mammary nodes 
Metastases (M) 
 Mx 
 M0 
 M1 
 
 Presence of distant metastases cannot be assessed 
 No distant metastases  
 Distant metastases (including supraclavicular nodes) 
 
 
Stage 0= Tis, N0, M0 
Stage 1= T1, N0, M0 
Stage 2a= T 0/1, N1 or T2, N0 , M0 
Stage 2b= T2, N1 or T3, N0. M0 
 
Stage 3a= T3, N1 or T1-3, N2 , M0 
Stage 3b= T4, Any N, or Any T, N3 , M0 
Stage 4= Any T, Any N, M1 
 
Table 3: The TNM index for staging breast cancer (Sabel, 2009) 
 
Interrogation of the NPI also highlights the importance of the number of involved 
axillary lymph nodes. A women with a Grade II, 2 cm invasive tumour with no 
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lymphovascular invasion and no distant metastases (NPI = 3.4) has an anticipated 85% 
survival rate at 5 years. This is reduced to 50% if greater than 3 lymph nodes are 
positive (NPI = 5.4). As will be discussed later these factors also guide further treatment 
of the axilla after axillary surgery. 
 
 
 
Figure 8- Percentage 5 year survival according to TNM stage or NPI score (Cancer Research UK 2009). 
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1.3. Lymph Nodes and the Lymphatic System 
 
In the management of breast cancer lymph nodes are vital indicators of the spread of 
cancer beyond the breast. Metastasis of the cancer to the lymph nodes is an important 
factor in predicting the overall prognosis of an individual’s disease. The status of the 
lymph nodes is used to help stage the disease and this helps guide treatment options and 
regimes (Rovera et al. 2008; Kurosumi and Takei 2007). 
 
1.3.1. Anatomy of the Lymph Nodes 
 
The lymph nodes are part of the lymphatic system which is divided into lymphoid 
tissues, such as the thymus, bone marrow or lymph nodes, and the circulating network 
that connects them. The circulatory network consists of permeable lymphatic vessels 
and capillaries which extend throughout the body. 
 
Excess interstitial fluid within tissues drains into the lymphatic vessels and is eventually 
returned to the cardiovascular circulatory system. During this process the fluid is 
filtered through lymph nodes that are found at various positions throughout the body 
(Figure 9). Specific lymph nodes are responsible for filtering lymph from specific 
organs and regions. Within the lymph node the fluid drained from these specific areas is 
exposed to a large number of lymphocytes and other cells of the immune system. If an 
antigen is recognised it will trigger a cascade of events both within the lymph node and 
subsequently beyond it. Immune response mediators will drain from the lymph nodes to 
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enter the cardiovascular circulatory system along with the filtered interstitial fluid 
(Ioachim and Ratech 2002). 
 
As a result of the topographical function of lymph nodes, examination of particular 
nodes enables one to gain information about disease within the organs that they drain. A 
familiar example of this is the easily palpable cervical lymph nodes which become 
enlarged when a patient has tonsillitis. In this scenario the infective process in the 
oropharynx causes antigens to be identified in the interstitial fluid draining from the 
region to the nodes. This causes an immune response in the lymph node as it mounts a 
response to the antigen and as a result the node enlarges.  
 
Figure 9- A stylised diagram representing the lymphatic system (adapted from Ellis 2002). 
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Lymphatic drainage from the breast is primarily to two groups of lymph nodes, the 
ipsilateral axillary lymph nodes and the internal thoracic nodes (Figure 10). A small 
percentage of lymph will drain to the supra-clavicular and contra-lateral internal 
thoracic nodes. Examination of these groups of nodes gives us information about 
underlying disease within the breast. Infection, inflammation and importantly in this 
study cancer will result in pathological changes within the nodes. These changes may be 
determined by clinical examination, radiological imaging or histopathological analysis. 
Within the context of this study it is hoped that interrogation of the axillary nodes using 
Raman spectroscopy will help determine whether the breast cancer has metastasised to 
the lymph nodes.  
 
The axillary nodes are divided according to either their anatomical position or their 
relation to surrounding structures. Anatomically they may be defined as lateral, central, 
posterior, anterior or apical (Figure 10). Surgically they are more often defined 
according to their position in relation to pectoralis minor. They are termed level I if they 
are inferior to the pectoralis minor, level II if they are posterior to the pectoralis minor 
and level III if they are superior to the pectoralis minor (Ellis 2002). Within the axilla 
the lymph nodes lie close to a number of structures including the axillary vein and 
artery, the long thoraciac nerve, the thoraco-dorsal nerve and the intercostobrachial 
nerve (Figure 11).  Careful identification and preservation of these structures, where 
possible, helps reduce the morbidity associated with operative dissection of the nodes in 
this region. 
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Figure 10- The anatomy of the axillary lymph nodes (adapted from Ellis 2003). 
 
Figure 11- Anatomy of the Axilla  
(Adapted from Medscape (http://emedicine.medscape.com/article/880878-overview)). 
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1.3.2. Histology of the Lymph Node 
 
Lymph nodes are bean shaped aggregations of lymphocytic tissue and can vary from a 
few millimetres to several centimetres in diameter dependent upon the reactive status of 
the node at that time (Figure 12) (Obwegeser et al. 2000).  
 
 
 
 
Figure 12- The structure of an axillary lymph node (adapted from Cacaecu 2008). 
 
 
Lymph nodes are intrinsically involved in both humoral, involving antibodies, and cell 
mediated immunity. Antigens in the afferent lymphatic fluid will be trapped within the 
node by either lymphocytes or accessory cells such as dendritic reticular cells, inter-
23 
 
digitating reticular cells or histiocytes. The antigenic cells are then processed and 
presented to further lymphocytes which trigger an immune response both locally and 
further a field (Ioachim and Ratech, 2002). 
 
Each node is surrounded by a fibrous capsule that envelopes an inner core. This inner 
core may be divided into four contiguous sections, the subscapular space, the outer 
cortex, the para-cortex and the medulla (Figure 12).  This is structurally supported by a 
framework of reticular fibres, reticular cells and elastin. Lymphatic fluid arriving in 
afferent vessels on the convex surface of the node will drain through each of these 
sections in turn before leaving the node at the hilum and draining into efferent 
lymphatic vessels.  
 
1.3.2.1. The Subscapular Space 
 
The node is surrounded by dense collagenous tissue which extends into the node to 
form trabaculae. The afferent lymph vessels will converge on the outer surface of the 
node and drain through this tissue before entering the subscapular space. It is in this 
space that individual tumour cells, the first sign of metastatic spread, may be found.  
 
1.3.2.2.  The Outer Cortex 
 
The outer cortex of the lymph node is just medial to the subscapsular space. It is 
characterised by the presence of primary lymphoid follicles and contains B 
lymphocytes, macrophages and dendritic reticular cells. Following antigenic stimulation 
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this area becomes the source of B cell proliferation. The primary lymphoid follicles, 
which in a resting state, are composed of homogenous cell populations of dormant 
lymphocytes, become activated. These, activated, secondary follicles are seen 
characteristically 4-7 days after antigenic stimulation. Activation occurs due to 
migration of activated B and T cell lymphocytes to the primary follicle. Their 
interaction with dendritic reticular cells (DRC) at these sites causes the antigenic 
sequence to be displayed to the B lymphocytes within the primary follicle. The DRC 
cells present the antigenic sequence on its surface and produces growth factor which 
causes B cell activation and the formation of a germinal centre within the follicle. 
Within the germinal centre B cells divide rapidly and differentiate into either B memory 
cells, or plasma cells (sometimes referred to as B effector cells). The plasma cells 
produce antibodies and the B memory cells are stored to help mount a greater response 
to the antigen if it is encountered again (Ioachim and Ratech 2002). 
 
1.3.2.3.  The Para-cortex 
 
Located more medially within the node is the para-cortex where T cells predominate. 
Inter-digitating dendritic cells (IDCs) are also found in this area and their role is 
primarily to present antigenic sequences to the T cells so triggering an immune 
response. T cells go on to differentiate into either TH cells that produce cytokines to 
recruit and activate further lymphocytes, macrophages and neutrophils or cytotoxic T 
cells that seek and destroy infected cells by inducing apoptosis (Kuby 1997). 
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1.3.2.4. The Medulla 
 
The medulla is the innermost part of the lymph node and is the area most sparsely 
populated with lymphocytes. The majority of cells found within the region are plasma 
cells that have originated from the germinal centres in the outer cortex. Within the 
medullary region they differentiate and produce antibodies. These antibodies leave the 
node in the efferent lymphatics and blood vessels and circulate around the body to target 
specific matching antigens.  
 
1.3.2.5. Lymph Node Sinuses 
   
The lymphatic fluid drained from individual tissues passes through the different sections 
of the node via a series of interconnecting sinuses. These sinuses are lined with 
endothelial cells and lymphocytes. Plasma cells and phagocytes can also be found 
within the sinus walls. At the cellular level this is an important site for the initial 
interaction between the antigens and the cells of the immune system.  
 
The result of this complex filtering network is that the lymph node is able to rapidly 
alter both its own cellular components and the composition of the efferent lymphatic 
fluid that drain from it. Following immune reactions, in response to both infection and 
tumour metastasis, the node becomes enlarged and the concentration of lymphocytes 
and antibodies leaving the node is greatly increased. In the context of metastatic spread 
this may provide a degree of regional control of cancer cell dissemination. Metastasis to 
the lymph node is therefore most often seen prior to distant spread to other organs 
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(Ioachim and Ratech 2002). Within the node itself metastatic cells will first appear in 
the subscapular space before progressing through the node to the sinuses, medulla and 
cortex. Once established metastatic disease starts to proliferate from the medulla and 
eventually the whole node can be over run by self replicating cells (Figure 14).  
 
 
 
Figure 14- Histological slide (H and E stained) showing normal lymph node tissue and metastatic breast 
cancer in an axillary lymph node (adapted from Wheater, Burkitt and Daniels 1995). 
 
As will be discussed later, these metastatic deposits may be termed isolated tumour 
cells, micrometastases or macrometastases. The clinical significance of each of these 
differs and will be reviewed later in the chapter. The presence of self-replicating 
metastatic cells with the lymph node activates myofibroblasts and cytokines. In turn this 
will also stimulate the overgrowth of the surrounding connective tissue which may 
result in the formation of scar like tissue around the metastases which is referred to as 
desmoplastic change (Ioachim and Ratech 2002). 
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The histological changes seen in positive lymph nodes, when metastatic cells replicate, 
reflects the histology of the underlying tumour. There is a correlation of greater than 
95% between the tumour seen in the breast and the changes seen within positive axillary 
lymph nodes (Ioachim and Ratech 2002). It is argued that if the changes within a 
positive lymph node do not match those seen in the underlying tumour then further 
examination of the breast tumour should be carried out to ensure that there is not 
another primary source.  
 
1.4. Treatment of Breast Cancer 
 
As has been discussed patients may present with breast cancer in one of three ways. 
They can present with symptomatic changes, via the national breast screening 
programme, or due to an incidental finding when investigating another problem. The 
initial role of the team caring for that patient is to confirm the diagnosis, remove the 
tumour and then stage the disease. Armed with this information a multi-disciplinary 
team will then plan the optimal treatment for each individual.  
 
Confirmation of the diagnosis of breast cancer is made after a triple assessment. This 
involves clinical examination, radiological assessment, in the form of a mammogram or 
an ultrasound scan, and histopathological review of fine needle aspiration samples or 
core needle biopsy samples of the suspicious area. This assessment most often takes 
place in secondary care and usually at a one stop clinic. If a diagnosis of invasive breast 
cancer is made then initial assessment of the axilla for evidence of metastasis should 
also be offered at this early stage (National Institute of Health and Clinical Excellence 
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2009). Further details of the assessment and management of the axilla will be discussed 
in subsequent sections.  
 
The management of breast cancer continues to evolve and varies from patient to patient. 
In this section a brief overview of the treatment options will be given to help set the 
scene for this project although it is recognised that this is not an exhaustive review.  
 
1.4.1. Management of Invasive Breast Cancer 
 
The first procedure in the treatment of invasive cancer is the excision of the primary 
tumour with adequate clear margins. If the tumour is locally advanced or there is 
evidence of inflammatory breast cancer then a course of neo-adjuvant treatment may be 
offered (whereby endocrine therapy or chemotherapy is given as the primary modality 
prior to surgery) (National Institute of Health and Clinical Excellence 2009). Surgical 
excision may be performed by a number of techniques including breast conserving 
methods, such as a wide local excision, or by means of a mastectomy (a surgical 
procedure to remove all of the breast tissue) with or without immediate or delayed 
breast reconstruction. Assessment of the axillary lymph nodes, if not achieved 
preoperatively, is also performed during this initial operation. 
 
Further adjuvant treatment in the form of radiotherapy, chemotherapy or endocrine 
medication (such as Tamoxifen, an oestrogen receptor antagonist or Aromatase 
Inhibitors, that block production of oestrogen)  is offered based on the grade of the 
tumour, the stage of the disease and the receptor status of the tumour (Table 4).  
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Nodal 
Status 
Tumour Type 
(See Table 3) 
 
ER + and 
HER + 
ER + HER + ER /HER - 
Normal  
Nodes 
T1a None 
 
None 
 
None 
 
None 
 
 T1b 
(well differentiated) 
None 
 
None 
 
None None 
 T1b  
( moderate or poorly 
differentiated)  
Endocrine  
+/- Chemo 
Endocrine  
+/- Chemo 
Chemo Chemo 
 T1c Endocrine  
+ Chemo 
Endocrine  
+ Chemo 
Chemo Chemo 
 T2 or above Endocrine  
+ Chemo 
Endocrine  
+ Chemo 
Chemo Chemo 
Micro 
Metastases 
T1a  Endocrine 
Treatment 
Endocrine 
Treatment 
+/- Chemo +/- Chemo 
 T1b Endocrine 
Treatment 
Endocrine 
Treatment 
+/- Chemo +/- Chemo 
Macro 
Metastases 
Any T Endocrine  
+ Chemo 
Endocrine  
+ Chemo 
Chemo Chemo 
 
Table 4- Recommendations for the adjuvant treatment of breast cancer dependent on the tumour type and 
the status of the axilla (National Institute for Health and Clinical Excellence 2009). ER= Oestrogen 
Receptor, HER = Human epidermal growth factor receptor-2, Chemo=Chemotherapy, Endocrine 
Treatment = Tamoxifen or Aromatase Inhibitors.  
 
1.4.2. Management of Ductal Carcinoma in Situ  (DCIS) 
 
As previously discussed the management of DCIS has become a significant part of the 
breast services remit. Following the introduction of a national breast screening 
30 
 
programme up to 1 in 5 cancers detected by screening in the UK are proven to be DCIS 
(National Institute for Health and Clinical Excellence 2009). It is expected that 
 
this number will continue to rise with further technological improvements in imaging 
and the expansion of the breast screening programme (Patani, Cutuli and Mokbel 2008). 
Although classified as a pre invasive condition not all patients will go on to develop 
invasive breast cancer following a diagnosis of DCIS. Estimates of the percentages that 
will progress to invasive cancer range from 14-75% (Patani, Cutuli and Mokbel 2008). 
Progression to invasive cancer is most likely to occur in high grade DCIS especially if 
combined with other risk factors such as a palpable mass at presentation, a family 
history of breast cancer, wide spread micro-calcifications on mammography and 
extensive disease.  
 
Similarly to invasive cancer the management of DCIS starts with the excision of the 
affected area. This is most often achieved with breast conserving surgery but if the 
tumour is greater than 4 cm, multi-centric or at the site of reoccurrence mastectomy is 
the preferred option. Adjuvant radiotherapy to the breast has been shown in a meta-
analysis of randomised controlled trials to reduce the local recurrence by 60% and 
should be offered to those patients undergoing breast conserving surgery (Patani , Cutuli 
and Mokbel 2008).  
 
The investigation and management of the axilla, in DCIS, is more controversial as by 
definition the tumour cells should not have invaded beyond the basement membrane. 
However, extensive DCIS may harbour foci of invasive disease and assessment should 
be offered to patients with either high grade or widespread disease. A retrospective 
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study of lymph node positive DCIS patients demonstrated that careful examination of 
the tumour revealed small foci of invasive disease that had not originally seen. 
Therefore lymph node assessment in DCIS is reserved for patients where extensive 
disease is present (Sakr et al. 2006). The role of further adjuvant treatment in the form 
of tamoxifen has been evaluated in the NSABP-B24 trial and the UK/ANZ DCIS trial 
(Sibbering 2009). These studies report minimal reductions in local reoccurrence and 
must be balanced against the potential side effects of the treatment.  
 
1.5. The Assessment and Management of the Axillary lymph nodes 
 
The prognostic importance of local metastatic spread to the axillary lymph nodes can 
not be over emphasised. Indeed it has consistently been shown to be the most important 
marker of prognosis in patients newly diagnosed with breast cancer (Rovera et al. 2008 ; 
de Boer et al. 2010). Indeed since the end of the 19
th
 surgical treatment of breast cancer 
included axillary node dissection as standard (Kurosmi and Takei, 2007; Suami et al. 
2008).  
 
The method by which axillary node assessment and hence staging is carried out has 
altered over time, reflecting the move to increasingly less extensive surgical techniques. 
Like assessment of the breast, axillary lymph nodes may be examined clinically, 
radiologically or by histopathological methods. In this section the current methods by 
which axillary nodes are sampled and assessed will be reviewed. Current controversies 
in this area will then be discussed and the potential clinical role that Raman 
spectroscopy could play in lymph node assessment in the future will be highlighted. 
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1.5.1. Lymph node assessment 
 
Initial attempts at lymph node assessment should take place after the diagnosis of breast 
cancer is made. It is recommended that all patients newly diagnosed with invasive 
disease undergo ultrasound examination of the axilla with guided biopsy of areas of 
suspicion prior to their initial surgery (National Institute of Health and Clinical 
Excellence 2009). The reported sensitivity (its ability to identify true positives) and 
specificity (its ability to identify true negatives) of ultrasound scans (USS) at detecting 
metastatic spread depends on the criterion of positivity (Alvarez et al. 2006). When 
lymph node size is used the sensitivity is between 66 and 73% and the specificity is 
between 44 and 98%. If morphological characteristics of the node are used then the 
reported sensitivity ranges from 55 to 92% and the specificity from 80 to 97% (Alvarez 
et al. 2006).  The recommended technique is USS of the axilla and either FNA (fine 
needle aspirate) or core biopsy if there are abnormal morphological features. Sensitivity 
for this approach varies between 31 and 63% with reported specificities of 100% 
(Damera et al. 2003 ; Alvarez et al. 2006). Factors that influence the success of this 
technique are the experience of the radiologist, the imaging and biopsy equipment and 
the number of aspiration or biopsy samples taken (Damera et al. 2003).  
 
If the nodes are found to be positive then the patient is recommended to have an axillary 
dissection most often at the same time as surgery to excise the tumour in the breast. Due 
to the low sensitivities of this technique patients with a negative USS still require 
further evaluation of their axilla.  
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The use of preoperative positive emission tomography (PET) for staging the axilla has 
also been investigated. However a recent systematic review and meta-analysis reported 
wide variations in both sensitivity (20-100%) and specificity (75-100%). Given these 
results along with the costs and resource implications the authors concluded that the 
technique should not replace USS as a pre-operative method of evaluating the axilla 
(Cooper et al. 2011). 
 
The traditional method of axillary node sampling, which took place as part of the 
operation to remove the breast tumour, involved dissection of the tissue in the axilla, 
referred to as axillary node dissection (ALND). Between 15 and 20 nodes were excised 
along with the tissue in that area (Steele et al. 1985; Mansel et al. 2006). An alternative 
approach was 4 node sampling followed by radiotherapy if they were found to be 
positive (Steele et al. 1985). 
 
Axillary sampling using these methods carried significant co-morbidities including 
nerve injury, resulting in parasthesia of parts of the ipsilateral arm, lymphoedema and 
shoulder stiffness (Mansel et al. 2006). With the emergence of breast conserving 
surgery in the 1980s focus shifted to developing surgical techniques that reduced the 
invasiveness of axillary sampling and reduced the risks to the patient. The onset of 
breast screening programmes and hence the earlier stage of breast cancer at presentation 
added impetus to this goal.  
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1.5.2. Sentinel Lymph Node Biopsy (SLNB) 
 
The last decade has seen the emergence of SLNB as the standard of care for the 
sampling of the axillary lymph nodes. The technique was developed on the principle 
that cancer cells that have invaded lymphatic vessels draining the breast will initially 
reach specific (sentinel) lymph nodes.  
 
The principle of the sentinel node and its role in predicting metastases from the primary 
tumour had been developed in penile cancer and malignant melanoma (Kurosmi and 
Takei 2007). In many ways a deceptively simple idea it was proposed that all lymph 
drains via the guardian or sentinel node.  Therefore sampling and then assessing this 
node will predict whether metastases to any of the nodes have occurred (Goyal and 
Mansel 2008) (Figure 15). 
 
 
Figure 15- A stylised diagram to illustrate the principles of sentinel lymph node biopsy, whereby 
lymphatic drainage from a breast tumour drains via the sentinel node.  
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The status of the sentinel node has been demonstrated to reflect the overall status of the 
axilla in 97% of cases (Layfield et al. 2011). If the sentinel nodes are negative then the 
axilla is deemed clear of metastases and the rest of the nodes need not be dissected. This 
has been shown to reduce the morbidity and complications associated with traditional 
methods of node sampling (Mansel et al. 2006). 
 
The technique of SLNB was first described in breast cancer in the early 90s (Krag et al. 
1993; Giuliano et al. 1994). Since then a number of case series and randomised control 
trials have been published documenting its use. A meta-analysis of 69 studies published 
in 2006 pooled data from more than 8000 patients and concluded that the technique was 
successful at identifying the sentinel node in 95% of cases and had a false negative rate 
of less than 7% (Kim et al. 2006). These results, combined with the marked reduction in 
morbidity has meant that SLNB has now been adopted as the standard for the initial 
sampling of the axillary lymph nodes and is being used more and more widely 
throughout the UK (National Institute for Health and Clinical Excellence 2009). It is 
well accepted by patients due to its lower risks and the shorter associated hospital stay 
(Purushotham et al. 2005). 
 
The procedure involves the patient receiving either a sub dermal or intra dermal 
injection of Technetium
99
, a radioactive tracer, to the breast not more than 24 hours 
prior to surgery. Prior to the operation scintigraphy is performed to help localise the 
sentinel lymph nodes.  At the time of surgery a further injection is made in the peri-
areolar region of 2.5% Patent V blue dye (Guerbet, Roissy, France) (Figure 16).  The 
combination of these two markers has been shown to be the most effective method of 
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correctly identifying the sentinel lymph node (Goyal and Mansel 2008). During the 
procedure the lymph node position is confirmed using a hand held gamma probe. A 
small incision is then made over the site and the node is identified visually before being 
excised. 
 
 
Figure 16- An intra operative photograph of an axillary lymph node (arrow) stained blue identified 
during a sentinel lymph node biopsy (Authors own copy).  
 
1.5.3. Histopathological Assessment of Axillary Nodes 
 
The presence of metastatic spread within an axillary node may be defined as either 
macrometastases, cell masses greater than 2 mm in diameter, micrometastases, cell 
masses between 0.2 and 2 mm in diameter or isolated tumour cells, single cells or 
clusters of cells less than 0.2 mm in diameter.  
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The gold standard assessment of lymph nodes following excision is histopathological 
analysis. Lymph nodes are wax embedded before being cut and stained using 
haematoxylin and eosin (H and E) stains (Pinder 2009). These stains are widely used in 
cancer diagnostics. They colour the cell nuclei blue and other eosinophilic structures 
varying shades or red or pink. Further techniques that aid the identification of either 
micrometastases or ITCs include immuno-histochemistry staining of cytokeratins and 
other epithelial markers.  
 
Up until the introduction of SLNB, axillary lymph nodes were assessed by single 
sectioning of the node whereby a single slice of the node was examined. As a result 
some metastatic deposits may have been missed as the whole node was not sampled. 
More intensive serial sectioning of the quantity of nodes collected during an axillary 
dissection was not practically feasible (de Boer et al. 2010). The reduction in the 
numbers of nodes collected during a SLNB and the importance of avoiding false 
negative results has meant that sentinel nodes are now assessed by use of a 2 mm step 
sectioning procedure often with immuno-histochemical staining (de Boer et al. 2010). 
Not unsurprisingly this has resulted in an increase in the detection of small metastatic 
deposits (Quan and McCready 2009; Cserni et al. 2005). Retrospective review of nodes 
assessed using single slices has demonstrated an up staging of between 7 and 42% (Tan 
et al. 2008). Slicing the sentinel node into 2 mm sections will identify all 
macrometastases greater than 2 mm in diameter but will not always pick up 
micrometastases (Figure 17).  
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Whilst it is recognised that this technique may miss some micrometastases it is designed 
to ensure that all macrometastases are detected. More extensive techniques that have a 
greater sensitivity for micrometastases have been described. The implications these 
have on resources has meant that they are unlikely to be fully implemented as the low 
clinical significance of micrometastases and isolated tumour cells (ITCs) becomes more 
fully understood (Veronesi et al. 2001). New techniques, such as Raman spectroscopy, 
may therefore have an advantage over standard histopathology as more of the node will 
be sampled without the associated increased resource requirement.  
 
 
 
Figure 17- An illustration of the importance of sectioning a lymph node to demonstrate how micro-
metastases could be missed. 
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Before the introduction of SLNB all lymph nodes with metastatic deposits of < 2 mm in 
diameter were classified as lymph node positive micrometastases (de Boer et al. 2010). 
However current UK guidelines state that the presence of either macro or 
micrometastases renders the lymph node positive for metastatic spread but nodes with 
purely isolated tumour cells are regarded as negative (Pinder  2009).  
 
1.5.4. Management of the positive axilla 
 
The further management of the axilla once positive nodes have been detected depends 
on the method by which the metastases were detected. A summary based on current 
NICE guidelines is shown in Figure 18.  
 
Figure 18- A flow chart demonstrating the management of the axilla in breast cancer.  
 
40 
 
If there is evidence of metastases from the primary tumour in the SLN then it is 
recommended that the patient undergoes an axillary dissection to remove all of the 
lymph nodes in the region (National Institute for Health and Clincal Excellence 2009). 
Until recently it has been argued that this was necessary for complete staging, improved 
loco-regional control and perceived improvement in overall survival (Giuliano et al. 
2010). It is also worth noting that the current NICE guidelines suggest that all node 
positive patients receive docetaxal chemotherapy as part of an adjuvant chemotherapy 
regimen. This is important as a false positive node assessment will result in the patient 
undergoing both an unnecessary axillary dissection, and if there is no opportunity for 
post operative result confirmation, a course of chemotherapy (National Institute for 
Health and Clinical Excellence 2009). 
 
Data from the recently published ACOSOG-Z0011 trial has ignited discussion in this 
area and questioned our current management of patients with positive lymph nodes. It 
will be discussed further in subsequent sections (Giuliano et al. 2010).  
 
1.5.5. Intra-operative Assessment of Sentinel Lymph Nodes 
 
Standard post operative assessment of axillary lymph nodes sampled during a SLNB 
necessitates the need for a second surgical procedure, an axillary lymph node dissection 
(ALND), at a later date if the sentinel node is positive. Given that 25-30% of patients 
undergoing a SLNB will have positive nodes a method of intraoperative nodal (IO) 
assessment has been actively sought (Layfield et al. 2011).  
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There would be advantages to IO assessment for the patient, the surgeon and the health 
care system. It has been reported that the delay whilst waiting for results and the effect 
of requiring a further operation adds to the psychological stress the patient experiences, 
and a methodology of immediate nodal assessment and ALND, if required, is favoured 
by patients (Chicken, Sivanadarajah and Keshtgar 2007). Economic analysis carried out 
in the UK supports the use of intra-operative testing with estimated savings of up to 
£1000 per patient receiving immediate ALND (Burke and Setters 2010).  It has also 
been argued that further surgery delays the onset of adjuvant treatment which may have 
an impact on long term outcomes (Snook et al. 2011). 
 
Despite these advantages caution has been expressed because of questions about the true 
economic benefits of IO assessment, the psychological effect on the patient and the true 
prognostic role of SLNB detected metastases. It has been argued that the number of 
patients who could benefit from intra-operative analysis is less than that used in the 
economic analysis of intra-operative testing (Benson and Wishart 2010). Despite 25-
30% of patients having positive nodes data from our own unit suggest that less than 
10% of these will return to theatre purely for an ALND (10/121 patients over a 12 
month period) (Horsnell et al. 2012). The re-excision of tumour margins, or more 
significant breast surgery such as a completion mastectomy or breast reconstruction all 
require second operations during which time an ALND could be performed.  Further to 
this the psychological impact of patients finding out in the recovery room that they have 
positive nodes by discovering an axillary drain in situ (necessary because of the 
increased invasiveness of the surgery) has also not been fully explored and will require 
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careful explanation by the operating surgeon prior to the surgery (Benson and Wishart 
2010). 
 
Despite this support has grown for an effective method of intra operative node 
assessment and has been endorsed by the NHS Technology Adoption Centre (NTAC). 
The ideal technique in this setting would therefore need to be both sensitive and specific 
in comparison to the gold standard, quick and user friendly within the theatre setting, 
economically viable and operable without significant added expertise. 
 
There are currently 3 established techniques for the intra-operative assessment of 
axillary lymph nodes, frozen section analysis, imprint cytology and molecular assays. 
Each of these techniques has a number of disadvantages and thus despite the evident 
potential benefits their use varies. A pan-European survey published in 2004 reported 
that of the 240 units that responded to the authors, only 60% used some form of intra-
operative assessment (Layfield et al. 2011). 
 
1.5.5.1. Frozen Section Analysis 
 
Frozen section analysis is a well established technique that is familiar to all 
pathologists. It is used in a number of clinical situations where the information derived 
will be used to guide the patient’s immediate management. Current intra operative uses 
include the differentiation of malignant and benign causes of a frozen pelvis, the 
identification of resection margins in abdomino-perineal resections or the confirmation 
of tissue type in parathyroidectomy. Although widely used it has a number of 
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disadvantages. These include the effect of freezing artefact, the processing time and the 
need to have immediate access to both an experienced histopathologist and a skilled 
biomedical scientist (Keshtgar 2009). The sensitivity of this procedure compared to the 
gold standard, post operative analysis, has been reported as 57-76%, although the 
specificity is consistently reported as approaching 100% (Creager and Geisinger 2002; 
Chao 2004; Layfield et al. 2011). Methods of altering the technique to increase the 
sensitivity have been suggested including multi serial sectioning or the use of rapid 
immunohistochemistry (IHC) stains (Veronesi et al. 2001). The added workload that 
this would entail is not thought to be feasible within the UK health care setting 
(Keshtgar 2009).  
 
1.5.5.2. Touch Imprint Cytology  
 
Touch imprint cytology (TIC) is a simple and rapid method of preparing a cytological 
specimen for analysis. The excised lymph node is bisected and the cut surfaces are 
pressed onto a slide which is then fixed and stained. As a result there is no requirement 
for specialised equipment and there is no loss of tissue that would compromise the gold 
standard examination of paraffin embedded sections. There does however remain the 
need for an experienced histopathologist to interpret the slides that have been created 
(Keshtgar 2009). A meta-analysis of 31 studies where TIC had been used to assess the 
axillary lymph nodes reported a pooled sensitivity of 63% and a specificity of 99%. 
This sensitivity was improved to 82% if the presence of micro-metastases were 
excluded. The authors of the meta-analysis estimated that if all the patients whose nodes 
were included in the pooled studies had received intra operative TIC node assessment 
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then over 20% would have proceeded to a primary rather than an interval axillary 
clearance (Tew et al. 2005). One of the problems with interpreting the results of these 
studies has been the heterogenity of the sampling techniques used. In the four studies 
reviewed by Layfield variations in technique occurred in all four centres. However the 
pooled sensitivity of 63%, which is below that of frozen section, and the added 
expertise required accounts for why the technique is less widely used than frozen 
section analysis (Layfield et al. 2011). 
 
1.5.5.3. Molecular Assays 
 
Recently molecular assays using either reverse transcriptase polymerase chain reactions 
(RT-PCR) or reverse transcriptase loop-mediated isothermal amplifications (RT-
LAMP) have been developed to detect metastasis by quantitatively measuring the 
concentration of tumour specific mRNA markers. The two markers CK-19 (used in both 
techniques) and mammaglobin (used in the RT-PCR only) are expressed at high levels 
in cells of breast origin but are absent or a low level in normal axillary nodes. Studies 
analysing the efficacy of these methods to differentiate between positive and negative 
nodes have reported sensitivities of between 88 and 98% and specificities of greater 
than 93% for the RT-PCR technique (Blumencranz et al. 2007; Tafe 2010). An 
unpublished  meta-analysis of 8 similarly run studies carried out within our group, 
which included a total of 1547 patients, revealed a sensitivity of 88% and a specificity 
of 95%. 
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Sensitivities of 95% and specificities of up to 97% have been reported with the RT-
LAMP technique (Tamaki et al. 2009; Visser et al. 2008). A four centre study that 
included 204 patients within the UK using OSNA (the commercially available RT-
LAMP equipment) has recently published data with a sensitivity of 91.7% and a 
specificity of 96.9% (Snook et al. 2011). 
 
The advantages of these molecular assays include the ability to perform the test without 
the need for a specialised histopathologist to interpret the results and in a time frame 
that does not delay the surgical procedure. Disadvantages include the need to 
homogenise the node which prevents subsequent gold standard histopathological 
analysis. This is a particular danger as the false positives would mean that the patient is 
condemned to both an unnecessary axillary clearance and a course of chemotherapy as 
previously highlighted. It is worth noting that GeneSearch ® (Veridex, LLC, Warren 
NJ, and USA) the first commercially available product to exploit the RT-PCR technique 
has recently been withdrawn from the market. The high set up costs, logistical 
difficulties and the level of false positives were all cited for the low demand that 
prompted its withdrawal from the market (Loftus 2010). 
 
1.6. Controversies 
 
It has always been clear that the status of the axillary lymph nodes in breast cancer is 
crucial for staging and prognostic prediction. Techniques to both sample and assess 
these nodes have changed, particularly since the introduction of sentinel lymph node 
biopsy. However in the modern breast screening era patients are often presenting at an 
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earlier stage and this has caused many to re-examine the clinical significance of the 
axillary nodes and the need for an ALND if the nodes are found to be positive. This 
project is based on the perceived clinical need for a new method of intra-operative 
lymph node assessment that would allow immediate ALND to take place if required. 
Therefore an understanding of the nature of the ongoing debate is crucial to appreciate 
the implications it may have for the future applicability of this research. 
 
1.6.1. What is the significance of positive nodes? 
 
As has been discussed the increased thoroughness of pathological assessment now 
applied to sentinel lymph nodes has resulted in up to 40% of nodes being “upstaged”. 
Clinicians have therefore asked whether the clinical significance of these positive nodes, 
particularly micrometastases and isolated tumour cells (ITCs), is the same as the 
traditional H&E single sliced positive nodes on which their long held prognostic 
importance is based. 
 
Initially the focus of this debate had been the implication of finding micrometastases 
and isolated tumour cells. A recent meta-analysis examined 12 cohort studies 
comparing the 10 year outcomes of patients with single sliced H&E positive nodes 
(micrometastases and ITCs) against those with negative nodes. This confirmed the 
traditional view that patients had a poorer disease free survival rate and overall survival 
at 10 years if micrometastases or ITCs were present on the single slice (de Boer et al. 
2010). 
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This survival difference was less clear in studies that compared an “occult” group of 
positive nodes (where retrospective pathological assessment of single sliced H&E 
negative nodes had subsequently identified micrometastases or ITCs) with nodes that 
remained negative after step sectioning. Overall survival was not reduced in 3 out of 6 
studies that used multivariable analysis and disease free survival was not significantly 
different in eight out of 12 studies that recorded this outcome (de Boer et al. 2010). 
 
Analysis of data published since the advent of SLNB was more difficult as relevant 
studies were “hampered by small numbers, short follow-up and lack of multi variable 
analysis”. The authors went on to include some of the earlier studies that had included a 
sub population of patients who underwent SLNB and this suggested a lower disease free 
survival and overall survival if metastases of less than 2 mm were present (de Boer et al. 
2010). This finding is supported by a retrospective cohort study of more than 2500 
Dutch women who had a SLNB. Even after adjustment for diagnosis, tumour grade, 
hormone receptor status and ALND there was an increased risk of events among 
patients with either micrometastases (hazard ratio 1.56 (95% CI 1.15 to 2.13)) or ITCs 
(hazard ratio 1.5 (95% CI 1.15 to 1.94)) as compared to node negative women (de Boer 
et al. 2009) (Figure 19). This increased risk was reduced if patients who had 
micrometastases or isolated tumour cells received systemic adjuvant therapy. 
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Figure 19- Disease free survival curves over 5 years after diagnosis in patients who are node negative or 
who have ITCs and micrometastases (a.) with and without adjuvant treatment (b.) This demonstrates the 
worse outcome in patients who had nodal metastases and how this could be mitigated with adjuvant 
treatment (adapted from de Boer et al. 2009). 
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This is important as critics of the retrospective studies argue that much of this data is 
based on old cohorts of patients who were identified pre-screening programmes and 
who did not receive adjuvant treatments.  A more contemporary American cohort study 
suggested that there was no added benefit for patients with micrometastases who 
underwent an ALND after a SLNB in either preventing axillary reoccurrence or overall 
survival (Bilimoria et al. 2009). Both the local reoccurrence and the overall survival 
were no different if the patient underwent an ALND or not (disease free survival 98% v 
99% at 5 years in ITCs and 90 v 89% at 5 years in micrometastases in the no ALND v 
ALND groups). This study further went on to show a marked reduction in numbers of 
patients having SLND if there was evidence of micrometastases or ITCs in the period 
2000 -2005.  
 
Two recent studies that have addressed the question prospectively were the American 
College of Surgeons Oncology Group Z-0010 trial and the National Surgical Adjuvant 
Breast and Bowel Project (NSABP) - 32 trial. The Z-0010 trial included patients whose 
clinicians were blinded to the results of immuno-histochemistry and treatment thus 
relied on the single cut H and E slide. This showed that the 5 year overall survival rates 
were 95.8% ,in the IHC negative, group as compared to 95.1% in the IHC positive 
group (Cote et al. 2010). The NSABP-32 trial showed a slight improvement in survival 
in the IHC negative group (95.8% 5 year disease free survival v 94.6%) (Weaver et al. 
2011). The differences remain small and thus the role of these “extra” metastases 
detected by immuno-histochemistry remains questionable. 
 
50 
 
Added to this debate are studies that support the concept of ITCs being found in a node 
for benign reasons. It has been argued that they may be a result of previous 
manipulation and instrumentation of the breast tumour. Both fine needle aspiration 
(FNA) and core needle biopsy may displace epithelial cells and either benign or 
malignant cells have been found in the granulation tissue along the site of the biopsy. 
Part of the healing process after these procedures involves interstitial fluid draining to 
the axillary lymph nodes. In this way cells of epithelial type may be transported to the 
node as a result of a natural healing reaction. Comparison of the cell type may help to 
clarify this. If the ITCs are different to the primary tumour it is unlikely to be related to 
the tumour. Further if there is evidence of the debris from tissue trauma such as red 
blood cells or haemosiderin deposits within the node then a traumatic cause is more 
likely (Carter et al. 2000 ; Bleiweiss, Nagi and Jaffer  2006). 
 
These studies support the current UK guidelines that nodes with ITCs are deemed to be 
negative. Within these guidelines the presence of micrometastases, as has been 
discussed, renders the node positive currently. Based on the studies above this remains a 
very controversial area and the benefits of further treatment may be questioned. The 
importance of the MDT in discussing the risks and potential benefits of further 
treatment in individual patients with these findings is clearly crucial. Thus the place for 
immediate ALND, following intra-operative diagnosis, prior to MDT discussion in 
these patients may be questioned.   
 
Until recently the position of macrometastases was much more straightforward. The 
most recent contribution to the debate has been the results of the Z-OO11 trial (Giuliano 
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et al. 2011). This was a prospective randomised trial of SLNB and no further axillary 
treatment versus SLNB and ALND for patients with T1 or T2 tumours and either micro 
or macrometastases discovered on H&E slides, who were undergoing breast conserving 
treatment and adjuvant therapy. There were a number of exclusion criteria that included 
palpable nodal disease, extra nodal spread and more than 3 nodes affected.  The results 
of this study have shown, at a median follow up of 6.3 years, that there were no 
statistically significant differences in either local or regional recurrence amongst the two 
treatment groups. The authors suggested a number of possible reasons for this result. 
Firstly that SLNB removed the nodes with metastatic spread, stating that in 40-60% of 
cases the sentinel node is the only positive node. Secondly they proposed that not the 
entire metastatic load in axillary nodes has the ability to develop into clinically 
significant disease. As a result of this study they suggest that we may be over treating 
the positive axilla. They do sound a note of caution by explaining that this is only 
relevant to patients with T1/T2 tumours, undergoing breast conserving surgery with no 
clinically palpable axillary disease and less than 3 positive nodes. They also concede 
that all the patients in the study underwent opposing tangential field whole breast 
irradiation which may well have treated the axilla. Further to this 96% of patients 
received systemic adjuvant therapy which may confound the results. However as a 
result of these findings the lead author has suggested that the role of ALND needs to be 
re-examined and may in the future be eliminated as a requirement for most women with 
“contemporary” breast cancer.  
 
The latest National Comprehensive Cancer Network guidelines for the management of 
invasive cancer have thus included a category of patients that meet the criteria for the Z-
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0011 trial and should be “considered” for no further axillary surgery (National 
Comprehensive Cancer Network 2012). Despite the finding of the Z0011 trial, SLNB 
remains the standard of care for breast cancer patients in the UK and completion ALND 
is still recommended if there are macro- or micro-metastases within an axillary lymph 
node. Practice is changing and for the management of micro-metastases the place of 
ALND is now questioned and thus the role of intra-operative node analysis will be 
limited if there is no plan to proceed to an ALND. For macrometastases there remains a 
clear place for ALND even if it is in a smaller group of patients in the post Z-0011 era. 
This is clearly an issue which will continue to be debated and the results of a number of 
ongoing trials will help shape the debate. Trials that look at the outcome of axillary 
node dissection versus no axillary node dissection in patients positive for 
micrometastases (IBCSG 23-01 Trial) and that assess whether axillary dissection or 
axillary radiotherapy is the best treatment option for patients with metastatic spread 
(AMAROS (After mapping of the axilla: Radiotherapy or Surgery) Trial) may add 
greater pressure onto the advocates of ALND. The results of these trials will be keenly 
followed and help shape future management of node positive breast cancer. 
 
As the management of breast cancer continues to progress new methods of prognostic 
assessment may also influence the future management strategies. OncotypeDX 
(Genomic Health Inc) is a multi gene diagnostic assay based on the gene expression of a 
tumour specimen. It is currently being marketed to quantitatively predict the likelihood 
of chemotherapy benefits and distant reoccurrence. Based on the level of expression of 
16 genes patients can be stratified into one of three groups. This allows patients to make 
decisions based on the risk benefit ratio for each sub group, rather than the population 
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as a whole. As a result those patients who would receive the maximum benefit of 
systemic treatments can be identified and given the treatment whilst those who would 
receive minimal benefits could decide against it due to the side effects and toxicity of 
the treatment.  (Paik et al. 2006). Studies to date suggest that these techniques may also 
be able improve upon standard staging although questions remain with regard to their 
efficacy at predicting local reoccurrence and their use for rarer sub types (Gelmon 
2010). 
 
1.7.  Conclusions 
 
Breast cancer remains a significant cause of morbidity and mortality. It is a disease 
which attracts a great deal of clinical research, of which this Raman based study, is one 
such example. As a result, the management of the disease will continue to change to 
embrace new technologies and techniques. It is of the authors’ opinion that ALND will 
continue to retain a place in the management of breast cancer, particularly for patients 
with nodes positive for macrometastases that fall outside the criteria of the Z-0011 trial. 
As has been demonstrated in this chapter, determining the nodal status of each patient’s 
axilla remains important both to guide treatment and to achieve the very best clinical 
outcome.  
 
There are pathological differences that exist between a normal axillary lymph node and 
one in which metastatic spread has occurred. It is these differences which are exploited 
by current techniques. As has been discussed they all have their own advantages and 
disadvantages and have not been universally implemented. As a result there remains a 
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need for a technique that can provide patients with the benefits of intra-operative 
axillary node testing, in a cost effective way that could be made available to all.  It is 
hoped that within this study, and thus this thesis, that the potential role of Raman 
spectroscopy to fill this void will be established. To achieve this experiments performed 
at a preparatory stage, prior to use within an operating theatre, will be reported before 
focusing on experiments that were carried out within an operating theatre using fresh 
tissue, to establish the technique as one that could be used in a real life clinical setting. 
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2. Raman Spectroscopy and Clinical Diagnostics. 
 
As concluded at the end of the first chapter the aim of this project is to determine 
whether Raman spectroscopy could be used as a means of assessing axillary lymph 
nodes intra operatively in patients newly diagnosed with breast cancer. In this chapter 
the technique and concepts underpinning the use of Raman spectroscopy will be 
introduced. Evidence supporting its use in this project will be discussed and supported 
by reviewing previously published work. 
 
2.1. The Ideal Diagnostic Tool. 
 
When considering the development of a new diagnostic tool it is important to first 
highlight what features would constitute the ideal tool for the scenario in which it is to 
be used.  As previously discussed in Chapter 1 there are a number of techniques that are 
already being used to assess lymph nodes intra-operatively. They all have significant 
disadvantages which have prevented their universal use. Analysis of these techniques 
suggests the key parameters which a new diagnostic tool entering this environment must 
meet.  
 
Firstly and most importantly the tool must be both sensitive (its ability to detect true 
positives) and specific (its ability to detect true negatives) in comparison with the gold 
standard histopathology assessment. The clinical consequences of a false positive result 
would see a patient undergoing an ultimately unnecessary axillary node dissection and 
adjuvant chemotherapy. The consequences of a false negative result whilst being less 
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severe would mean that a patient with a positive node was under-staged and potentially 
under treated. This can partially be mitigated for by the ability to post-operatively cross 
check the tests results. This would however mean that a false negative patient needed a 
second operation and thus negate the very benefit it could provide.  
 
Secondly the diagnostic tool must be able to produce a result without unnecessarily 
disrupting or delaying the ongoing procedure. It is the author’s opinion that the best way 
to achieve this is for the equipment to be used within the operating theatre. This would 
reduce the added costs of having separate staff, particularly pathologists, to operate the 
device outside theatre and help prevent time delays as well as reducing the risk of tissue 
loss whilst transporting the node to an alternative venue. For the device to be used 
within theatres it needs to be safe, unaffected by the theatre surroundings and simple to 
use. It should be the aim that theatre staff can easily produce a result without significant 
added expertise, either in tissue preparation or diagnostic interpretation.   
 
Finally in the current economic environment it is important that the tool is cost 
effective. Raman spectroscopy, unlike the other intra-operative methods, has the 
potential to fulfil these criteria and this will be demonstrated in this project (Table 5). 
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 Frozen Section 
Analysis 
Touch Imprint 
Cytology 
Molecular 
Assays 
Raman 
Spectroscopy 
 Sensitive 
  
 
 
To be 
determined 
 Specific 
    
To be 
determined 
 Post Operative 
Cross Check   
 
 
 Use within theatre 
  
 
To be 
determined 
 Time Frame 
    
To be 
determined 
 Cost Effective 
   
 
To be 
determined 
 
 
Table 5- The features of an ideal diagnostic tool for intra-operative lymph node assessment. For 
illustrative purposes the strengths and weakness of current intra-operative techniques are shown, along 
with the areas that need to be determined for Raman spectroscopy (further details of the non-Raman 
spectroscopy techniques can be found in Chapter 1). 
 
 
2.2. Raman Spectroscopy - An Introduction 
 
Raman Spectroscopy is based on the inelastic scattering of monochromatic light as it 
interacts with molecules. This interaction between light and molecules was first 
observed by C.V. Raman in 1928. It is one of a number of interactions that may occur 
when light interacts with matter. Light may be reflected, absorbed or as in the Raman 
effect, scattered. Each of these modalities may be harnessed to assess matter. To 
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appreciate these interactions we need to consider that light is a form of electromagnetic 
radiation and may further be conceptualised as small packets of energy or photons that 
exhibit wave particle duality. The relationship between the energy (E) of a photon of 
light and its wave frequency (v) is given by the equation; 
 
E=hv 
 
Where h is Planck’s constant (6.63 x 10-34 J/s molecule-1) 
 
The frequency is related to the wavelength (λ) of light by the equation; 
 
v = c / λ 
Where c is the velocity of light (2.998 x 10
8
ms
-1
) 
 
It is thus apparent that that the energy of a photon of light is inversely proportional to its 
wavelength.  
 
The majority of scattering interactions are elastic in nature. In this scenario a photon of 
light interacts with a molecule and causes polarisation of its electron cloud and a rise in 
its energy state. This new “virtual” energy state is very short lived (approximately 10-14 
secs.) after which the molecule returns to its initial energy state. As it returns to its 
initial energy state it releases a photon with the same energy and hence wavelength as 
the incident light.  
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In contrast Raman scattering is an inelastic interaction. The incident and emitted photon 
have different energies and therefore different wavelengths. This occurs because the 
molecule, having been excited to a virtual energy state from its initial state, does not 
return to the initial energy state but to a higher (or lower) energy state. Therefore the 
photon emitted will have an energy which is lower (or higher) than the incident photon.  
When the emitted photon has a lower energy it is termed Stokes Raman Scatter and 
when the emitted photon has a higher energy it is termed anti-Stokes Raman Scatter. 
Many times less than 1% of scattered photons have undergone Stokes Raman scattering, 
with even less undergoing anti-Stokes Raman scattering (Figure 20). 
 
 
Figure 20- The characteristics of Rayleigh, Stokes and Anti-Stokes light scattering, demonstrating that in 
Rayleigh scattering the energy level returns to the original state and thus the wavelength of the emitted 
light is the same as the incident light that caused the temporary energy level shift. In contrast in Raman 
(Stokes and anti-Stokes) the energy level does not return to the original state and thus emitted light has a 
different wavelength to the incident light. 
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Within each molecule there are defined numbers of energy modes. These may be related 
to the position of electrons in molecular orbits or to the vibrational mode of the 
molecule. The energy required to alter these energy modes differs for each molecule, 
dependent on their configuration, however the energy required to alter the vibrational 
state of a molecule is less than that required to alter the orbital positions of its electrons 
(Figure 21). 
 
Figure 21- Illustration of the energy levels of different vibrational states of a molecule. Moving from one 
vibrational energy( V1-5) level to another requires less energy than electron position levels (Ex). The 
arrows indicate the effect of Raman (Stokes) scattering (see also figure 20).  
 
Raman scatter occurs due to changes in the vibrational modes of the molecules that the 
light interacts with. The number of the different vibrational modes (vm) that each  
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molecule is capable of adopting is calculated by the equation; 
 
vm= 3n-6  
(where n equals the number of atoms in the molecule and 6 is subtracted to account for 
the translations and rotations of the molecule itself.) 
 
In ethane (C2H4) for example there are 12 vibrations possible: 4 C-H stretching, 1 C-C 
stretching, 2 H-C-H bending, 2 CH2 rocking, 2 CH2 scissoring and 1 twisting mode 
(Figure 22). 
 
 
Figure 22- One half of the ethane molecule demonstrating some of the types of vibrational conformations 
possible (adapted from http://en.wikipedia.org/wiki/Molecular_vibration). 
 
A change in vibrational mode may be detected using Raman spectroscopy but this is not 
always the case. For a change in vibrational mode to be  “Raman active” it must involve 
a change in the polarisability of the molecule. In its simplest form this means that the 
volume of the molecule is increased. An example of this is the symmetrical stretch of 
CO2 (Figure 23). 
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Figure 23- Demonstration of how the distortion of the molecules electron cloud by stretch vibrations will 
alter the volume and thus the  polarisability of the molecule.  
 
By contrast some vibrational mode changes will only alter the dipole moment and not 
the polarisability of the molecule (Figure 24). 
 
 
Figure 24- Demonstration of how asymmetrical stretching of a molecule alters the dipole moment of the 
molecule. Following the stretch part of the molecule (shaded red) becomes more “negative” and part 
becomes more “positive”. 
63 
 
 
This change is not detected by Raman spectroscopy but is detected using IR (infra-red) 
spectroscopy and thus the two methods are often said to be complementary to each 
other. This has important consequences particularly in the measurement of clinical 
tissue. Water has to be excluded from samples undergoing IR spectroscopy due to the 
marked dipole effect and the distortion of the spectra produced. This is not the case with 
Raman spectroscopy and allows the technique to be used on fresh tissue.  
 
Utilising the Raman scatter effect allows spectra to be plotted that are based on the 
molecular structure of the matter under investigation. The energy requirements required 
to alter vibrational modes are different for individual molecules and can further be 
influenced by the interaction with neighbouring molecules. A spectrum produced by a 
Raman spectrometer plots the intensities of emitted photons (y axis) as a function of the 
Raman shift (x-axis). The Raman shift is the difference between the energy of the 
incident photon and the emitted photon. It is measured in wavenumbers (with units of 
cm
-1
) that are equal to the reciprocal of the wavelength.  
 
Biological tissue is made up of a combination of different biochemical constituents.  
Broadly speaking these can be divided into 4 separate groups, nucleic acids, proteins, 
lipids and carbohydrates. As discussed in Chapter 1, when metastatic colonies establish 
themselves and proliferate, the proportion of each tissue constituent changes. Cells 
replicating quickly will increase the nucleic acid component of any tissue spectrum, in 
combination the immune response will increase the protein contribution and as the 
metastatic cells replaces the normal tissue then the lipid component will diminish 
(Ioachim and Ratech 2002). Due to the fact that the features of a Raman spectrum 
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collected from tissue are based on its molecular structure differences in the biochemical 
constituents of a tissue can be detected (Figure 25). It is anticipated that the biochemical 
differences between metastatic and normal lymph nodes will be sufficient to allow 
separation of the two groups based on their Raman spectral features. 
 
 
Figure 25- Raman Spectra from different biochemical compounds highlighting the variation in spectral 
features (Diem, Chalmers and Griffiths 2008).  
 
2.3. Raman Spectroscopy - Technical Considerations 
 
Modern Raman spectrometers are very different to the simple equipment employed by 
Raman in 1928. Then he used sunlight focused through a telescope as opposed to the 
high intensity single wavelength laser light sources that are employed now. Much of the 
previously published work using Raman spectroscopy to assess biological tissue has 
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used incident light in the Near Infra Red (NIR) region. This wavelength of light is 
absorbed much less readily by the tissue, causes minimal tissue damage and overcomes 
the effect of fluorescence seen with visible and ultraviolet light. The wavelength of light 
that is to be used in this study is 785nm.  
 
A key consideration in Raman spectrometer design is the prevention of interference 
from elastic scatter. As previously discussed the proportion of all scattered light that is 
inelastic is very small. Therefore a series of filters are used to reduce this effect. In the 
spectrometer used throughout this project, the B&W Tek MiniRam II (see Chapter 3), a 
notch filter allows Raman peaks to be detected as close as 175cm
-1 
from the Rayleigh 
line. Detection of the scattered light is achieved using a charged coupled device (CCD) 
that allows for the measurement of a whole spectrum at once. Built into the MiniRam II 
system is a thermo-electric cooler that reduces both the dark current and the background 
noise. This allows the spectrometer to be used with long collection times and permits 
the detection of weak optical signals. 
 
A number of techniques have been developed to enhance the Raman signal from tissue 
of interest. Although it is not intended that these techniques will be used in this project a 
brief discussion is pertinent for completeness. Examples of this include resonance 
Raman spectroscopy, surface enhanced Raman spectroscopy and spatially offset Raman 
spectroscopy.  
 
In resonance Raman spectroscopy the incident light is tuned so that it coincides with the 
energy required for an electron to move energy level. In this way photons maybe 
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scattered up to 10
6
 times more than using conventional Raman techniques. Thus 
vibrational transitions which are too weak to be detected normally can be identified.  
Surface enhanced Raman spectroscopy (SERS) is a further technique that is used to 
enhance the Raman signal. In this case samples are adsorbed onto Gold or Silver 
surfaces. This results in an increase in the intensity of the Raman scatter particularly 
when combined with resonance Raman spectroscopy (DoItPoms 2010). The exact 
mechanism for this action is still debated. It has been postulated that it may occur either 
due to an increase in the electromagnetic field that then increases the interactions with 
the incident light or due to the metal altering the electron energy levels of the molecule 
and thus providing a resonance effect (DoItPoms 2010). The in vivo use of this 
technique is currently limited by concerns about the ability of the body to excrete the 
markers and thus the long term effects of retained metals. Spatially offset Raman 
spectroscopy collects Raman scatter from a position several millimetres offset from the 
point of excitation. This overcomes the high intensity Raman scatter from the area of 
excitation which ordinarily dominates the spectra obtained. As a result this technique 
has been used to probe tissue many millimetres in depth (DoItPoms 2010).  
 
2.4. Raman Spectroscopy in a clinical setting 
 
The use of Raman spectroscopy to identify primary tumours and differentiate them from 
normal non malignant tissue has been demonstrated in a number of organs including 
oesophageal (Kendall et al. 2003), laryngeal (Stone et al. 2000), bladder (Stone et al. 
2004), prostate, (Stone et al. 2004) and colon (Molckovsky et al. 2003). A review of all 
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the different tissue types would be beyond the scope of this report but this section will 
focus on the evidence supporting its use in breast cancer and lymph nodes.  
 
2.4.1. Raman Spectroscopy in Breast Tissue 
 
The first recorded spectra of human breast tissue were published in 1991 (Alfano et al. 
1991). They recorded the spectra using FT-Raman spectroscopy and an excitation laser 
with a wavelength of 1064 nm. Analysis was performed to compare the characteristic 
spectral peaks of three normal, four benign and seven malignant specimens. They 
observed differences in both the presence of particular peaks and the relative intensities. 
Four key peaks were identified in normal tissue at 1078, 1300, 1445 and 1651 cm
-1
. In 
comparison there was an absence of these peaks at 1078 and 1300 cm
-1
 in the malignant 
tissue. Further the intensities of peaks at 1445 and 1651 cm
-1 
where different in all three 
tissue types. The importance of these peaks was further demonstrated in a number of 
observational studies published in the 1990s and were attributed to differences in the 
spectral contribution of fatty acids (FA). 
 
Attempts to quantify what these differences equated to biochemically followed. Initial 
work attributed the observed changes to contributions of fatty acids and β-Carotene 
(Redd et al. 1993).  
 
Subsequent work collected 123 spectra from 41 tissue specimens excised during breast 
surgery procedures. The authors of this study used the data to compare the spectral 
features of normal breast tissue with those of invasive ductal carcinoma (Frank et al. 
68 
 
1995). The normal tissue demonstrated features consistent with the presence of lipid 
whilst the malignant tissue had peaks that were suggestive of an increased contribution 
by proteins. It was particularly noted that the peak in normal tissue at 1439 cm
-1
 
(attributed to the CH2 deformation) was shifted to 1450 cm
1
 in malignant tissue. The 
authors suggest that this change is consistent with a change from fatty acids to proteins. 
The previous use of β carotene as a discriminative feature was not evident because of 
the wavelength of the incident light source, 784 nm (Frank et al. 1995).  
 
A subsequent study that assessed 61 samples from 13 patients similarly compared 
spectral differences between normal breast tissue and invasive ductal carcinoma. The 
authors demonstrated that spectra from normal tissue were dominated by fatty acid 
features whereas spectra from positive samples were dominated by protein peaks. The 
key differences noted were a shift in the 1445 cm 
-1
 peak to 1450 cm 
-1 
as shown 
previously and a widening of the 1650 cm 
-1
 band in the positive spectra (Figure 26). 
 
Figure 26- Raman Spectra of three distinct types of breast tissue (Manoharan et al. 1998).  
Normal 
 
 
 
Benign 
 
 
 
Malignant 
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These differences were used to differentiate between normal and malignant tissue. 
Sensitivities of 100% for identifying malignant tissue, 88% for benign tissue and 94% 
for normal tissue were achieved using principal component analysis (Manoharan et al. 
1998). The authors of the paper accepted that the small number of samples did not allow 
adequate cross validation to support these results. However the potential for the use of 
Raman spectroscopy to aid clinical diagnosis of breast cancer was clearly set. 
  
A number of groups have subsequently pursued the use of Raman spectroscopy in the 
diagnosis of breast cancer. A novel approach to spectral difference analysis was adopted 
by Haka et al. who in 2005 reported the creation of a breast tissue spectroscopic model. 
The model was based on the analysis of 130 spectra from 58 patients undergoing breast 
cancer surgery. They demonstrated that the spectra from different tissue types could be 
replicated  by varying the percentages of the model components, namely collagen, fat, 
cholesterol, β carotene, cell cytoplasm and nucleus and calcium compounds (Figure 27). 
The key spectral differences were noted to be the fat, collagen and cell cytoplasm 
components. Using the component percentages they were able to distinguish between 
normal and malignant tissue with 94% sensitivity and 96% specificity based on the 
contributions of collagen and fat (Haka et al. 2005) (Figure 28). The authors recognised 
that this was an ex vivo study based in a laser laboratory on snap frozen specimens but 
they stated that it was an important step towards the clinical use of Raman spectroscopy 
in breast cancer. 
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Figure 27- Normalised Raman Spectra and model fits for four distinct tissue types. The percentage of 
each component included is also displayed, along with the H and E slide of the tissue type being assessed 
(Haka et al. 2005.)  
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Figure 28- Scatter plot demonstrating the contribution of fat and collagen components in spectra from 
different breast tissue types ( Haka et al. 2005).  
 
The same group went on to use this analytical technique to assess the ex-vivo margin 
status of tumour samples removed during breast cancer surgery.  30 samples were 
assessed using Raman spectroscopy in the study from a total of 9 patients. 29 of the 
samples were histopathologically reported as non malignant of which 21 were normal 
tissue and 8 demonstrated benign fibrocystic change. Only 1 sample was classified as 
positive , containing areas of ductal carcinoma in situ. The overall accuracy of the 
algorithm was 93%, with 20/21 normal samples, 6/8 fibrocystic samples and 1/1 DCIS 
samples being correctly classified. The authors recognised this as a pilot study and 
accepted the limitations of such small numbers particularly in the positive group. It does 
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further demonstrate the potential diagnostic capabilities of Raman spectroscopy, based 
on molecular differences, in the diagnosis of breast cancer (Haka et al. 2006).  
 
A follow up to this study published in 2009 reported the results of real time intra 
operative analysis of samples from 28 consecutive patients undergoing breast 
conserving surgery. A total of 220 Raman spectra were collected from 220 samples. 
Only 129 of these were deemed appropriate for analysis. The 91 that were excluded 
included samples from patients who had undergone pre-operative adjuvant 
chemotherapy (n=28), were having repeat surgery due to initial positive margins (n=33), 
or had pathology that was positive for DCIS (n=20). 10 spectra were excluded due to 
light contamination of the spectra collected. The remaining 129 spectra were classified 
based on the contributions of collagen and fat to their spectra. A sensitivity of 83% (5/6) 
and a specificity of 93% (114/123) was reported for the differentiation between invasive 
ductal carcinoma and non malignant tissue (normal and benign pathologies) 
respectively (Haka et al. 2009). However the positive predictive value of the test was 
reported as only 36%. This was due to the misclassification of 4/73 and 5/9 spectra from 
tissue with either fibroadenomatous or fibrocystic benign changes. As a result the 
authors felt that whilst the negative predictive value of 99% was very encouraging 
larger scale ex vivo and in vivo studies were required to improve their algorithm prior to 
clinical implementation. 
 
The biochemical differences between normal and malignant tissue were further 
demonstrated by Chowdray et al. (Figure 29). They reported the results of 258 spectra 
collected from 60 samples that were obtained from 60 patients undergoing routine 
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surgical operations or breast biopsies. A total of 29 normal, 24 malignant and 7 benign 
samples were included in the dataset. Using spectral difference plots they too 
demonstrated decreased lipid contributions and increased protein contributions in the 
spectra collected from positive samples (Chowdray et al. 2006).  
 
Figure 29- Mean Spectra of normal, malignant and benign breast tissue (Chowdray et al. 2006).  
 
In a later paper the group went on to use the spectral differences between pathology 
groups in the 1400-1750 cm 
-1
 region to prospectively match unknown samples to the 
training samples from the previous study.  Mahalanobis distance and spectral residuals 
were calculated against the training data and used in a “limit test” match/mismatch 
approach. In this way 29/30 normal samples, 17/21 cancer samples and 15/18 benign 
samples were correctly classified. 
 
Normal 
 
 
 
 
 
 
 
 
Malignant 
 
 
 
 
 
 
Benign 
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The spectra were subjected to curve fitting to help understand the biochemical 
differences between the three groups. This study confirmed that fat (peaks at 1301 and 
1440 cm
-1
), collagen/protein (peaks at 1246, 1271 and 1671 cm
-1
) and DNA (peaks at 
1340 and 1480 cm
-1
) contributions differed in the three pathology groups (Chowdray 
2009) (Figure 33). 
 
 Figure 30- Scatter plots demonstrating the differences in protein, lipid and DNA peaks in malignant (red 
circles) and normal (green circles) breast tissue (Chowdray et al. 2009).    
 
Two sub-types of Raman spectroscopy, spatially offset Raman spectroscopy (SORS) 
and transmission Raman spectroscopy, have also been explored as methods of 
improving the management of breast cancer. A clinical scenario where they have been 
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used is the problem of positive margins after breast conserving surgery. This is a 
significant cause of morbidity in breast cancer patients with up to 20% of patients 
requiring further surgery to obtain adequate clearance (NHS Breast Cancer Screening 
Programme 2008). One way of reducing the need for a second operation would be the 
development of a technology that immediately assesses tissue margins. Research 
performed on tissue models have demonstrated that using spatially offset Raman 
spectroscopy (SORS)  spectral features of breast cancer tumours as small as 1-2 mm in 
diameter can be distinguished through up to 2 mm of normal tissue (Keller, Majumder 
and Mahadevan-Jansen 2009) (Figure 31).  
  
Figure 31- Mean Spectra of normal and breast tumour measured using SORS techniques (Keller, 
Majumder and Mahadevan-Jansen 2009).  
 
The authors state that the key spectral differences between the two tissue types are the 
presence of the phenylalanine peak at 1006 cm 
-1 
, a decreasing ratio of the 1265 to 1303 
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cm 
-1
 peaks (indicative of an increase in protein content) and an increase in the width of 
the peak around 1656 cm
-1 
(indicative of an increase in the contribution of amide I ) in 
the cancer spectra. This coupled with the decrease in the relative intensity of the 1445 
cm
-1 
peak in the cancer spectra is consistent with the increase in proteins and the 
decrease in lipids that other groups have demonstrated in breast cancer spectra (Figure 
34). 
 
Further work by the group has highlighted a number of confounding factors which need 
to be overcome before a clinical application is possible. They reported that the results 
are only achieved with a tumour of 1 mm in diameter which may not be the case if a 
small focus of cancer is near to the margin. They further state that calculation of the 
depth of the tumour below normal tissue is difficult without prior knowledge of the 
tissue geometry (Keller, Majumder and Mahadevan-Jansen 2010). 
 
The use of transmission Raman spectroscopy has and continues to be explored for use 
in the initial diagnosis of breast cancer. The aim of the work is to develop a means of 
non invasively probing areas of calcification that are detected during mammography 
screening. This technique is based on the differentiation of firstly Type I and Type II 
calcifications and then secondly the carbonate substitutions within Type II breast micro 
calcifications. These differences have been demonstrated to differentiate between 
benign and malignant breast disease. To date transmission Raman spectroscopy within 
the laboratory has been able to determine the amount of carbonate substitutions in type 
II calcifications and spectral differences between Type I and Type II calcifications 
through 16 and 27 mm of breast phantom tissue respectively (Matousek and Stone 
2007;  Kerssens et al. 2010). 
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These papers suggest that, by exploiting the differences in protein and lipid 
contributions to spectra collected from normal and malignant breast tissue, Raman 
spectroscopy could be used in a number of clinical situations pertaining to breast cancer. 
As has been demonstrated this may include the assessment of margin status after breast 
conserving surgery or potentially the assessment of core biopsy samples that are used in 
the initial diagnosis of the disease. Differences in the calcification types can also be 
detected using Raman spectroscopy and these could reduce the morbidity associated 
with breast screening.  
 
The ability of Raman spectroscopy to differentiate between normal and malignant tissue 
is important in this study. Although the tumour itself will not be assessed, metastatic 
cells that spread from the breast to the lymph nodes have very similar histological 
properties to the original tumour. It is anticipated that the differences previously 
described between normal and metastatic tissue will have different spectroscopic 
features and that these differences can be exploited to differentiate between normal and 
metastatic nodes. 
 
2.4.2. Raman Spectroscopy in Lymph Nodes 
 
To date there have been very few papers published that document the use of Raman 
spectroscopy for the assessment of lymph nodes. One of the first papers that reported 
Raman spectral assessment of axillary lymph nodes used the technique as a method of 
examining whether silicon breast implants had split. Axillary node tissue specimens 
were obtained during surgery following silicone implant leak and compared to nodes 
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from patients with lung cancer that were undergoing lymph node dissection. The 
authors of the paper did not report in great detail the peak assignments of the spectra 
that they acquired other than to comment that peaks above 1000 cm
-1 
were due to lipid 
components. The presence of silicon was clearly demonstrated and the authors 
concluded that Raman spectroscopy could provide a rapid diagnostic test that could be 
used in this context (Frank et al. 1993) (Figure 32). 
 
 
Figure 32- Spectra of normal lymph nodes and those upstream of a silicone implant leak. The added 
peaks (circled in blue) between 400 and 750 cm
-1
 allow for the differences to be distinguished (adapted 
from Frank et al. 1993).   
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A further study published in 2005 used Raman spectroscopy to confirm the presence of 
silicone within the axillary lymph nodes of 71/96 patients with breast implants. The 
authors did not comment on the  features of the lymph node spectra other than to 
highlight the presence of polymethysiloxane and polyurethane peaks in the spectra 
obtained from patients with implants. The sensitivity of Raman spectroscopy at 
detecting changes in the lymph node associated with silicone implants was worse than 
standard pathological assessment but was felt to relate to the small area of the node that 
was assessed using Raman spectroscopy (Katzin et al. 2005). 
 
To date only one group (ours) has used Raman spectroscopy to assess the presence or 
absence of metastatic cells within human lymph nodes in breast cancer. 59 lymph node 
samples were collected from 58 patients undergoing axillary lymph node excision due 
to breast cancer. Raman spectroscopy mapped images were created from 7 μm sections 
of tissue with a step size of 100 μm in the x and y direction. The differences in the mean 
spectra of positive versus negative nodes suggested that there were decreases in the 
DNA and tyrosine contributions within the negative nodes. It was interesting to note 
that the lipid contribution appeared to be similar in both groups, in contrast to the 
findings in the breast papers previously reviewed. Principal component fed linear 
discriminant analysis (PCA fed LDA) was used to create a pathology classification 
model. This achieved a sensitivity of 91% and a specificity of 93% at differentiating 
between the positive and negative nodes. Whilst these results were very encouraging the 
authors recognised that the time taken to produce these mapped images, 12 to 120 
hours, was inadequate for intra operative use (Smith 2005). 
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 A potential method of overcoming the disadvantage of mapped images was to use a 
probe and collect spectra from a greatly reduced but evenly spread area of tissue. The 
effects of this change were modelled by selecting 5 and 10 points at equally spaced 
positions across the mapped images of 53 and 47 nodes respectively . The estimated 
time to collect the spectra obtained from these points was 9 and 18 minutes in the two 
groups. Sensitivities of 71%, in the 5 probe point group, and 81% , in the 10 probe point 
group, with specificities of 97% in  both groups were achieved based on a cross 
validated model (Horsnell et al. 2011). These results support the use of a Raman 
spectroscopy probe for the assessment of axillary lymph nodes as they produced results 
that were equivalent to both frozen section and touch imprint cytology, in a time frame 
that would be suitable for intra-operative use. The low sensitivity was attributed to the 
small total area of the node assessed, 2800μm3 and 5600 μm3 in the two respective 
groups. The authors felt that the increase in sensitivity that was achieved by doubling 
the total area assessed in the 5 and 10 point group could be further enhanced by using 
probes that collected spectral data from an even greater tissue area (Horsnell et al. 
2011).  
 
Lymph nodes from patients with oesophageal cancer have also been investigated using 
Raman spectroscopy.  76 halved lymph node samples from 57 patients were collected 
and snap frozen at the time of surgery. 30 of these samples were said to be positive for 
cancer and 46 were negative for cancer after histopathological analysis. The samples 
were then assessed using both Raman and FTIR spectroscopy within a laser laboratory. 
The mean Raman spectra of positive and negative nodes were compared and 
demonstrated lipid, carbohydrate and protein peaks in the negative nodes and stronger 
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nucleic acid peaks in the positive nodes. PCA fed LDA was then used to assess the 
diagnostic capability of these differences. Cross validated results achieved a sensitivity 
of 97% and a specificity of 89% for the differentiation of negative and positive nodes. 
The authors of this study concluded that these results provided a “launchpad” for the 
development of in vivo applications of Raman spectroscopy in lymph node diagnostics 
(Isabelle et al. 2008).  
 
The use of Raman spectroscopy as a diagnostic tool for the assessment of axillary 
lymph nodes remains in its infancy. Whilst the studies to date have been encouraging 
they have been limited by low sample numbers and have been laboratory based using 
frozen tissue. This study will be the first to move the spectrometer out of the laboratory 
into the operating theatre and will assess freshly excised human tissue. 
 
2.4.3. Alternative optical methods of assesing lymph nodes  
 
Other forms of optical spectroscopy have been used to assess lymph nodes. These 
include elastic scattering and infrared spectroscopy. Elastic scattering spectroscopy 
(ESS) is a technique that is based on the elastic scattering of light. Short pulses of white 
light from a source such as a Xenon lamp are delivered to the tissue. Scattered light 
which has the same wavelength as the incident light is collected by a collection fibre 
that is offset from the light source. Spectra collected in this way are sensitive to the 
sizes, refraction indices and structures contained within sub cellular tissue components. 
A recent study used this technique to create a diagnostic algorithm based on the results 
of 331 negative and 30 positive lymph nodes. They went on to test an independent data 
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set of 129 samples at the time of surgery and achieved a sensitivity of 76% (69% with 
micrometastases) and a specificity of 96% at differentiating between positive and 
negative nodes (Keshtgar et al. 2010) (Figure 33 and 34).  
 
Figure 38- False colour coded scan of a node, using optical spectroscopy, showing a single metastasis 
alongside its histology (H and E) image ( Keshtgar et al. 2010).  
 
Figure 34- Mean elastic scattering Spectra from 331 normal nodes and 30 metastatic nodes with 
standard deviations (Keshtgar et al. 2010).  
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The authors recognised that the level of sensitivity achieved in this study is a potential 
limitation to the technique although it is comparable to results with both frozen section 
and TIC. They suggest improving their detection of positive nodes would require 
sampling of an increased area of the node. The results reported in the paper are based on 
the measurement of an area 10 x 10 mm x 0.5 mm. Using their current instrumentation 
this took 8 minutes to assess. If they were to assess multiple lymph node slices then they 
expect their sensitivity to increase but recognise that this will have a detrimental effect 
on the total assessment time.   
 
As has been discussed Infra Red (IR) Spectroscopy is often grouped with Raman 
spectroscopy under the title “Vibrational spectroscopy”. As previously noted, unlike 
Raman spectroscopy, for a molecule to be IR active the molecule must undergo a 
vibrational change that alters the dipole moment of the molecule. Thus vibrational 
changes not seen with Raman techniques can be seen with IR spectroscopy. However 
due to the effect of the IR activity of water the clinical in vivo applications of this 
technique are limited. However it can be used to interrogate desiccated tissue samples 
which provides biochemical information that maybe complimentary to that gained from 
Raman spectroscopy (Figure 34a). 
 
Fourier transform IR (FTIR), so called because of the mathematical technique that 
converts raw data into spectrum, has been used to analyse axillary lymph node tissue. 
Recent work highlighted the potential role of this technique in the identification of 
micro-metastases and isolated tumour cell in the axillary lymph nodes of patients with 
breast cancer.   
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Figure 34a- Spectra obtained from the same sections of human cervical tissue using Raman (blue) and IR 
(green) spectroscopy. This highlights the very different spectral information available from the two 
techniques and why they can be used as complimentary tools to each other (Adapted from images held 
within our own department). 
 
 
In this study 20 nodal tissue sections from 20 patients were cut from formalin fixed 
paraffin embedded archived tissue blocks. Spectra were collected in 6.25 μm steps such 
that a 1 mm x 1 mm tissue black was represented by 160 x 160 spectra. Higher cluster 
analysis was used to reproduce histological features of the cut lymph node surface 
(Figure 35) (Bird et al. 2009). 
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Figure 35 - FTIR Mapped images (centre and right) that show excellent correlation with the associated 
histology slide (left) (Bird et al. 2009).  
 
Good correlation was achieved in comparison to H and E slides of the same area. Using 
this technique macrometastases, micrometastases and isolated tumour cells were 
identified although no attempt was made at creating a classification model based on the 
results. 
 
The use of FTIR in the assessment of lymph nodes from other areas of the body has also 
been published. When used to differentiate between positive and negative lymph nodes 
from patients with oesophageal cancer sensitivities of 91% and specificities of 85% 
were achieved. Spectra from positive nodes displayed a greater contribution of protein 
and DNA than those spectra collected from negative nodes (Isabelle et al. 2008). FTIR 
was also used in a study that assessed the touch imprint samples collected during 
parathyroid surgery. The ability to correctly identify the parathyroid, thyroid or lymph 
nodes during a parathyoidectomy is vital and can often only be confirmed by the 
pathological assessment. Clear spectral differences were evident between these tissue 
types. In particular it was noted that the lymph nodes displayed strong lipid peaks at 
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1166, 1380, 1464 and 1748 cm
-1 
(Figure 36). The authors therefore suggest that FTIR 
could be used in conjunction with TIC to provide an automated and subjective method 
of tissue analysis (Das et al. 2007). 
 
Figure 36 - Mean FTIR spectra (bold black line in each spectra) of thyroid, lymph node and parathyroid 
tissue highlighting the distinct differences that allow for differentiation of tissue type (Das et al. 2007). 
 
 
2.5. Conclusions 
 
There is a strong base of knowledge that supports the use of Raman spectroscopy as a 
method of differentiating between normal and malignant tissue. It has consistently been 
shown that the key differences in the spectra obtained are an increased contribution of 
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lipid in the normal tissue relative to malignant tissue and an increased contribution of 
protein and DNA in the malignant tissue relative to the normal tissue. These results are 
supported by FTIR results in axillary, oesophageal and head and neck cancers. 
 
A number of groups are now trying to harness these techniques as a means of improving 
the management of breast cancer. This project will aim to build on these previous 
studies to demonstrate that Raman spectroscopy could be used within the theatre setting 
to assess axillary lymph nodes. If this is proven to be the case then Raman spectroscopy 
has the potential to be the first method that can fulfil all the features that were 
previously highlighted as the requirements of an ideal method of intra-operative 
analysis.  
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3. Towards using a probe in theatre. 
 
3.1. Introduction 
 
As discussed in the previous chapter earlier in vitro work has demonstrated the potential 
for the use of Raman spectroscopy to differentiate between malignant and non 
malignant lymph nodes in breast cancer (Smith 2005; Horsnell et al. 2011). However 
this work had a number of significant draw backs that would need to be overcome if 
Raman Spectroscopy were to be used in the clinical setting. 
 
1. The time taken for spectral acquisition – The mapping images previously used to 
differentiate between the two pathologies were obtained over time frames that 
would have precluded their use in an intra operative setting.  
 
2. The equipment used – Previous studies have utilised expensive laboratory based 
systems that would be beyond the reach of most surgical units. The footprint of 
the instruments would also have significant implications as safe and suitable 
storage facilities would be difficult.  
 
3. The environment – The previous work had been performed within a specialised 
spectroscopy laboratory in standardised conditions. If, as is envisaged, the node 
assessment were to take place within the operating theatre these conditions could 
not be easily replicated.  
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4. Exposure to node markers – The lymph nodes in previous studies were obtained 
following either axillary sampling procedures or during axillary dissections. At 
the time of that study SLNB was not routinely performed. As a result there was 
no dye used to identify the lymph nodes. There is significant concern with 
regard to the affect this will have on the diagnostic capability of the technique 
because dyes used to orientate the specimens within the lab demonstrated 
significant fluorescence.  
 
5. Sample preparation - Previous work has demonstrated the efficacy of Raman 
spectroscopy using sections of lymph node material. This would significantly 
add to the overall assessment time as well as render assessment within the 
operating theatre impossible without significant further investment in equipment 
and expertise. 
 
In this chapter experimental work will be presented  that has been designed to determine 
if and how these problems could be overcome. A key part in this has been the selection 
of the spectrometer. Therefore the probe based Raman spectrometer that was selected 
for use in this project will be described and its capabilities in this setting reviewed. 
Results of a small feasibility study that was performed using human axillary lymph 
nodes will be reported before concluding the chapter with some experiments that looked 
at the effect of the theatre environment on spectral acquisition. 
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3.2.  The Raman Spectrometer  
 
The first and most significant hurdle that had to be overcome in this project was the 
selection of equipment that could be used outside of the laboratory. As previously 
discussed mathematical modelling had suggested that a probe based system could be 
used to assess axillary lymph nodes rather than the more traditional mapping techniques 
that had been used in the past (Horsnell et al. 2011).    
 
The B&W Tek MiniRam II (B&W Tek, Newark, DE, USA) Raman spectrometer  was 
purchased for use in this project and is utilised in all of the experimental data reported 
in this thesis. This spectrometer features a 785nm laser with a spot size diameter of 
85μm and a maximum power of 300mW at the probe tip. The laser light is delivered via 
a hand held probe and a distance regulator, that fits the tip of this probe, ensures that 
samples are positioned 59mm from the tip of the probe. This distance has been 
determined by the manufacturer as the optimum position for spectral acquisition. 
Collected light is passed through a spectrometer that provided spatial resolution of 
10cm
-1
 with a built in thermo-electrically cooled CCD (Figure 37). The nominal ocular 
hazard distance was calculated at less than 10cm and was a key feature of the local rules 
that were designed for its use. 
 
The whole system is both lightweight and has a small footprint that would be ideal for 
use within the operating theatre setting (Figure 38). Further the price of the 
spectrometer, circa £12000, is significantly less than most laboratory based systems and 
the equipment used for intra-operative assessment based on molecular assays.  
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Figure 37 – A stylised diagram of the Raman spectrometer device. 
 
Figure 38- The B&W Tek © Mini Ram II on a standard theatre trolley, with a standard 30 cm ruler in the 
foreground illustrating the small footprint of the product. 
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To overcome any daily variation in spectral acquisition standard measurements were 
collected at each session.  Spectra from green glass, pipette tip, and cyclo-hexane were 
recorded and stored and then used later to calibrate the spectral data. A dark scan was 
recorded at the start of each session and is subtracted from the spectra recorded in the 
subsequent session. This overcomes the “hot” pixels on the CCD and is as per the 
manufacturers recommendations. 
 
3.3. Experiment 1 - Depth of Spectral Acquisition.   
 
Prior to embarking on clinical studies to ascertain the efficacy of the system if was felt 
that a greater understanding of the capabilities of the probe based system was required. 
As has been discussed previous work assessing axillary lymph nodes has been 
performed using Raman spectroscopy systems that collected spectral information from 
an area of 45 μm2 and from samples that were only 7 μm thick.  This would not be 
amenable to intraoperative use as the time taken to collect mapped images was between 
12 and 120 hours.  Further the time taken for tissue preparation would not be acceptable 
in an intra-operative setting and is one of the disadvantages of frozen section analysis 
that is used currently.  
 
When designing an ideal diagnostic tool it was felt that minimal tissue preparation 
would be desirable as this would reduce the time taken to output a result and reduce the 
need for added expertise and equipment. Thus the design of the clinical part of this 
study anticipated that the node would simply be denuded of surrounding axillary fat and 
then bisected. Spectra would then be acquired from the two halves of the node 
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individually. An appreciation of the depth from which the probe collected scattered light 
was vital both in samples with macrometastases and micrometastases (Figure 39). 
 
 
Figure 39- An illustration of the importance of sampling depth using a Raman probe to try and gain an 
appreciation of what might be “seen” using the system. 
 
3.3.1. Experiment 1 – Methods. 
 
To determine the depth from which the probe receives scattered light an experimental 
model was created. This was designed such that a standard material could be advanced 
towards the probe through a variety of different media. As demonstrated in figure 44 a 
standard 20ml syringe (BD, Oxford, UK) was used to contain the media being tested. 
Four experimental media, standard room air (i.e. an empty space), sterile water for 
injection (Baxter, Newbury, UK), standard olive oil (Napolina, Liverpool, UK) and lard 
(everyday value range, Tesco, UK) were used. 15 ml of each media (aside from the 
room air) was placed within the syringe whilst in a liquid state. Olive oil and lard were 
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chosen as they most closely resembled the fat composition of a lymph node. This 
composition has previously been estimated as containing 29% saturated fats, 57% 
unsaturated fats, and 9% polyunsaturated fats (Pond and Mattacks, 2003; US and 
Finnish Food Database 2009). 
  
A 1 mm
3
 block of PTFE was then placed on the surface of the media. This was attached 
to a translation stage (Thorlabs, Ely, UK) that allowed the block to be advanced in 
0.5mm steps through the media under investigation (Figure 40).  
 
Figure 40- The experimental set up to measure the depth from which spectral information is gathered 
 
In the first part of the experiment the PTFE block was placed at the maximal distance 
away from the probe tip (14.5mm) and then advanced in 0.5mm intervals. 5 spectra 
were obtained at each of these positions and the process was repeated for all 4 media. 
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The MiniRam II was used throughout and each spectra was obtained by combining 16 x 
1 sec acquisitions. Control spectra from each of the media and the PTFE were also 
recorded. In the second part of the experiment an attempt was made to approximate the 
volume from which spectral information was collected. The experimental set was 
modified so that the PTFE standard could be moved in both the z  (up and down) and y 
(side to side) plane. The chamber was filled with olive oil, which not only closely 
resembled the fatty composition of a lymph node but which also, due to its liquid state 
at room temperature was easiest to handle. 5 spectra were collected from 25 different 
positions. The PTFE block was moved in 1.0 mm steps to 4 mm from the optimum 
point in the z direction and 0.25 mm steps to 1mm offset in the y direction. The initial 
measurement was made with the PTFE block at 0mm offset in both the z and y plane. It 
was then moved in the y plane before being returned to the initial position and then 
moved in the z direction. Further spectra were obtained at each y position before 
returning to the y=0 position and altering the z position again. Spectra were obtained as 
described for the first part of the experiment and all data was then transferred to a 
desktop PC for interpretation using Matlab ® software. 
 
3.3.2. Experiment 1 - Results. 
 
Examination of the spectra from the PTFE block revealed a peak at 738cm
-1
 that was 
not present in any of the other control media. The intensity of this peak was calculated 
when the PTFE block was at the optimal distance from the probe tip (5.9 mm) in all the 
media. This figure was then used to calculate the relative intensity of the 738 cm
-1
 peak 
at increasing distances from the optimal point by calculating an intensity percentage at 
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each 0.5mm step in the first experiment and each position in the second experiment.  
These percentages were plotted to produce curves for the change in intensity with 
increasing offset for each of the four media (Figure 41, 42). In the curves the gradient of 
the slope has started to level out by 3mm from the optimal point of the probe although 
the clearest peaks are recorded at less than 1.5mm. The distinct differences seen using 
lard may have been explained by the solid nature of lard at room temperature. Thus 
maintaining a consistent volume of the media between the probe tip and the PTFE was 
difficult. The results of the second part of the experiment were plotted graphically to 
give a visual idea of the volume of tissue from which spectral information is collected 
using this system (Figure 44). It was evident that beyond 0.5 mm movement in the y 
direction there was no discernable contribution of the PTFE block.  
 
3.3.3. Experiment 1 – Conclusions. 
 
Although these results were part of an observational study they do allow some 
appreciation of the volume from which spectral information could be gathered using 
this MiniRam II system. Before proceeding to discuss the results further it is important 
to state that definitive interpretation of the results does need to be carried out cautiously 
as it is likely that the optical properties of a lymph node and media used in this 
experiment will differ. In particular the elastic scatter of tissue will cause many more 
transverse scattering events than these media and thus the results were used as a guide 
when discussing the technique with clinicians rather than an absolute. 
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 Within this media it is clear that beyond 3 mm depth the contribution of the PTFE 
block is negligible and that beyond 0.5 mm lateral movement the contribution is non 
discernable. This is the point beyond which any surface of the block is in line with the 
laser.  In this media as long as a part of the block is in line with the laser then spectral 
information will be acquired to a depth of 3 mm. Transposing this to tissue the best 
possible volume from which spectral information from a metastatic deposit could be 
detected is  given by the formula 
(π x (diameter of the deposit 2 )) x (height of the deposit +3 mm)  
If we relate this to a macrometastases, which by definition is at least 2 mm in diameter 
the maximum size of a node sample that a 2 mm deposit could be detected in is a node 
visualised as a cylinder of 4 mm diameter x 5 mm depth. The volume of tissue in which 
it will be detected is 62.8 mm
3
 (Figure 43, 44). 
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Figure 41- Changes in the Intensity of the 738 cm
-1
 peak at increasing offset from the probe tip in 4 
different media over a 15mm range. The clear drop off of the contribution of PTFE beyond 3mm is seen 
(shown more clearly in Figure 46). The very different plot for Lard may be explained by its solid state at 
room temp (see text). 
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Figure 42- Changes in the Intensity of the 738 cm
-1
 peak at increasing offset from the probe tip in 4 
different media as shown in Figure 41. In this figure this is shown over a 5mm range to give greater 
clarity.  
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Figure 43- An illustration of the total volume of tissue within which macro-metastases of at least 2mm in 
diameter could be detected (not to scale). 
 
Lymph node metastases are first found within the medulla of the nodes. It was thus 
decided that all nodes will be bisected and samples taken from the inner cut surface. 
Thus the MiniRam II should, if this model is projected forward, be able to detect all 
macrometastases in lymph nodes that are smaller or equal to 10 mm x 4 mm. This 
information was used to determine the clinical study design. It has previously been 
reported in a review of 1249 axillary nodes that 47% were less than 5 mm in diameter , 
34% were between 5 and 9 mm in diameter , 17% were between 10 and 20 mm and 2% 
were greater than 20 mm in diameter (Obweseger et al.2000). Therefore there was 
obvious concern that as a result macrometastases may be missed in 19% of nodes. It is 
reasonable to suggest that this situation would be mitigated because the first colonies of 
metastatic cells will establish themselves within the medulla of the lymph node and that 
spectra would be collected from the inner cut surface of the node. Further methods of 
increasing the volume of node assessed would be to divide the node into further 
sections. The tissue used in the real time clinical part of this study will be relied upon to 
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guide patient treatment. Further manipulation of the tissue was thus deemed 
inappropriate.  As will be discussed in Chapter 4, an alternative method of increasing 
the volume tested would be to collect spectra from both the inner and outer surface of 
the node. In this way it could be anticipated that the depth of collection may be doubled.   
 
Accepting the assumptions commented on above, for micrometastases, of at least 0.2 
mm in diameter the total depth of collection from a lymph node sample would be 3.2 
mm and the volume from which micrometastases could be detected would be only 0.8 
mm
3
. 
 
Figure 44- 3D plot demonstrating the intensity profile of the B and W Tek Miniram II as determined in 
the depth experiment. 
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3.4. Experiment 2 - Feasibility Study.  
 
Prior to launching into a theatre based study it was felt prudent that a feasibility study 
should be performed with the equipment that was planned to be used in the theatre 
setting. This not only allowed confirmation that the modelling studies were reproducible 
using an actual Raman spectroscopy probe but it also afforded  the opportunity to 
overcome any technical issues prior to carrying out spectral acquisition within the 
operating theatre environment.   
 
3.4.1. Experiment 2 – Methods. 
 
Following local ethical approval (approval code 01/158G – “The Development of 
Raman Spectroscopy in the Diagnosis of Breast Cancer”)  lymph nodes were collected 
from a small cohort of 20 consecutive patients presenting with newly diagnosed 
invasive breast cancer.  All patients were consented prior to taking part. They all 
underwent either a sentinel lymph node biopsy or an axillary node dissection as part of 
an operation that also included a wide local excision or a mastectomy to excise the 
primary breast tumour. These procedures were performed at Russell Hall Hospital, 
Dudley by a single consultant surgeon. Pre-operative preparation for the SLNB 
followed national standards. Not more than 24 hours prior to surgery patients received a 
peri-tumoral  injection of radio-labelled Technetium 
99m
 and immediately prior to 
surgery the surgeon injected patent V blue dye into the subcutaneous tissue overlying 
the tumour. 
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During the operative procedure the node was identified and its status as the sentinel 
node confirmed by measuring the radioactivity of the node, using a hand held gamma 
probe. The visual “blueness” of the node was also recorded on an analogue scale of 0-3 
(0= not blue, 1= faint blue, 2 = mild blue, 3= strong blue). The node was then excised 
and denuded of fatty tissue before being divided into two halves. One part was sent for 
routine histopathological examination and the other half was used for research purposes.  
 
The sample for research use was placed in a cyrovial, labelled and immediately 
immersed in liquid nitrogen. The sample was then transported to the histopathology 
laboratory at Russell’s Hall Hospital, Dudley. Here it was stored at approximately -48ºC 
prior to being transferred to the research department at Gloucestershire Hospitals NHS 
Trust. Once in Gloucester the nodes were stored within the pathology laboratory freezer 
at a temperature of -80ºC. Sections of each node were cut, according to local protocols, 
by staff within the pathology department for preparation of a standard H&E slide. These 
slides were examined by a consultant histopathologist to define the “gold standard” 
result for each of the nodes.  
 
The remaining tissue was transferred to the research laboratory where it remained 
frozen at temperatures of approximately -80ºC. This tissue was used for experiments 
using the portable Raman system. All samples used in these experiments were defrosted 
for 30 minutes at laboratory temperature (21ºC) prior to spectroscopic analysis within a 
laser laboratory. Following this spectra were collected as described in Chapter 4.2 for 
freshly excised nodes. Data was then transferred to a desktop PC and all spectra were 
pre-processed by a standard set of processes which will be discussed in more detail at 
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the start of Chapter 4. Matlab® software was then used to interpret the spectra. Mean 
spectra were calculated for each pathological group. Peak assignment was performed 
based on tables held within the department. The statistical significance of differences 
between the intensities of these peaks in each group was calculated using the Student’s 
t-test. Principal component analysis (PCA) and linear discriminant analysis (LDA) 
(details described further in Chapter 4) was then used to split the two groups and mimic 
a diagnostic process.  
 
3.4.2 Experiment 2 – Results. 
 
A total of 38 nodes were analysed in this study from 17 different patients (mean 2.35 
nodes, range 1-4). 25 of the nodes studied were reported by histopathology as negative 
(i.e. no metastases) and 13 were reported as positive (i.e. metastases present). All of the 
positive nodes were be defined as macrometastases. A total of 3602 spectra were 
obtained from the 38 lymph nodes assessed. A mean of 95 spectra were obtained from 
each node (range 25 -100 spectra) (Table 6).  
 
Nodal Status based on 
H and E assessment  
Total Number of Nodes Total Spectra Numbers Mean number of 
Spectra per node 
Negative 25 2384 95.4  
(Range 95 -100) 
Positive  13 1218 93.7  
(Range 25 -100) 
 
Table 6- Details of data included in the feasibility study split into two groups based on H and E 
assessment.  
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Figure 45- Mean spectra for nodes defined as normal (i.e. negative) (n=25, spectra=2384) and positive 
(i.e. contains metastases) (n=13, spectra=1218) by H and E assessment in the feasibility experiment. 10 
peaks identified using tables held within the department marked.   
The first stage in the analysis of this dataset was to calculate mean spectra for each of 
the two histological groups (Figure 45). 10 peaks across the spectra were identified and 
the intensities of these peaks were analysed to determine differences between the two 
histological groups (Figure 45).  The statistical differences between the intensities of the 
ten peaks in the two histological groups were calculated using the Student’s t-test (Table 
7). 
 
 
Peak 
Number 
 
Peak 
Position 
(cm
-1
) 
 
Mean Intensity of the peak 
in H and E defined negative 
samples 
(spectra no. = 2384) 
(SD and SEM) 
 
Positive Intensity of the peak 
in H and E defined positive 
samples 
(spectra no. = 1218) 
(SD and SEM) 
 
P Value 
(Student’s 
t-test) 
1 874 0.0367 
(0.003,0.00006) 
0.0366 
(0.002, 0.00006) 
0.2593 
2 1087 0.0421 
(0.0063, 0.00013) 
0.0426 
(0.005, 0.00015) 
0.0209 
3 1159 0.0222 
(0.0028,0.00006) 
0.0232 
(0.0026, 0.00007) 
0.0001 
4 1272 0.037 
(0.0053, 0.0001) 
0.0379 
(0.004, 0.0001) 
0.0001 
5 1305 0.051 
(0.01, 0.00024) 
0.0522 
(0.01, 0.0003) 
0.0033 
6 1444 0.0663 
(0.02, 0.0004) 
0.0677 
(0.017, 0.0005) 
0.0039 
7 1458 0.0521 0.0546 0.0001 
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(0.0132, 0.0003) (0.01, 0.0003) 
8 1530 0.0142 
(0.0032, 0.00007) 
0.0152 
(0.0028, 0.00008) 
0.0001 
9 1660 0.0327 
(0.0067, 0.00014) 
0.0331 
(0.0051, 0.00015) 
0.0754 
10 1751 0.0142 
(0.0011, 0.000023) 
0.0142 
(0.001,0.00003) 
1.0 
 
Table 7- The mean intensities of the 10 peaks labelled in figure 45 for H and E defined negative and 
positive nodes.. The p-values given by a Student’s t-test represent the statistical significance of the 
difference between the means of the intensities of each peak in the two histological groups (SD= standard 
deviation , SEM= standard error of the mean) 
 
Statistically significant differences were calculated for the intensities of 7 of the ten 
peaks. These peaks were at 1087, 1159, 1272, 1305, 1444, 1458 and 1530cm
-1
. These 
peaks may represent a variety of biochemical constituents including lipid, protein and 
nucleic acids. The implications of these differences will be discussed in greater detail 
when the results of the larger intraoperative study are discussed.  
 
In the second stage of spectral interpretation principal component analysis (PCA) was 
used to help separate the two histological groups. As is explained in Chapter 4.4.1.2 
PCA allows simplification of the data into fewer variables (loads) whilst retaining the 
overall information. Self programmed Matlab® functions were used to determine the 
loads and the contribution that they made to each spectra (scores). Differences in the 
scores for the first 10 principal components of each histological group where analysed 
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using a Student’s t-test and differences between the first 9 were shown to be statistically 
significant (Table 8). 
 
Principal 
Component 
(PC) 
Mean Value for the score of each PC  
in H and E defined negative nodes 
(spectra no.= 2384) 
(SD and SEM) 
Mean Value for the score of each 
PC  in H and E defined negative 
nodes (spectra no.= 1218) 
(SD and SEM) 
p value 
1 -0.0053 
(0.1588, 0.0032) 
0.0117 
(0.1348, 0.004) 0.0019 
2 -0.0056 
(0.121, 0.002) 
0.0125 
(0.0113, 0.00034) 0.0001 
3 -0.0015 
(0.014, 0.000281) 
0.0034 
(0.009, 0.0003) 0.0001 
4 -0.0018 
(0.0125, 0.0003) 
0.0041 
(0.0067, 0.0002) 0.0001 
5 -0.0009 
(0.0122, 0.0002) 
0.002 
(0.0063, 0.0002) 0.0001 
6 0.0007 
(0.0097,0.0002) 
-0.0016 
(0.007, 0.0002) 0.0001 
7 -0.0009 
(0.01, 0.0002) 
0.002 
(0.0046, 0.0001) 0.0001 
8 -0.0017 
(0.0069, 0.0001) 
0.0038 
(0.0076, 0.0002) 0.0001 
9 -0.0011 
(0.0067, 0.0001) 
0.0024 
(0.0073, 0.0002) 0.0001 
10 0 
(0.0033, 0.0001) 
-0.0001 
(0.01, 0.0003) 0.6649 
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Table 8- The mean value for the score of each principal component (PC) in H and E defined negative and 
positive nodes  in the feasibility study. The p-values given by a Student’s t-test represent the statistical 
significance of the difference between the means of the score for each PC in the two histological 
groups.(SD=standard deviation and SEM=standard error of the mean) 
The loads relating to each of the principal components were plotted and although 
spectral features became increasingly difficult to differentiate from noise beyond the 
first 3 principal components (PCs) clear features were seen in the loads of the first two 
principal components (Figure 46, 47 and 48). 
 
The plot for the load of principal component (PC) 1 bears distinct similarities to 
spectrum of fatty acids, particularly mono-unsaturated fatty acids such as oleic acid. 
This is consistent with previously published work (discussed in Chapter 2) that 
demonstrated a difference in the concentration of fatty acids in malignant tissue. This is 
explored more in the intra-operative work in Chapter 4. 
 
The key question that this feasibility study sought to answer was how successful the test 
was at differentiating between negative and positive nodes. Initially an attempt was 
made to split the two groups based on the scores of the most statistically significantly 
principal component, PC2. Whilst there was a degree of overlap this PC alone achieved 
a sensitivity of 69.3% and a specificity of 77.2% at differentiating between the two 
pathological groups (Figure 49). 
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Figure 46- Spectral plot of the load for principal component 1 in the feasibility study, some peaks marked 
for clarity. The contribution that this load made to the overall spectra is given by the scores (see table 8). 
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Figure 47- Spectral plot of the load for principal component 2 in the feasibility study, some peaks marked 
for clarity The contribution that this load made to the overall spectra is given by the scores (see table 8). 
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Figure 48- Spectral plot of the load for principal component 3 in the feasibility study some peaks marked 
for clarity. The contribution that this load made to the overall spectra is given by the scores (see table 8).  
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Figure 49- Histogram plotting the scores for principal component 2 of both H and E defined negative 
nodes (green) and positive nodes (red) in the feasibility study to demonstrate its ability to divide the two 
groups. 
 
In the third phase of spectral interpretation linear discriminant analysis (LDA) fed by 
the principal components was used to improve the separation of the two pathological 
groups by providing a supervised classification algorithm (as is explained further in 
Chapter 4). In this calculation the first 25 principal components were used. The results 
of this analysis revealed a sensitivity and specificity of differentiation between the two 
groups of 95.7% and 98.9% respectively (Table 9) (Figure 50). This is clearly 
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comparable with many of the current methods of intra-operative analysis and strongly 
supports the potential of this technology in that role.  
 
 H and E defined 
Positive Nodes 
H and E defined 
Negative Nodes 
 
Raman Spectra ( Positive) 
 
1166 
 
26 
 
Raman Spectra (Negative) 
 
52 
 
2358 
  
Sensitivity =95.7% 
 
Specificity=98.9% 
 
Table 9- The sensitivity and specificity achieved in the feasibility study on an individual spectral basis 
using linear discriminant analysis fed by the principal components. 
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Figure 50- Histogram plotting the scores for the linear discriminant analysis fed by the principal 
components of both H and E defined negative (green) and positive (red) nodes in the feasibility 
experiment . 
 
The influence of each of the principal components in achieving this result were assessed 
by repeating the LDA calculation with increasing numbers of PCs , starting with just 
the first PC. These training results achieved a sensitivity and specificity of >90% using 
only the first 8 PCs although the best results were achieved when all 25 PCs were 
included (Figure 51). 
 
In the fourth stage of spectral interpretation the strength of these findings were 
scrutinised using a leave one node out validity test. Initially all spectra from one node 
were removed and individual spectra projected onto the training set using 25 principal 
components. This demonstrated that Raman spectroscopy was 75% sensitive and 94% 
specific when differentiating between normal and metastatic tissue for this dataset. This 
remains comparable to the sensitivities and specificities achieved for other intra-
operative techniques; particularly frozen section analysis and touch imprint cytology, 
but a larger dataset would be expected to improve upon these results. 
 
116 
 
0
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
Principal Components
Percentage 
Sensitivity
Specificity
Figure 51- Sensitivity and specificity at splitting H and E defined negative and positive nodes in the 
feasibility study using  increasing numbers of principal components in the linear discriminant analysis. 
 
To help simulate acquisition of data in a time frame that was suitable for intra-operative 
use the next section of analysis went on to alter the numbers of spectra from each node 
that were included in the analysis. 5, 10 and 25 spectra from each node were randomly 
selected from the total spectra acquired from each node. These numbers were selected 
following discussions with the clinicians involved in the project. Data related to current 
techniques and surgical experience suggests that there would be approximately 40 
minutes per patient to process and assess all the nodes sampled. If up to 5 nodes were 
sampled from each patient and divided into two then there would be less than 4 minutes 
to prepare and assess each sample It was important therefore to appreciate the affect 
that smaller spectral numbers would have on the results achieved. 
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A Matlab® programme was written that randomly selected 5, 10 and 25 spectra from 
the total spectra sampled from each node. These were then used to create a mean 
spectrum for each sample. The sensitivity and specificity of the test based on the results 
of PCA fed LDA and leave one node out cross validation was then calculated based on 
mean spectra containing 5, 10 and 25 spectra each (Table 10). 
 
  
5 spectra per node 
 
10 spectra per node 
 
25 spectra per node 
 
Sensitivity 
 
77% (10/13) 
 
85% (11/13) 
 
92% (12/13) 
 
Specificity 
 
96% (24/25) 
 
100% (25/25) 
 
100% (25/25) 
 
Table10-The sensitivity and specificity achieved in leave one node out cross validity testing using a range 
of spectra per node.  
 
In the final stage of analysis the above results from 5 spectra per node (Table 10) were 
used to mimic the clinical scenario in which the system might one day be used. Of the 
17 patients included in the feasibility study, 11 had a negative axilla (i.e. all nodes 
negative) and 6 had at least one node positive (range 1-4). If any of these nodes 
sampled were found to have evidence of metastases then an axillary node clearance 
would have been recommended. Using the data presented here, 5 out of the 6 patients 
who were advised to have an axillary clearance post operatively would have been 
successfully identified and been able to receive the benefits of an immediate rather than 
a delayed axillary clearance. One patient with a single positive node would initially 
been deemed to have a negative axilla only to have this changed on post operative H 
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and E analysis. Of the 11 patients with negative axilla none would have been 
recommended an axillary clearance based on the Raman results (Table 11). The only 
false negative was in a node from a patient with other positive nodes. One possible 
explanation for this could be that the H and E analysis had missed a metastasis which 
was then picked up by the Raman analysis.  
 
  
H and E defined 
Positive Axilla 
 
H and E defined 
Negative Axilla 
 
Raman Positive Axilla  
 
5 
 
0 
 
Raman Negative Axilla 
 
1 
 
11 
  
Sensitivity = 83% 
 
Specificity=100 % 
 
Table 11: The sensitivity and specificity achieved in the feasibility study at identifying positive and 
negative axilla using Raman spectroscopy.  
 
3.4.3 Experiment 2 – Conclusions.  
 
Given the sensitivity and specificity achieved both with PCA fed LDA (supervised 
testing)  and leave one node out cross validation (unsupervised testing) it was  felt that 
these results support the potential of a hand held Raman spectroscopy device for use in 
the intra-operative assessment of axillary lymph nodes. Importantly the feasibility study 
also enabled one to demonstrate that equivalent results could be achieved by selecting a 
smaller subset of spectra from each node. Even when only 5 spectra per node were 
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assessed the sensitivity and specificity remained consistent. Given the pressures on time 
that are going to be evident when using fresh tissue in a clinical setting this is an 
important concept to demonstrate. Importantly if Raman spectroscopy had been used to 
guide management 5 patients would have benefited from immediate axillary surgery 
and none would have been advised to have an axillary clearance that later was deemed 
to be unnecessary.  
 
3.5. Experiments 3 and 4 - Overcoming the effects of operative theatre lighting  
 
Encouraged by the results of the feasibility study planning of an intra-operative study 
using the portable probe Raman spectroscopy system continued. One of the key 
problems that needed to be overcome if this was going to be possible was the effect of 
theatre lighting on the spectra obtained. The first step in this process was understanding 
the nature of theatre lighting. Lighting within the operating theatre includes both the 
general illumination as well as the operating lights. The illumination of the surgical site 
is vital to optimise the surgeon’s view of the operating field and operating lights are 
therefore specifically designed to meet this goal.  
 
The majority of operating field illumination is provided by overhead lights. These are 
often white fluorescent but may also be incandescent. Whilst the level of general 
illumination should be at least 200 foot candles (2095 lux) to allow the theatre staff 
including the anaesthetist to work safely the surgical lights should be in the range of 
2500-27,000 foot candles (26,190-290,628 lux) (Berry and Kohn 2000). These lights 
need to be able to provide contrast between both tissue types and tissue depths without 
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casting shadows and focused in such a way as to avoid a dark centre. There are a wide 
variety of different lights marketed by an array of different companies. Not only do the 
lights in different theatres vary but the way the lights are set up and used also varies. 
41% of German surgeons report that they use a single main light with a smaller satellite, 
43% use two equally sized large lights and 16% use three equally sized large lights 
(Matern and Koneczny 2007). Further complicating this is the preference of some 
surgeons to operate with low levels of ambient or general light whilst others maintain 
the general lighting throughout the procedure. Many UK hospitals have developed in 
stages over a number of years with new operating suites added as the need arose. As a 
result operating suites will have a variety of different theatre lights within a single 
hospital.  
 
Background lighting has an adverse effect on Raman spectroscopy as it is recorded at 
intensities that swamp the low intensity of Raman scattered light. The spectral 
acquisition from biological tissue is often performed in darkened laser laboratories. 
Providing mechanisms to exclude background light is vital to the effective functioning 
of an intra operative Raman device.  
 
Potential solutions included switching all the theatre lights off to create a darkened 
environment or applying filters to all the lights.  Creating a darkened theatre was 
rejected due to the potential negative consequences this may have for the patient and the 
safety implications for the theatre staff. The application of filters to all the theatre lights 
was considered impractical because of the variety of theatre light designs in use, as well 
as the problems with infection control and the possibility of surgical site contamination 
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if the filter were to become loose. An alternative was theorised based on excluding the 
light from the immediate area around the probe tip. In this way the device could be used 
in all lighting conditions within the operating theatre without the potential deleterious 
side effects. 
 
3.5.1. The Light Eliminator design 
 
The basis of the design was the standard film case used to prevent light contamination. 
This was modified to allow the Raman probe to be housed within it. The design of the 
probe includes a tip that ensure the optimal positioning of the matter being investigated 
when it is in contact with the tip. A removable lid allows the matter to be positioned in 
the correct position (Figure 52, 53). 
 
3.5.2. Experiment 3 (The Light Eliminator Experiment, Part A) – 
Methods. 
 
The light eliminator was first tested within the operating theatres at Gloucestershire 
Royal Hospitals NHS Foundation Trust. Prior to its use within this environment local 
rules were designed to ensure safe use and the experiments were carried out at times 
when the operating theatres were not in clinical use.  
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Figure 52 Outline design drawings for a light eliminator (not to scale)(left) and photograph of the Light 
eliminator in place over the end of the probe tip(right).  The probe is held facing upwards. The sterile 
sheath is placed around it and the eliminator is then placed over this. The tissue can then be placed on 
the central flat surface and a light resistant lid placed and secured. . 
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Using the MiniRam II Raman spectrometer spectra were obtained from a standard block 
of PTFE. This block measured 2cm x 1cm and was used due to its clear and 
characteristic peaks. This is used as a standard measurement by the research group. 
Theatre temperature was maintained at 22 ºC throughout the experiment and the laminar 
ventilation system was switched off. The spectroscopy device was placed on a standard 
theatre trolley in the corner of the theatre approximately 3m away from the operating 
table, a position that may be mimicked when the device is used in the intra-operative 
setting. 
 
Spectra were obtained in four lighting conditions.  
1. Background lights and operating lights on. 
2. Background lights on and operating lights off. 
3. Operating lights on and background lights off. 
4. All lights within the theatre switched off. 
 
In each of these situations 10 spectra were recorded (by combining 16 1s acquisitions) 
both with and without the light eliminator device in situ. The data were transferred to a 
desktop PC and analysed using Matlab®  software.  
 
3.5.3. Experiment 3 – Results. 
 
The mean plots of spectra obtained without the eliminator demonstrated the deleterious 
effects of both the background and operating lights (Figure 54). The spectra obtained 
when the operating lights were on demonstrated saturation of the CCD and there were 
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multiple additional peaks in the spectrum obtained with only the general lights on. 
These results confirm that both the theatre lights and the general lighting make 
interpretation of the PTFE spectra either very much more difficult or impossible. Given 
the relatively high intensities of the PTFE peaks it is likely that this would be replicated 
or indeed made worse when using biological specimens.  
 
The effect of the eliminator in this observational study was evident when the mean 
spectra of the data were plotted for the four lighting settings both with and without it in 
place (Figure 55). It was thus hoped that the light eliminator would facilitate the use of 
the MiniRam II Raman spectrometer within the operating theatre. Due to the prominent 
PTFE peaks further experiments were designed to assess the effect of the light 
eliminator when using biological tissue.  
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Figure 54- Mean spectra (n=10) for PTFE from four lighting conditions collected in an operating theatre 
to demonstrate the deleterious effects of background and operating lights. 
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Figure 55- Mean spectra (n=10) for four lighting conditions both in the presence of the light eliminator 
(left) and without it (right) (y axis = intensity AU and x axis = Raman Shift cm
-1
). 
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3.5.4. Experiment 4 (Light Eliminator Experiment Part B) – Methods.  
 
To determine the effect of the eliminator when obtaining spectra from biological tissue 
the device was tested within the laser laboratory using axillary lymph node tissue rather 
than PTFE. A single lymph node that had been collected and stored as part of the 
feasibility study was used. This node was not included in the feasibility study but its 
handling both at the time of collection and during the experiment was a described in 
Chapter 3.4. Standard laboratory conditions were maintained except for the switching 
on of all the lights as required by the experiment. 
 
16 x 1 second acquisitions were used to collect 5 spectra from the node using the 
MiniRam II Raman spectrometer. These were obtained in the following conditions;  
 
 Standard laboratory conditions (all lights off). 
 Standard conditions with lights on. 
 Standard conditions with lights on and using the eliminator device. 
 
The data was then transferred to a standard desktop PC and interpreted using Matlab ® 
software. Principal component analysis, ANOVA analysis and Student’s t-tests were 
used to assess the results. 
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3.5.5. Experiment 4 – Results. 
 
Examination of the resulting spectra demonstrated that the spectra obtained in standard 
laboratory conditions were markedly different to the spectra obtained with the lights on. 
As expected the spectra obtained with the lights on, but without the eliminator, were 
overwhelmingly dominated by peaks resulting from the laboratory lights (Figure 56). 
 
The spectra obtained with the eliminator in place appeared very similar to the spectra 
obtained under standard laboratory conditions. There were differences in intensity and it 
was felt that this may represent the different orientation of the node which had been 
repositioned during the experiments (Figure 57a). 
 
The principal components of the three sets of spectra were then calculated using self 
built programmes in Matlab®. An ANOVA calculation was performed on the scores of 
each principal component to determine which the most significant principal components 
were. PC 1 and 2 were calculated to have f values of 110686 and 115 respectively. The 
loads that pertained to these PCs were plotted and it was evident from inspection of 
these plots that PC1 related to that of the laboratory lights and that PC2 related to that of 
the lymph node spectra (Figure 58). 
 
When the scores for PC1 were plotted it could be seen that the eliminator had been 
successful at eliminating the light as the scores for both the spectra taken with the light 
turned off and those taken with the lights on were very similar (Figure 59). 
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Figure 56- Mean spectra collected from an axillary lymph node (n=5) under standard laboratory 
conditions and with lights on.   
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Figure 57- Mean spectra (n=5) collected from an axillary lymph node under standard laboratory 
conditions and with the laboratory lights on with the light eliminator. 
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Figure 58- Spectral plots of the loads for principal components (PC) 1 and 2 in experiment 4. PC1 
appears to be representative of the laboratory lights and PC2 resembles the spectra that are obtained 
from an axillary lymph node.  
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Figure 59- Plot of the scores for PC1 in all lighting conditions in experiment 4. The circles are to 
emphasise the differences and similarities in the data plotted. The results of the statistical analysis of 
these results are shown in table 12. 
 
Statistical analysis using Students t-test confirmed that there was no statistically 
significant difference between the score for PC1 in the standard laboratory and lights on 
and eliminator group (p=0.13). There was however statistically significant differences 
between both of these groups and the lights on and no eliminator group (Table 12). 
 
It was thus felt that these results demonstrated that the eliminator would allow the 
portable Raman spectroscopy device to be used in theatre without the need to turn the 
lights in the whole theatre off.  
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Comparison 
Mean for the score of PC1 in each group 
(n=5) 
(SD and SEM) 
 
p value 
 
Standard laboratory conditions 
 v.  
Lights on (no eliminator) 
 
0.349 (0.001, 0.00045) 
 v 
0.661 (0.004, 0.002) 
 
 
p<0.0001 
 
Standard laboratory conditions 
 v.  
Lights on (with eliminator) 
 
0.349 (0.001, 0.00045)  
v.  
0.347 (0.005,0.001) 
 
 
p= 0.1303 
 
Lights on (no eliminator) 
v.  
Lights on (with eliminator) 
 
0.661 (0.004, 0.002)  
v.  
0.347 (0.005,0.001) 
 
 
p<0.0001 
 
Table 12: A comparison of the mean score (n=5) for PC1 in each of the three lighting conditions in 
experiment. The results of statistical analysis, using a Student’s t-test, to compare these results are shown  
(SD= standard deviation, SEM= standard error of the mean). 
 
3.6. Experiment 5 -Effect of theatre temperature variations.  
 
Having determined an effective way of overcoming the effects of theatre lighting the 
next variable that needed to be explored was that of temperature variations within the 
operating theatre. Previous work using Raman spectroscopy to assess axillary lymph 
nodes has been carried out in a laser laboratory where the temperature was regulated to 
remain at 21ºC. The ambient temperature of an operating theatre may vary as a result of 
the need to maintain the patient’s temperature throughout an operation. The importance 
of altering the theatre temperature is demonstrated by figures that suggest that up to 
70% of patients may experience a degree of inadvertent hypothermia during an 
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operative procedure (Burger and Fitzpatrick 2009). Not maintaining a suitable ambient 
temperature within the operating theatre was one of the key factors linked to this 
inadvertent hypothermia (Young and Watson 2006). 
 
A review of the literature pertaining to ambient temperature published in 2006 
suggested that an ambient temperature of at least 22°C should be maintained with some 
authors suggesting temperatures of up to 26°C (Young and Watson 2006). The 
importance of maintaining the balance between the patient’s core temperature and the 
ability of the surgical team to operate is recognised by the authors especially as the 
temperature rises above 22°C. Most surgeons prefer to operate at temperatures between 
18.5 and 22°C (Brock 1975). American guidelines for the prevention of surgical site 
infection published in 1999 suggest a slightly higher ambient temperature of between 
68-73°F (20-23°C) (Mangram et al. 1999). Given these competing interests it may be 
that ambient theatre temperature would vary both throughout a single operation and 
across different days.    
 
3.6.1. Experiment 5 – Methods. 
 
This experiment investigated the effects of varying the temperature across a range of 
18-28°C so as to over represent the anticipated ambient temperature range that intra 
operative spectral analysis would take place within. All experimental measurements 
were recorded within a laser safe laboratory which has a temperature control facility 
that allowed the room to be both cooled and heated. The instrumentation within this 
system allowed both the room temperature to be selected and then monitored to 
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maintain the desired setting. The temperature of the room is normally set at 21°C. 
Spectra of cyclo-hexane were obtained across the seven temperatures starting at 18°C 
and rising in 2°C intervals to reach 28°C. The temperature within the room reached the 
new temperature setting within 15 minutes. A period of 30 minutes was allowed 
between temperature alterations to ensure that a stable temperature had been achieved. 
All other factors within the room were kept stable. Five spectra of cyclohexane were 
recorded at each of the six temperature settings. Data analysis was performed using 
Matlab® mathematical software. The statistical significance of any observed differences 
was tested using ANOVA analysis. 
 
3.6.2. Experiment 5 – Results. 
 
Inspection of the mean spectra for each temperature revealed very few changes. As 
expected for cyclohexane four very distinct peaks were visible in the range of 750-1500 
cm
-1 
(Figure 60). The position of each of the 4 most prominent peaks (labelled in Figure 
60) were recorded to ensure there was no peak position drift over the temperature range 
(Figure 61). 
 
To assess the mean peak position at 6 different temperatures ANOVA, a statistical test 
that simultaneously compares two or more means, was employed to determine the 
statistical significance of the small shifts that had been observed. In this test the null 
hypothesis was that there was no difference between the peak positions at the six 
different temperature points. Using standard tables the critical “f” value at which the 
null hypothesis would be rejected can be calculated.  
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Figure 60- Mean spectra (n=5) of cyclo-hexane recorded at 6 different temperatures. The four prominent  
peaks are labelled A-D. 
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Figure 61- Mean peak position (n=5) of the 4 cyclo-hexane peaks (labelled in Figure 60) across the 
temperature range 18 -28ºC). 
 
The position of peak A was the only one that recorded an f value greater than the critical 
value. The relative peak positions of the 4 peaks were then calculated. The null 
hypothesis that there was no difference between the relative positions of the 4 main 
peaks at the level of p<0.01 was not rejected in any of the calculations (Table 13).  
 
This data demonstrated that across a range of temperatures, that correlate with those 
found in the operating theatre, the positions of each of the four main cyclo-hexane peaks 
did not significantly differ in relation to each other. Indeed the position of peak A, 
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which was shown the only peak to record a statistically significant shift only, alters by 
1cm
-1
. Discussion within the research group suggested that this degree of shift is not 
significant when comparing spectra recorded on multiple occasions. It was therefore 
concluded that the equipment could be used without significant peak shifts due to 
variations in theatre temperature. 
 
Relative Peak Position f -value 
D:A 1.5417 
D:B 0.3655 
D:C 1.6857 
C:B 0.7158 
C:A 2.5333 
B:A 2.7733 
The critical f-value above which the null 
hypothesis is rejected = 4.1 
 
Table 13- F values for the relative positions for each of the four cyclo-hexane peaks. As all the f values 
were less than 4.1 the null hypothesis, that there no difference between the relative peak positions related 
to temperature changes, was accepted. 
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3.7. Experiment 6 - Maintaining Sterility. 
 
One of the significant concerns of the surgeons involved with this study was the need to 
maintain sterility particularly if the device was to be used in an intra-operative setting. 
This is of course vital to ensure there is no cross contamination from one lymph node to 
the next as this could lead to false results.  Further to this it is anticipated that in the 
long term the device will be held by the operating surgeon possibly with the node in 
situ. It must therefore also remain sterile to prevent cross contamination of the operative 
field.  
 
3.7.1. Experiment 6 – Methods. 
 
To meet the requirement for sterility a sterile sheath that is designed for use with a hand 
held ultrasound probe was identified. The JAD01 ultrasound cover (Jade Medical, RG8 
9EX, UK) was used as it was readily available and due its primary purpose had a design 
that was easily adapted for the Raman probe. It is made of latex free polyurethane and 
measures 6 x 33 inches (Figure 62). 
 
The sheath was placed over the whole Raman probe and secured in place with sterile 
rubber bands that are supplied in each pack. The light eliminator was then placed over 
the top of this. Any material being measured is only in contact with the sterile sheath. 
An added advantage of mounting the sheath in this way was that small nodes could be 
placed over the aperture of the inverted probe spacer without risk of them falling though 
into the space above the probe tip. 
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Figure  62- The JAD01 sterile sheath used in  experiment 6. 
 
Spectra (made up of 16 x 1sec. acquisitions) were obtained from a standard block of 
PTFE using the B&W Tek MiniRam II within a laser laboratory. The first ten spectra 
were obtained under standard conditions and the second 10 spectra were obtained with 
the sterile sheath in place (Figure 63). Data were transferred to a standard desk top PC 
and interpreted using Matlab® software. ANOVA statistical analysis was then 
performed to assess the positions of the 4 most prominent peaks in the PTFE spectra. 
 
A further study was set up to ensure that there was no variation between the use of 
different sheaths as it was envisaged that a separate sheath would be used for each 
patient. 5 spectra were acquired from the same standard block of PTFE with the sheath 
in place. This was repeated with 10 different sterile sheaths from two different batches. 
Data interpretation took place using Matlab® software. 
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3.7.2. Experiment 6 – Results. 
  
Analysis of the data from the first part of the study, using ANOVA, revealed no 
statistically significant shift in the PTFE peaks. There were no additional peaks present 
in the spectra obtained whilst using the sterile sheath. Similarly analysis of the 50 
spectra collected in the second part of the experiment revealed that there was no 
significant shift in the position or intensity of the 4 most prominent PTFE peaks 
(labelled A, B, C, and D in Figure 63). Further there was no additional peaks evident for 
any of the 10 different sheaths used.  
 
It was thus concluded that the sterile sheath had little or no effect on the spectra 
collected. It would therefore be used throughout the intra operative work and to 
maintain sterility and avoid cross-contamination it would be changed after each patient. 
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Figure 63- All spectra (n=20) of PTFE collected in the presence and absence of a sterile sheath to 
demonstrate the consistency of the spectra obtained. The 4 most prominent peaks of PTFE are labelled 
(A-D). There was no significant difference between the position or intensity of these peaks. 
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3.8. Experiments 7 and 8 -The effect of Patent V Blue Dye. 
 
A critical part of the SLNB procedure is the correct identification of the axillary sentinel 
node. As has been described, the identification of the node involves a combination of a 
radio-labelled colloid and a visible dye. Locally a combination of technetium
99m
 
labelled colloid and Patent V blue dye is used as per the national guidelines 
(Somasundaram, Chicken and Keshtgar 2007). Previous work has demonstrated that the 
presence of marker dyes used to orientate samples saturated the spectra obtained (Smith 
2005). At that time sentinel node biopsy was not being performed routinely and the 
nodes used in that study had not been exposed to blue dye. Given that the use of Patent 
V blue dye is a standard part of the procedure it was vital to assess the effect that its 
presence would have on the spectra that we obtained.  
 
3.8.1. Experiment 7 – Methods. 
 
Samples of the Patent V Blue Dye (2.5%) (Guerbet, Roissy, France) routinely used in 
SLNB were obtained. There is no published data documenting the concentration of the 
blue dye within the axillary lymph node itself after it passes from the breast down the 
lymphatic channels. Clinically surgeons refer to the nodes on an analogue scale of 0-3 
dependent on the degree of “blueness” of the excised node. The only previous work 
which estimated the concentration of dye in breast tissue reported a concentration of 
0.08% of methylene blue in the tissues after injection of 0.1 ml of 1% of this dye 
(Hirsch et al. 1989). It is likely that the concentration of blue dye will be further diluted 
by the time it reaches the lymph node. Given that there was no definitive data 
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documenting the concentration of blue dye within the node experiments were planned 
that used concentrations greater than and including 0.08%.  
 
To help determine the effect of this blue dye an experiment involving thirty 1cm
3 
cubes 
of chicken breast (Tesco, UK) that had been dissected to mimic the size of a newly 
excised lymph node was set up. The 2.5% Patent V Blue Dye was diluted using Water 
for Injection (Baxter, Newbury, UK) to 1.25%. 0.63%, 0.31%, 0.16%, and 0.08%. Five 
chicken cubes were placed in a tube containing 10 mls of one of the five solutions and a 
further five cubes were placed in 10 mls of water for injection. These tubes were then 
left at room temperature for a period of 24 hours. At the end of this period the chicken 
cubes were removed from the tubes and placed on a new Petri dish.  
 
9 spectra were obtained from each of the 30 chicken cubes using the same technique as 
for axillary lymph nodes described in Chapter 4. The spectra were then transferred to a 
desktop PC and interpreted using Matlab® software. Principal component analysis and 
ANOVA was used to assess the differences between the different blue dye 
concentrations and the controls.  An unpaired t-test was used to determine the statistical 
significance of the differences in the PC scores between the groups. 
 
3.8.2. Experiment 7 - Results. 
 
A total of 270 spectra were included in data interpretation. The mean spectra (n=45) for 
the different concentrations of blue dye were calculated and compared to spectra of blue 
dye previously published (Stropp et al. 2003) (Figure 64). Analysis of this spectrum, 
145 
 
obtained with an excitation wavelength of 514.5nm using surface enhanced Raman 
spectroscopy techniques, revealed significant peaks at 1210 cm
-1
, 1432 cm
-1
 and 1620 
cm
-1
. Similar peaks were observed in the spectra recorded from the chicken samples that 
had been prepared in Patent V blue dye (Figure 64). Analysis of the spectra obtained 
from the controls without the presence of blue dye was characteristic of that from 
chicken breast with three evident peaks at 1328, 1455 and 1660 cm
-1
  ( Beattie et al. 
2006; Beattie et al. 2007) . 
 
Following principle component analysis statistical testing using ANOVA calculations 
revealed that the first principal component was the most significant at differentiating 
between those spectra obtained in the presence of blue dye and those without ( f value 
>1700). The scores obtained for the first principal component were plotted and showed 
a clear difference between the two groups (Figure 65). This was confirmed with 
statistical analysis (Table 14). 
 
Mean value (and SD and SEM) of the 
score for PC1 (all blue dye concentrations) 
(n=225) 
Mean Value (and SD and SEM) of the score 
for PC1 (all controls) 
(n=45) 
p Value 
-0.0359 
(0.0121, 0.0008) 
0.1673 
(0.015, 0.0022) 
<0.0001 
 
Table 14: The mean value for the score of PC1 in experiment 7 in samples exposed to blue dye v controls. 
The difference was highly statistically significant using an unpaired t-test. .  
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Figure 64-  Mean spectra (n=45) obtained from 1 mm
3
 chicken breast after 24hours in 5 concentrations 
of Patent V blue dye (right) compared to published spectra for patent V blue dye (left) (Stropp et al. 
2003). 
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Figure 65- Histogram plotting the score for PC1 for all spectra (n=270) in experiment 7. This 
demonstrates the clear separation of the scores for PC1 between the controls (red, n=45) and those 
exposed to blue dye (green, n=225). 
 
Analysis of the load associated with this principal component was very similar to that 
obtained from the control chicken cubes (Figure 66). This data suggested that all the 
spectra obtained in the presence of the blue dye were representative of the dye alone and 
this masked the spectral features of the underlying chicken breast. This would have a 
hugely detrimental effect on the proposed study as in the presence of blue dye the 
underlying spectral features of the tissue might be lost and any spectral differences seen 
in the tissue itself would be difficult to appreciate.  
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Figure 66 Mean spectra for controls (n=45) (blue) and plot of the load for principal component 1 in 
experiment 7.   
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These data cast significant doubt on the validity of Raman spectroscopy at 
differentiating between abnormal and normal lymph nodes in the presence of blue dye. 
However the method of preparation of the tissue in this experiment is very different to 
the processes which would transport the blue dye to the lymph node in vivo. It may be 
that the spectral features related to the blue dye on the surface of the chicken specimens 
rather than that which had diffused into the chicken tissue itself. This situation would 
not occur in the lymph node where the blue dye will arrive via the lymphatic system and 
then percolate its way through the node.  
 
3.8.3. Experiment 8 – Methods. 
 
Further studies to investigate this effect were evidently required. The results of the 
feasibility study were therefore reviewed to assess the affect of the patent V blue dye 
used (further details of the methodology of collecting and assessing the lymph nodes 
are contained in Chapter 3.4). In the feasibility study 11 nodes had been acquired during 
a sentinel lymph node biopsy and 27 had been collected during an axillary dissection. 
As part of the standard SLNB procedure the “blueness” of the node is recorded after it 
is excised from the patient. All the nodes in the feasibility dataset were rated on an 
analogue scale of 0 to 3 by the lead surgeon at the time of surgery (0 = no blue, 1 = 
faint blue, 2 = moderate blue and 3 = strong blue).  It was therefore possible to create a 
dataset that included nodes that had no exposure to blue dye at all and those with 
visually increasing concentrations of blue dye (Table 15). In addition to this 60 spectra 
were obtained, by the same methodology, from standard samples of 2.5% Patent V blue 
dye (Guerbet, Roissy, France). All the spectra were assessed using Matlab® software. 
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Principal component analysis was performed along with ANOVA statistical testing to 
determine which of the principal components was statistically most significant at 
differentiating between the groups.  The statistical significance of the difference in the 
mean scores for this PC was then confirmed using an unpaired t-test. 
 
Blueness of Node Number of Nodes Number of Spectra 
 
0 
 
27 
 
2448 
 
1 
 
4 
 
394 
 
2 
 
3 
 
291 
 
3 
 
4 
 
391 
 
Table 15- Numbers of nodes and total spectra in each group in experiment 8 (blueness measured at the 
time of surgery by the operating surgeon; 0 = no blue on visual inspection or not exposed to it, 1 = faint 
blue, 2 = moderate blue and 3 = strong blue) . 
 
3.8.4. Experiment 8 – Results. 
 
A total of 3584 spectra were included in the dataset. Principal component analysis was 
performed on the dataset to identify the principal component that was associated with 
blue dye.  The statistical significance of each of the PCs in differentiating between the 
four different node groups and the blue dye was determined using ANOVA statistical 
calculations. Principal component 2 was the most statistically significant with an f value 
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of 2103.  The plot of this PC closely resembled the mean spectra of Patent V blue dye 
with peaks at 1165,1219,1288 and 1610cm
-1
 being present in both plots (Figure 67). 
Examination of the mean scores for each group supports PC2 as the PC associated with 
the blue dye. This is firstly because the mean score for the pure dye spectrum is very 
positive and secondly that the mean score increases as the “blueness” of the nodes 
increases (Figure 68) (Table 16). The differences between the mean scores were then 
assessed using an unpaired t-test (Table 17).  
 
 
Group 
 
 
Total Number of 
Spectra 
Mean score for PC2 
(standard deviation and standard 
error of the mean) 
 
Blue dye score 0 
 
2448 
 
-0.0070  
(0.015,0.0003) 
 
Blue dye score 1 
 
394 
 
-0.0083  
(0.014, 0.0007) 
 
Blue dye score 2 
 
291 
 
-0.0054 
(0.01, 0.0006) 
 
Blue dye score 3 
 
391 
 
0.0004 
(0.006,0.0003) 
 
Patent V blue dye 2.5% 
 
60 
 
0.14 
(0.0008, 0.0001) 
 
Table 16 - Mean value for the score of PC2 in the 5 groups in experiment 8. Standard deviation and 
standard error of the mean are also shown  (blueness measured at the time of surgery by the operating 
surgeon ; 0 = no blue or not exposed to blue dye, 1 = faint blue, 2 = moderate blue and 3 = strong blue). 
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Figure 67- Mean spectra (blue, left) of Patent V blue dye (n=60) and the load of PC2 (red, right) in 
experiment 8 with the distinct similarities between the two highlighted. 
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Figure 68- Mean score with standard error bars for PC2 in experiment 8 in the five separate groups  
across the range of blueness (blueness measured at the time of surgery by the operating surgeon ; 0 = no 
blue (or not exposed to blue), 1 = faint blue, 2 = moderate blue and 3 = strong blue)(for numbers in each 
group see table 15). 
Groups being compared P value (unpaired t-test) 
0 v 1 0.107 
0 v 2 0.076 
0 v 3 p<0.001 
0 v 4 p<0.001 
1 v 2 0.002 
1 v 3 p<0.001 
1 v 4 p<0.001 
2 v 3 p<0.001 
2 v 4 p<0.001 
3 v 4 p<0.001 
 
Table 17: Statistical significance of the differences in the mean value for the scores of PC2 between each 
group using an unpaired t-test in experiment 8. (Group 0 = No dye, group 1= faint blue, 2=moderate 
blue, 3 = strong blue and 4=Patent V blue dye 2.5%).  
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None of the loads for the other principal components appeared to have peaks suggestive 
of blue dye. Further they were neither as statistically significant using ANOVA analysis 
or displayed the same change in mean score as was demonstrated for PC2. This 
principal component was thus deemed to most closely represent the contribution of blue 
dye.  
 
To assess the effect of this component on the ability of the system to differentiate 
between the different pathologies PCA fed LDA was performed both in the presence of 
and in the absence of this PC. When PC fed LDA was calculated for all the scores 
trained on gold standard histopathology results the sensitivity and specificity of the 
Raman system at differentiating between cancer and normal tissue was 95.7% and 
98.9% respectively as discussed previously. When the same calculation was performed 
using all the scores except for that from PC 2 the sensitivity and specificity remained 
virtually unchanged at 95.1% and 99.6%.  
 
Given these results it was felt, despite the results of experiment 7,  that the presence of 
blue dye of varying concentrations would have little effect on the spectra obtained. 
Indeed further it does not significantly adversely affect the ability to differentiate 
between normal and metastatic lymph nodes.  
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4. Intraoperative Analysis of Axillary Lymph Nodes  
 
Having demonstrated that the Mini Ram II could be used within the operating theatre 
context to differentiate between positive and negative nodes the next phase of the 
project moved onto using the equipment within the operating theatre, on freshly excised 
tissue, in real time. Prior to embarking on this phase both ethical and laser safety 
approval needed to be achieved. 
 
Ethical approval was granted by the Gloucestershire Local Ethics Committee (approval 
code 01/158G – “The Development of Raman Spectroscopy in the Diagnosis of Breast 
Cancer”). Patients were eligible for inclusion in the study if they had a diagnosis of 
breast cancer and were undergoing lymphatic surgery as part of the management of this 
condition. Patients were excluded from the study if they were unable to give informed 
consent. A leaflet explaining the nature of the study was distributed to eligible patients 
at the time of their pre-admission clinic. Consent forms were signed by all patients who 
agreed to take part in the study prior to the operative procedure. As involvement in the 
study did not change patient management in any way recruitment was fairly 
straightforward and well received by patients. 
 
To satisfy laser safety requirements the portable Mini Ram II system was used in a 
room situated next to the operating theatre. This room was chosen as it was both 
windowless and had a lockable door. It was deemed that despite the relative safety of 
the laser within the spectrometer this location would further mitigate against potential 
risk. Whilst in the future it is hoped that the tissue will be assessed and thus remain in 
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the operating theatre it was felt that this was a suitable interim step during the evolution 
of the technique. 
 
4.1. Materials and Methods 
 
Axillary lymph nodes were analysed in the study from patients who were undergoing 
either a sentinel lymph node biopsy (SLNB) or an axillary clearance. Samples were 
obtained from a total of 72 operative procedures (57 SLNB and 15 axillary clearances). 
6 patients had nodes assessed during both an initial SLNB and a subsequent axillary 
clearance. Thus 66 individual patients were included in this phase of the study. Of these, 
55 (83%) had an invasive ductal carcinoma of the breast, 6 had lobular carcinoma, 2 had 
mucinous tumours, 1 had a tubular adenocarcinoma, 1 had a metaplastic tumour and 1 
was having a SLNB because of extensive DCIS. Of the 55 patients with invasive ductal 
carcinoma 23 (42%) had grade III disease, 27 (49%) had grade II disease and 5 (9%) 
had grade I disease. These numbers were broadly consistent with the UK population as 
discussed in Chapter 1.  
 
19 (29%) patients included in the study had lymph nodes positive for either 
macrometastases (n=13) or micrometastases (n=6). 15 of these patients had their 
positive nodes discovered following SLNB and 4 had received preoperative diagnosis 
following an USS and core biopsy.  A total of 176 axillary lymph nodes were assessed 
during the 72 operative procedures. To minimise the risk of nodes being assigned to the 
wrong patient all analysis was performed before another patient entered theatre.  Prior to 
spectral analysis nodes were cleared of surrounding fat and cut into two equal halves. If 
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the node was too small for this to be done easily then the node was measured as a whole 
node. This occurred in 13 cases and in all cases the maximum diameter of the node was 
5 mm. As a result 339 samples were assessed. All samples were assessed post 
operatively by standard histopathological protocols. Nodes sampled during SLNB were 
cut at 2 mm intervals and underwent H and E and immuno histochemistry staining. 
Nodes sampled during axillary clearance were cut in two planes and exposed to H and E 
staining only. Histopathology classification was provided for each separate node 
sample.  
 
In the clinical context of deciding further treatment for each patient included in the 
study the node was assessed based on the results from both halves of the node.  Thus the 
overall status of a node with a macrometastases in only one half was macro metastasis 
positive. However within the context of this study the results from each separate node 
half were used. 
 
Of the 176 nodes assessed, 139 were defined as negative on histological examination, 
18 were positive for macrometastases, 5 were positive for micrometastases, 8 were 
positive for ITCs and 6 samples were reported as having no lymphoid tissue present 
within the sample (Table 18). When the node halves were examined, 276 were negative, 
32 were positive for macrometastases, 8 were positive for micro metastasis, 10 were 
positive for ITCs and 13 had no evidence of lymphoid tissue present (Table 18). The 
negative halves were further sub-divided into 160 that were from patients who had no 
other positive nodes, N0 patients, or 116 that were from patients who had at least one 
other positive node. 
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 Number of Nodes Number of separate tissue samples 
 (either halve a node or a whole small node) 
 
Negative 
 
139 
 
276 
 
Positive – Macro 
 
18 
 
32 
 
Positive – Micro 
 
5 
 
8 
 
ITCs 
 
8 
 
10 
 
Non Lymphoid 
 
6 
 
13 
 
Table 18- The number of samples and nodes in each classification group. The whole nodes were 
classified according to their highest group ( i.e. a node which had a macrometastases in one halve and 
an ITC in the other half was classified as a macrometastases) and the halve node samples were classified 
according to their halve only. The majority of nodes were divided into two halves. However due to their 
small size 13 nodes were assessed as a whole.  
 
4.1.1. Spectral Acquisition.  
 
After excision and preparation each node was placed on the upturned probe. Prior to 
assessment, a sterile sheath had been placed over the probe tip to prevent cross 
contamination. The node was placed in an approximately central position and spectra 
were obtained by combining 16 1s acquisitions. A total of 2627 spectra were collected 
from the 339 samples. (Mean 7.2 spectra per node, range 5-25 per sample). Once 
collected, spectral data was uploaded into Matlab® for spectral analysis.  
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Three standard spectra were collected during each session as is routine within the 
research group. Standard spectra were obtained from a green glass standard, 
cyclohexane, and a plastic pipette tip. Data was stored within a password protected 
database that recorded patient details, the type of tumour, hospital number, the date of 
surgery, the operating surgeon, the surgical procedure, the size of the node and the final 
pathology data. 
 
4.1.2. Spectral Analysis. 
 
Spectra were collected from the lymph node samples at the time of surgery as described 
previously. No spectra were removed during data processing as any spectra that were 
either saturated or contained cosmic rays were identified and removed during collection. 
 
Each spectrum was subjected to a stepwise sequence of processing. Initially all raw 
spectra (Figure 69) were corrected for peak position and intensity. This was performed 
using in house Matlab® functions and based on the calibration standards that were 
recorded at the start of each session (Figure 70). Peak position calibration was first 
performed based on the peak positions of the four highest intensity Cyclohexane peaks. 
The Matlab® programme used cropped the spectra to 400-1800cm
-1
. The resulting 
spectra were then intensity corrected based on the spectra recorded from the green glass 
standard. 
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Figure  69 – Raw spectra collected from all lymph node samples in the intra-operative series (n=2627). 
This demonstrates the wide range of background intensity of the samples collected. 
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Figure  70 – Raw spectra for green glass (above) and cyclohexane (below) standards obtained in the 
Cheltenham series demonstrating the stability of the system over the course of the study (y axis intensity 
is arbitrary units). 
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Following these steps the spectra were baseline corrected, smoothed and finally 
normalised using in house and self programmed Matlab® functions. A mean spectrum 
was then calculated for each of the nodes analysed (Figure 71). 
 
Figure 71– Mean corrected spectra for all node samples (n=339) in the intra-operative study. 
  
Using this methodology a dataset that pertained to the 339 samples was created that had 
been corrected in a uniform and consistent way. This dataset was organised so that it 
could easily be manipulated based on individual patients, node pathology or date of 
spectral acquisition. This was referred to the “overall dataset” and separate pathology 
subgroups and sub-datasets were created from it.   
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4.2. Results - Dataset 1: Macrometastases v.  Negative N0 Nodes. 
 
Of the five pathology groups identified from the histopathology results the two with the 
greatest histopathological differences were the groups that were identified as containing 
macrometastases  (n=32) and the group that were defined as negative nodes from N0 
patients (n=160). It was anticipated that the spectral differences between these groups 
would be the most significant. Initial comparison of the spectra for these two subgroups 
was performed after calculating the mean spectra for each one (Figure 72). 
 
Significant areas of difference were evident simply on inspection of the mean spectra 
and this was emphasised by plotting the mean spectra with 95% confidence intervals 
either side of the mean value for each wavenumber (Figure 72, 73). This change was 
enhanced when we subtracted the mean positive spectra from the mean negative spectra. 
A plot of the result of this manipulation for each wavenumber gave further clarity to the 
distinct differences (Figure 74). Those peaks that remained positive were representative 
of increased relative concentrations within the N0 node subgroup and those peaks that 
were negative indicated increased relative concentration within the macrometastases 
subgroup of nodes.  
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Figure 72 – Mean spectra of NO Nodes (green, n=160) and  macrometastases (red, n=32) in the intra-
operative study. 
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Figure 73 – Mean spectra of N0 Nodes (green, n=160) and macrometastases (red, n=32) with 95% 
confidence intervals in the intra operative study. 
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Figure 74 – Plot of spectral subtraction to demonstrate key areas of spectral differences between N0  
Nodes (n=160) and macrometastases positive nodes (n=32) in the intraoperative study . Where the plot is 
green the peaks are more prominent in the N0 spectra and where the plot is red the peaks are more 
prominent in macrometastases spectra. Labelled peaks are discussed further in table 19. 
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Examination of the plots of the subtracted differences enabled us to identify the 
wavenumbers associated with each of the positive and negative peaks. Peak labelling 
and assignation was performed using Matlab® programmes and compiled tables of peak 
assignments held within the department (Kendall 2002).  In this way a total of 34 peaks 
that appeared significant were labelled and their biochemical association recorded 
(Table 14). 
 
Peak 
Label in 
Fig. 79 
Peak 
Position 
(cm
-1
) 
Biochemical 
assignation 
Mean peak 
intensity N0 nodes  
(SD and SEM)  
Mean peak intensity 
macrometastases 
(SD and SEM)   
t  
Value 
p  
Value 
a 510 Disulphide 0.026 
(0.002, 0.00016) 
0.031 
(0.0021, 0.0007) 
 
12.8 p<0.0001 
b 525 Disulphide 0.026 
(0.003, 0.00026) 
0.030 
(0.0032,0.0006) 
 
6.3 <0.0001 
c 540 Disulphide 0.025 
(0.005, 0.0004) 
0.032 
(0.0039,0.0007) 
 
7.5 p<0.0001 
d 571 Trytophan 0.021 
(0.006, 0.0004) 
0.027 
(0.0038, 0.0007) 
 
5.7 p<0.0001 
e 642 Tyrosine 0.018 
(0.008, 0.0006) 
0.023 
(0.0042, 0.0007) 
 
3.5 p=0.0007 
f 681 Guanine 0.015 
(0.008, 0.0006) 
0.021 
(0.005, 0.0009) 
4.1 p<0.0001 
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g 710 Adenine 0.016 
(0.007, 0.0004) 
0.021 
(0.004, 0.0007) 
 
4.8 p<0.0001 
h 749 Thiamine 0.014 
(0.0055, 0.0004) 
0.018 
(0.0028,0.0005) 
 
4.01 p<0.0001 
i 787 Cysteine 0.012 
(0.006, 0.0005) 
0.016 
(0.0032, 0.0006) 
 
3.78 p=0.0002 
A1 840 Glucose 0.030 
(0.0024,0.0002) 
0.023 
(0.0026,0.0005) 
 
14.9 p<0.0001 
A2 876 C-C Stretch 0.033 
(0.003, 0.0002) 
0.026 
(0.0033, 0.0005) 
 
11 p<0.0001 
j 926 DNA 0.023 
(0.0026,0.0002) 
0.023 
 
(0.0024, 0.0004) 
0 p=1 
k 941 C-C (protein) 0.020 
(0.0033, 0.0003) 
0.023 
(0.0026, 0.0005) 
 
4.9 p<0.0001 
A3 971 =C-H 0.021 
(0.0023, 0.0002) 
0.020 
(0.0024,0.0004) 
2.6 p=0.01 
l 1004 Phenylalanine 0.017 
(0.004,0.0003) 
0.023 
(0.0026, 0.005) 
 
8.1 p<0.0001 
A4 1029 Proline 0.020 
(0.002, 0.0002) 
0.017 
(0.0016, 0.0002) 
8.0 p<0.0001 
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m 1062 ?DNA ?Lipid 0.042 
(0.004,0.0003) 
0.046 
(0.0053,0.0009) 
4.8 p<0.0001 
A5 1079 C-C Stretch 
Lipid 
 
0.044 
(0.007, 0.0005) 
0.033 
(0.0054, 0.0009) 
8.4 p<0.0001 
n 1130 C-N protein 0.021 
(0.007, 0.0005) 
0.038 
(0.009, 0.0002) 
 
12.1 p<0.0001 
o 1172 C-O stretch/ 
Tyrosine 
 
0.007 
(0.005,0.0004) 
0.016 
(0.004, 0.0007) 
9.5 p<0.0001 
p 1205-
1213 
Thiamine/ 
Tyrosine/ 
Phenylalanine 
0.006 
(0.005,0.0004) 
0.012 
(0.004,0.0007) 
6.4 p<0.0001 
Q 1231 Amide III 0.012 
(0.005, 0.0004) 
0.018 
(0.004, 0.0007) 
 
6.4 p<0.0001 
A6 1263 Lipid (=C-H) 0.034 
(0.004, 0.0003) 
0.029 
(0.003, 0.0005) 
 
6.7 p<0.0001 
R 1293 Amide III 0.055 
(0.007, 0.0005) 
0.059 
(0.009, 0.0002) 
 
2.8 p<0.0001 
A7 1306 Lipids 0.060 
(0.012, 0.0009) 
0.049 
(0.007, 0.001) 
5.0 p<0.0001 
S 1348 Nucleic Acid/ 
Tyrptophan/ 
Adenine 
0.014 
(0.005, 0.0004) 
0.022 
(0.004, 0.0007) 
8.5 p<0.0001 
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T 1376-
1397 
Thymine/ 
adenine/ 
guanine 
0.010 
(0.005,0.0004) 
0.017 
(0.003, 0.0005) 
7.6 p<0.0001 
A8 1440 Lipids 0.095 
(0.022, 0.0012) 
0.07 
(0.013, 0.002) 
 
6.2 p<0.0001 
U 1479 Purine Bases 0.019 
(0.002, 0.00016) 
0.023 
(0.002, 0.0004) 
 
10.3 p<0.0001 
V 1536 Tryptophan 0.009 
(0.006, 0.0005) 
0.015 
(0.003, 0.0005) 
 
5.5 p<0.0001 
W 1609 Tyrosine 0.013 
(0.006, 0.0005) 
0.022 
(0.004, 0.0007) 
 
8.2 p<0.0001 
A9 1652 Lipid 0.046 
(0.007, 0.0005) 
0.039 
(0.005, 0.0009) 
 
6.2 p<0.0001 
X 1673 Amide III 0.021 
(0.006, 0.0005) 
0.029 
(0.004, 0.0007) 
 
7.22 p<0.0001 
A10 1746 C=O stretch 
lipid 
0.025 
(0.002, 0.0002) 
0.020 
(0.003, 0.0005) 
11.7 p<0.0001 
 
Table 19- Peak assignments of the key spectral differences highlighted by spectral subtraction and 
labelled in Figure 74 (Kendall 2002). The mean intensity for each of these peaks in N0 nodes and 
macrometastases is also given, along with their standard deviation and standard error of the mean. The 
results of an unpaired t-test are also shown (both the t value and the p value) (SD=standard deviation, 
SEM= standard error of the mean). 
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To add a degree of robustness to this process and to ensure that any significant peak 
differences had not been missed statistical analysis of the mean intensity of each 
wavenumber in the two groups was performed. An unpaired t-test was performed and 
the degree of freedom for the analysis was calculated.  The unpaired t-test was chosen 
as it is a statistical test that compares the mean of one variable between two groups. 
 
A null hypothesis was defined which stated that there was no difference in the mean 
peak intensity between the two groups.  The t value was compared to standard tables of 
significance to determine whether the difference between the means was unlikely to 
have occurred by chance alone. The level of statistical significance was set at 99%, thus 
if the t value was greater than the published value for this significance level with 190 
degrees of freedom, 2.6, then the null hypothesis could be rejected. All but 2 of the 
previously identified peaks had t values which allowed us to reject the null hypothesis. 
The two peaks that did not achieve this were those labelled A3 and J at 971 and 926cm-
1 respectively. These were then excluded from further evaluation. 
 
The t values for each wavenumber were examined and used to identify further 
significant differences between the two groups. It was evident that three further 
wavenumbers, that had not been initially selected, recorded highly significant t values.  
These were found; 
 
 below peak a at 488cm-1 (N0 mean = 0.027 (standard deviation (SD) = 0.001, 
standard error of the mean (SEM) 0.0001) v. macrometastases mean 0.031 (SD 
= 0.001, SEM = 0.0005)). 
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 above peak a2 at 889cm-1 (N0 mean = 0.031 (SD = 0.002, SEM = 0.0002 v. 
macrometastases mean 0.026 (SD = 0.003, SEM = 0.0005)).   
 above peak t at 1419cm-1 (N0 mean = 0.025 (SD = 0.002, SEM = 0.0002) v. 
macrometastases mean 0.031 (SD = 0.003, SEM = 0.0005)). 
 
The t values for these peaks were 13.7, 11.8 and 14.2 respectively. Potential peak 
assignments of glycogen, CH2 rock and adenine/guanine were made based on available 
tables. The t values for the 32 peaks identified initially and the 3 further wavenumbers 
identified confirm that there are statistically significant differences between the two 
groups. As spectrum recorded in Raman spectroscopy is based on the molecular 
composition of the tissues being assessed these spectral differences can be assigned to 
molecular differences between the two groups.  
 
Evaluation of the different peaks associated with each pathology subgroup suggests 
significant differences in the biochemical composition. Analysis demonstrated that the 
positive nodes had increased relative levels of protein and nucleotides in comparison to 
the true negative nodes. This is supported by the peaks associated with disulphide and 
C-N bonds (510, 525, 540 and 1130 cm
-1
) amide III (1293 and 1673 cm
-1
) as well as 
those associated with amino acids such as phenylalanine (1004 cm
-1
), tryptophan (1348 
and 1546 cm
-1
) tyrosine (642, 1172, 1609 cm
-1
) as well as the region 1205-1213 cm
-1
. 
Peaks associated with adenine (710 and 1348 cm
-1
), cystine (787 cm
-1
), thiamine (749 
cm
-1
) and guanine (681 cm
-1
) and in the region 1376-1397 cm
-1
 all support the increased 
intensity of DNA within metastatic nodes. Within the negative nodes peaks at 876, 
1079, 1263, 1306, 1440, 1652, and 1746 cm
-1
 are associated with lipids and support the 
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relative increased levels of lipids within negative nodes. The peak at 840 and 894 cm
-1
 
suggest that there may also be increased levels of glycogen and glucose in the normal 
nodes.  These findings are both consistent with previous studies of lymph nodes using 
Raman spectroscopy and with the histological changes that occur during cancer cell 
metastases. In areas where metastatic cells predominant their large nuclei account for 
the increased levels of DNA and the decreased levels of lipid associated with normality. 
The increased protein levels correlate with an up regulation of the immune response due 
to the presence of foreign cells and the decrease in energy stores maybe accounted for 
by the energy requirements of rapidly replicating cancer cells that have lost their normal 
cell regulatory mechanisms.   
 
These initial results confirmed that there were significant differences between the two 
pathological groups. Further, using peak assignment, it was demonstrated that these 
differences appeared to represent biochemical changes within the node. These results 
were consistent with previous work, presented in Chapter 2, which has shown decreased 
lipid and increased protein and DNA spectral contributions in malignant tissue. 
 
4.2.1. Dataset 1- Diagnostic Tool. 
 
4.2.1.1. Molecular Differences. 
 
The next stage in the analysis of the data was to determine if the results could be used to 
differentiate between the positive (macrometastases) and the N0 nodes. An initial model 
was based on the relative intensities of the lipid, protein and DNA peaks that had been 
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highlighted above. The combined intensity of the 9 peaks attributed to lipids, the 15 
peaks related to proteins and the 10 peaks attributed to DNA were combined for each 
node to give a lipid, protein and DNA score. Separation of the two groups was then 
attempted based on each of these three values and finally the combined value of the 
three intensities. As it was expected that the lipid value would be higher in the negative 
nodes and that the protein and DNA value would be higher in the positive nodes an 
overall score was calculated based on the formula given below. The lipid score was 
subtracted from 0.5 as no node achieved a value of greater than 0.45.  
 
Overall Score= (Protein score + DNA score) + (0.5-lipid score) 
 
Plots of each of these composition scores highlighted the differences between the 
macrometastases and N0 samples (Figure75-79). Although these compositional scores 
demonstrated statistically significant differences between the two pathology sub-groups, 
using an unpaired t-test (Table 20) (Figure 80) they were not sufficient to separate them 
with a sensitivity and specificity sufficient for clinical use.  
 
It is interesting to note the negative nodes appear to separate into two further subgroups 
based on the protein score. It is postulated that this may reflect either a greater immune 
response in nodes earlier in the nodal chain or that it may represent a response to recent 
breast biopsies or due to isolated histopathologically undetected metastatic cells. 
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Figure 75 – Histogram demonstrating the combined intensity of all lipid related peaks for each spectra in 
dataset 1 (green = N0 negative nodes, red= macrometastases positive nodes). 
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Figure 76 – Histogram demonstrating the combined intensity of all protein related peaks for each spectra 
in dataset 1 (green = N0 negative nodes, red= macrometastases positive nodes). 
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 Figure 77 – Histogram demonstrated the combined intensity of all DNA related peaks for each spectra in 
dataset 1 (green = N0 negative nodes, red= macrometastases positive nodes). 
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Figure 78 – Histogram demonstrating the overall score for positive and negative nodes for each spectra 
in dataset 1(green = N0 negative nodes, red= macrometastases positive nodes). 
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Figure  79 –3D plot demonstrating the ability of the three scores (lipid, protein and DNA contribution) to 
separate macrometastases positive nodes (red) from N0 negative nodes(green) in dataset1. 
 
 Mean  
Lipid Score 
(SD, SEM) 
Mean  
Protein Score 
(SD, SEM) 
Mean 
DNA Score 
(SD, SEM) 
Mean  
Combined Score 
(SD, SEM) 
Macrometastases 
(n=32) 
0.32 
(0.03, 0.005) 
0.40 
(0.04,0.007) 
0.24 
(0.02, 0.004) 
0.82 
(0.06, 0.01) 
N0 Negative  
(n=160) 
0.40 
(0.05, 0.004) 
0.30 
(0.06,0.005) 
0.19 
(0.04, 0.003) 
0.59 
(0.04, 0.003) 
Unpaired t-test p<0.0001 
t=8.29 
p<0.001 
t=9.02 
p<0.001 
t=6.9 
P<0.001 
t=27  
  
Table 20: The total intensities of peaks attributable to lipid, protein and DNA in the macrometastases and 
N0 groups. Results of an unpaired t-test confirm the statistical significance of these differences. 
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Figure  80 – Box and Whisker plots demonstrating the mean and 95% confidence intervals for the 
contributions of lipid, protein and DNA peaks as well as the overall molecular score for macrometastases 
(positive, green) v N0 (negative, green) nodes (see also table 14a). 
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The combined compositional score was then used to assess whether it could be used to 
discriminate between positive and negative nodes. Analysis of the data suggested that 
the “score” which best discriminated between the two groups was 0.75. If a node had a 
combined score of greater than 0.75 it was defined as positive and if the combined score 
was less than 0.75 it was defined as negative. Using this score a sensitivity of 81% 
(27/32) and a specificity of 84% (128/160) was achieved. Whilst the sensitivity is at 
least comparable to current intraoperative techniques the specificity is significantly 
worse. As has been discussed this is clinically of most significance to avoid ultimately 
unnecessary axillary dissections and adjuvant chemotherapy. To investigate how the 
specificity could be improved the calculation was repeated with separation scores of 0.7 
to 0.9. As the score was raised the specificity did indeed improve but at the expense of 
the sensitivity (Table 21). 
 
Combined Score Diagnostic Cut 
Off Point 
(if > cut off = positive) 
 
Sensitivity 
(%) 
 
Specificity 
(%) 
 
0.7 
 
84 
 
80 
 
0.75 
 
81 
 
84 
 
0.8 
 
72 
 
86 
 
0.85 
 
56 
 
91 
 
Table 21- Change in sensitivity and specificity at differentiating between macrometastases nodes and N0 
nodes using a combined biochemical score ((protein + DNA contribution) + (0.5 – lipid contribution)) as 
the diagnostic cut off point is altered.  
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Whilst these results are encouraging it was felt that they would not acceptable for a 
diagnostic test within this clinical scenario. Therefore further methods of data analysis 
were required to develop the technique as a diagnostic tool.  
 
4.2.1.2. Principal Component Analysis fed Linear Discriminant 
Analysis (PCA fed LDA) 
 
Due to the complexity of the data contained within a spectrum many authors have used 
chemometric recognition techniques to help interpret the information. A widely used 
technique is linear discriminant analysis (LDA) fed by principal component analysis 
(PCA). Using PCA allows one to simplify the data into fewer variables whilst retaining 
the overall spectral information. Each dataset is split into a number of components 
(loads) which contribute to each of the spectrum within the dataset. The contribution of 
each component is different for each spectrum and is defined by the principal 
component score. Each original spectrum has a different score for each load. The scores 
for each principal component (PCs) can then be used to simulate a linear boundary 
between the classes in the model (Sattlecker et al. 2010). 
 
Initial data analysis used all spectra that had been collected from the nodes in the two 
groups. Thus a total of 1325 negative spectra and 290 positive spectra were included. 
When PCA fed LDA was performed a specificity of 99% and sensitivity of 95% was 
achieved. However it was felt that in a clinical scenario all spectra acquired from a 
single sample would be combined to provide a single output for each node. Therefore 
the mean of the spectra collected from each sample was subsequently assessed. 
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Figure 81 – PCA fed LDA scores for spectra from macrometastases positive samples (red) and N0 
negative samples (green) in dataset 1. 
 
After mean centring the processed spectral data, principal component analysis was 
performed to generate 25 PC loads and scores. An unpaired t-test was performed to 
assess the statistical significance of the differences between the mean of the 25 scores 
for both positive and negative nodes. For each of the principal components the null 
hypothesis was that there was no difference between the mean score in the two groups. 
With 188 degrees of freedom the null hypothesis could be rejected at the 99% 
confidence level if the t score generated was greater than 2.6. Only 4 PCs achieved this 
level of significance, PC 1, 2, 11 and 12 (Figure 82, 83). 
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 Figure 82 – Plots of the loads of the 4 most statistically significant PCs in the intraoperative study, as 
demonstrated in figure 83. 
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Figure 83 – t score from an unpaired t-test to assess the statistical significance of differences in the mean 
value of the scores for the first 25 PCs between macrometastases and N0 node (n=32 and n= 160 
respectively) .The horizontal line represents the 99% statistical level.  
 
Closer examination of PC1 revealed peaks at positions identical or very similar to those 
previously identified as representative of negative nodes (Figure 84). Examination of 
PC 2 revealed that there were 20 of the peaks previously identified as positive evident in 
the plot (Figure 85). It was postulated that PC1, resembling lipids, represented negative 
nodes and that PC2, representing a combination of protein and DNA, was representative 
of positive nodes. This is supported by the finding that the mean score for PC1 amongst 
the positive nodes is -0.155 whereas that of the negative nodes is 0.03. Similarly for 
PC2 the mean score for the negative nodes is -0.17 and for the positive nodes it is 0.085. 
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Figure 84- Plot of PC1 from principal component analysis of the dataset No and macrometastases nodes 
with key peaks marked for clarity. 
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Figure 85- Plot of PC2 from principal component analysis of the dataset No and macrometastases nodes 
with key peaks marked for clarity. 
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The four most significant PCs from the T test analysis were then used to develop an 
LDA classification model. The training performance of this model achieved a 
sensitivity of 94% (30/32) and a specificity of 99% (158/160) (Figure 86). 
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 Figure 86- Histogram demonstrating the ability of the 4 most statistically significant PCs to separate the 
two tissue groups (N0 negative nodes, green, n=160, and macrometastases positive nodes, red, n=32) 
based on the LDA result generated using PCA (principal component analysis) fed LDA (linear 
discriminant analysis).  
 
This analysis was then repeated using all 1 to 25 PCs to determine the optimum result 
that could be achieved (Figure 87). The best result was achieved when the first 14 
principal components were included in the model, although only small improvements 
187 
 
are made beyond the first two PCs. Using PCs 1 to 14 to train the LDA model a 
sensitivity of 96.9% (31/32) and a specificity of 99.4% (159/160) was achieved in the 
training model.  
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Figure  87– Improvement in the sensitivity(red) and specificity (blue) with increasing numbers of PC in 
dataset 1 (N0 negative  and Macrometastases positive nodes) . 
 
The robustness of this data was further tested by using leave one node out cross 
validation. In this test the data from one sample is left out and the data from the 
remaining samples is then used to build a training set. This training set is split according 
to known pathology results and is used to predict the group membership, in this case 
positive or negative node, of the sample that had been left out. The leave one node out 
testing achieved a specificity of 99.4% (159/160) and a sensitivity of 93.8% (30/32) 
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when using all 25 PCS. When using only 14 PCs which we have previously shown 
achieved the best training set result using LDA a specificity of 98.8%(158/160) and a 
sensitivity of 90.6% (29/32) was achieved (Fig 88). 
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Figure 88- Improvement in the cross validation based sensitivity (red) and specificity (green) with 
increasing numbers of PC in dataset 1 (N0 negative  and Macrometastases positive nodes) . 
 
This data was then used to assess the clinical impact it would have had on the patients 
involved in the study had it been used to guide clinical decisions.  This dataset included 
nodes samples from 48 patients undergoing a SLNB. On subsequent histopathological 
testing Of the 57 sentinel lymph node biopsies performed 40 a negative axilla and 8 had 
evidence of macrometastases. If the results of the leave one node out cross validation 
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testing had been used, 38 out of 40 (95%) patients with a negative axilla would have 
been correctly identified. 6 out of 8 (75%) patients with an axilla containing 
macrometastases would have been correctly identified and would have benefited from 
an immediate axillary clearance. Thus 2 patients would have suffered from a false 
positive result and had an unnecessary axillary clearance. The two patients with false 
negatives would have been identified following post operative gold standard node 
assessment and recommended a delayed axillary clearance. These results are 
comparable to both other Raman spectroscopic studies (outlined in Chapter 2) and the 
current techniques used in the intra-operative assessment of axillary lymph nodes in 
breast cancer. However it needs to be remembered that these results are for the 
comparison of the two groups, macrometastases and normal nodes from N0 patients 
which would be expected to demonstrate the most significant pathological differences.  
 
4.3. Results - Dataset 2: Macrometastases v all Negative nodes. 
 
In the second dataset a larger group of negative nodes were assessed. This included both 
the negative nodes from N0 patients (n=160) and the non-N0 group (n=116). As stated 
previously these nodes are those that were histopathologically negative but that came 
from patients with other positive nodes. Mean spectra of the two groups were plotted 
and the intensity of the same 34 peaks, that had previously been used to examine the 
differences in the protein, DNA and lipid spectral contributions were calculated (Figure 
89). These, along with the combined score were used to compare both between the 
positive and negative groups, as well as the two negative groups.  
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The results revealed that there were slightly higher levels of DNA and protein and 
slightly lower levels of lipid within the non-N0 negative group in comparison to the N0 
negative group (Figure 90) (Table 22). An unpaired t-test revealed statistically 
significant differences between the Non-N0 nodes and both the N0 and macrometastases 
nodes (Table 23).  
 
 Mean Lipid Score 
(SD, SEM) 
Mean Protein 
Score 
(SD, SEM) 
Mean DNA Score 
(SD, SEM) 
Mean Combined 
Score  
(SD, SEM) 
Non N0 negative 
nodes (n=116) 
0.38 
(0.05, 0.004) 
0.32 
(0.07,0.007) 
0.20 
(0.04, 0.004) 
0.63 
(0.03, 0.003) 
 
Table 22: The intensities of peaks attributable to lipid, protein, DNA and a combined score in the non N0 
negative nodes. For comparison to No nodes and macrometastases see table 20 (SD=standard deviation 
and SEM= standard error of the mean). 
 
 Lipid 
Score 
Protein 
Score 
DNA 
Score 
Combined 
Score 
 
N0 v. Non- N0 negative nodes 
p=0.009  
(t=2.63) 
p=0.0073 
(t=2.70) 
p=0.01 
(t=2.60) 
p<0.001 
(t=9) 
 
Macrometastases v. Non- N0 
negative nodes 
 
p<0.001 
(t=8.29) 
 
p<0.001 
(t=9.02) 
 
p<0.001 
(t=6.9) 
 
p<0.001 
(t=24) 
 
Table 23: Results of unpaired t-tests comparing the mean lipid, protein, DNA contribution and a 
combined  score for N0, non-N0 negative and macrometastases nodes (n=160,116 and 32 respectively). 
See also tables 20 and 22 for mean, standard deviation and standard error of the mean for each group. 
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Figure 89– Mean spectra of the two tissue groups in dataset 2 (all negative nodes, green n=276 and 
macrometastases positive nodes, red n=32). 
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Figure 90- Mean intensity scores (with 95% confidence intervals) for peaks related to Protein, DNA and 
lipid and a combined score in dataset 2. (N0 (green,) non-N0 negative (orange) and macrometastases 
(red) nodes (n=160,116 and 32 respectively)). 
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If a combined score of 0.7 was used as a diagnostic cut of a sensitivity of 84% and a 
specificity of 76% was achieved. As previously demonstrated in the first model if the 
score required to differentiate between the two groups rose then the sensitivity fell and 
the specificity rose (Table 24). 
 
Combined Score Diagnostic Cut 
Off Point 
Sensitivity Specificity 
0.7 84 76 
0.75 81 80 
0.8 72 84 
0.85 56 89 
 
Table 24- Change in sensitivity and specificity as the diagnostic cut off point is altered in dataset 2.  
 
As outlined earlier in this chapter principal component fed linear discriminant analysis 
was then used to differentiate between the negative and macrometastases groups. The 
best sensitivity achieved was 91% (29/32) and the best specificity achieved was 98% 
(270/276) when using 25 PCs. Leave one node out cross validation testing was 
performed and a specificity of 96% (265/276) and a sensitivity of 84% (27/32) were 
achieved. Whilst still very acceptable this result is poorer than that achieved in the true 
negative v macrometastases model. 
 
This result prompted questions as to why this was the case? It could be postulated that 
there are changes in the non-N0 negative group that are due to the immune response to 
metastases in another node, as detailed in Chapter 1. This is supported by the results of 
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the individual component analysis that demonstrated that the differences in the protein 
score were the most statistically significant between the N0 negative nodes and the non-
N0 negative groups. The mechanism behind this difference may be explained by 
immune mediators produced in response to metastatic deposits in other nodes being 
filtered through nodes higher in the chain. These differences would not render the node 
“positive” pathologically but could alter the spectral features of the sample sufficiently 
to influence the classification model.  This is an important finding to be aware of in the 
future particularly if models are created based on this data. Misclassification of these 
non-N0 nodes is in itself not likely to be clinically important as other nodes would 
already have seen the patient classified as having a positive axilla. Their role however in 
altering the model classification could render positive nodes negative as it has done in 
this dataset and increase the false-negatives. 
 
4.4. Results - Dataset 3: All Positive nodes (Macro+Micro+ITCs) v Negative 
Nodes. 
 
The final dataset included the macrometastases (n=32), the micrometastases (n=8), the 
isolated tumour cells (n=10) and all the negative nodes (n=276). As the micrometastases 
and ITC group sizes were so small these were combined into one group term “non-
macrometastases positive nodes” (n=18).As discussed previously the protein, lipid and 
DNA scores for each sample were calculated (Table 25). The differences between the 
macrometastases and the “non-macrometastases” positive nodes were statistically 
significant for lipid, protein and DNA. Although none of the changes were statistically 
significant for “non macrometastases” positive nodes versus N0 negative nodes and non 
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N0 negative nodes there did appear to be a trend from macrometastases to N0 negative 
nodes (Table 26) (Figure 91).  
 
 Mean Lipid 
 Score 
(SD, SEM) 
Mean Protein 
Score 
(SD, SEM) 
Mean DNA 
 Score 
(SD, SEM) 
Mean Combined 
Score 
(SD, SEM) 
 
Non Macrometastases 
Positive Nodes (n=18) 
 
0.38 
(0.05, 0.012) 
 
0.32 
(0.04,0.01) 
 
0.195 
(0.04, 0.01) 
 
0.63 
(0.09, 0.02) 
 
Table 25: The combined intensities of peaks attributable to lipid, protein, DNA and a combined score in 
non-macrometastases. For comparison to No nodes, non N0 negative nodes and macrometastases see table 
20 and 22. 
 
 Lipids Protein DNA Combined 
score 
N0 v. Non Macrometastases 
Positive nodes 
p=0.1915 
(t=1.3) 
p=0.1402 
(t=1.48) 
p=0.42 
(t=0.8) 
p=0.1 
(t=3.4) 
Non- N0 negative nodes v. 
Non Macrometastases Positive 
nodes 
p=1 
(t=0) 
p=1 
(t=0) 
p=0.628 
(t=0.5) 
p=1 
(t=0) 
Macrometastases v. Non 
Macrometastases Positive 
nodes 
p<0.001 
(t=5.17) 
p<0.001 
(t=6.8) 
p<0.001 
(t=5.3) 
p<0.001 
(t=8.9) 
 
Table 26: Results of unpaired t- tests comparing the mean lipid, protein DNA contribution scores and a 
combined score for N0, non-N0 negative and macrometastases nodes v. non-macrometastases positive 
nodes (n=160,116, 32 and 18 respectively). For further details see Tables 20, 22 and 25. 
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Figure 91- Mean intensity scores (with 95% confidence intervals) for peaks related to Protein, DNA and 
lipid and a combined score in N0 (green,) non-N0 negative(orange), non-macrometastases positive nodes 
(light red) and macrometastases(dark red) nodes (n=160,116,18 and 32 respectively) 
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The width of the standard error bars for the non macrometastases positive nodes is 
partly explained by the small group size but may also be explained by the presence of 
what appear to be two distinct subsets within the data (Figure 98). In one subset there 
are high levels of lipid with low levels of protein and DNA (resembling negative nodes) 
and in the other there are low levels of lipid with high levels of protein and DNA 
(resembling the macrometastases nodes). These two subsets are not related to a 
comparison between the ITCs vs. Micrometastases. Chemometric analysis revealed that 
only 50% (4/8) of the micrometastases and 40% (4/10) of the ITCs were correctly 
categorised. The small group size made further evaluation of this finding difficult but it 
could be suggested that one reason for the difference was that an insufficient volume of 
the node is being sampled to detect the small areas of change associated with either 
micrometastases or isolated tumour cells in those samples that appeared similar to the 
negative nodes. It is not altogether surprising that those eight samples that were 
correctly categorised were the eight that had features most closely resembling the 
positive nodes and thus would be examples of where the nodal change was identified 
from the volume of tissue analysed (Figure 92). 
 
 These results demonstrate the difficulties that may be experienced detecting 
micrometastases and isolated tumour cells using this technique. As was discussed in 
Chapter 1 it is likely that a decision to proceed to an ALND would not be clear cut and 
that MDT discussion would be required prior to proceeding to an ALND. 
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 Figure 92- 3d plot of the lipid, protein and DNA contributions in micrometastases and ITC 
demonstrating two clear groups, one with high DNA and protein contributions and low lipid 
contributions (consistent with a positive node) and one group with lower DNA and protein contributions 
and high lipid contributions (consistent with a negative node). This supports the suggestion that in the 
micrometastases and isolated tumour cell samples because of the small volume of disease this was not 
being ”seen” by the Raman technique in all of the nodes investigated. 
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4.5. Measurements from the inner cut surface versus those from the outer 
surface. 
 
Discussion within the group at the outset of this study questioned whether spectra 
needed to be obtained from the cut inner surface of lymph nodes, as had previously been 
performed, or whether spectra could be collected from the outer surface of the node 
without altering the sensitivity and specificity of the test. Looking forward this would 
mean that lymph node analysis might be able to be performed with the node still in situ 
and negate the need to excise the lymph node if it were negative. Various groups 
throughout the world are beginning to develop either minimally invasive lymph node 
sampling or in a few centres laparoscopic sampling techniques (Lim and Lam 2005). If 
Raman spectroscopy could differentiate between positive and negative nodes based on 
spectra obtained from the outer surface of the node this technique would be further 
enhanced and the invasiveness of the procedure further reduced. Further, analysis of the 
results, as discussed above, suggested that further volume sampling may help improve 
the detection of micrometastases and isolated tumour cells. 
 
4.5.1. Inner vs. Outer Experiment - Methods. 
 
282 of the samples collected during the study described at the start of Chapter 4 were 
assessed both from the inner cut surface and also from the outer surface. At the time of 
analysis 5 spectra were obtained from the inner cut surface and then the node was 
simply turned 180° and further spectra were acquired. Spectral acquisition and tissue 
handling was as described at the start of Chapter 4. Data analysis was performed using 
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Matlab® software.  Statistical analysis was performed using a paired t-test to compare 
the mean intensity of each wavenumber in the two datasets. The null hypothesis was 
that there was no difference between the two groups at each wavenumber. The null 
hypothesis was rejected if the t value was greater than 2.33 (the critical value for a test 
with >500 degrees of freedom at the 99% level). More detailed analysis of the 
biochemical differences was performed by examining the mean intensity of the peaks 
attributable to lipid, protein and DNA as described earlier in this chapter. Further 
analysis using PC fed LDA was then performed as has been discussed earlier in this 
chapter.  
 
4.5.2. Inner vs. Outer Experiment - Results. 
 
Of the 282 samples which were assessed in this way. 132 were negative nodes from N0 
patients, 90 were negative nodes from non-N0 patients, 31 were samples with 
macrometastases, 8 were samples with micrometastases, 9 had ITCs and 12 were from 
fat (thus not included in further analysis). For comparative purposes two datasets with 
spectra obtained from either the inner or the outer surface of each sample was created. 
Mean spectra (n=270 in both groups) from the two datasets looked very similar on 
initial inspection and this was confirmed by performing a paired t-test on each of the 
wavenumbers (Figure 93, 94).  
201 
 
Figure 93 – Mean spectra collected from the outer (n=270, green) and inner surface (n=270, blue) of the 
lymph nodes. 
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Figure 94 –The results of the t-test for each wavenumber to demonstrate the statistical significance of the 
differences between the mean intensity of each wavenumber for spectra from the inner and outer surface 
of each lymph node. Statistical significant differences were only present if the t-value was above 1.66 
(95% significance level) or 2.33 (99% significance level). 
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The null hypothesis was only rejected for one wavenumber at 1321 cm
-1
. Even if the 
significance level is reduced to 95% the null hypothesis is rejected at only two further 
wavenumbers at 469 and 1282 cm
-1
. Chemometric analysis was then performed on the 
data to calculate whether the two sets of data could be categorised. The differences 
between the two groups were not sufficient to differentiate between the spectra obtained 
from inner or outer surfaces. The overlap between the two groups was very evident 
when the scores for the LDA analysis were plotted (Figure 95). These findings therefore 
support the statement that there is little difference between the mean spectra acquired 
from the outer and inner half of the lymph node. 
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Figure 95–PCA fed LDA scores for spectra from the inner (blue) and outer (green) surface of each node 
demonstrating the difficulty separating the two datasets. 
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Whilst the results from the overall mean spectra were encouraging it was theorised that 
greater differences may be seen in the nodes with metastatic disease. As previously 
discussed metastatic cells that have spread to axillary lymph nodes are first found in the 
subscapular sinuses before passing to the medullary sinuses from where they penetrate 
the medulla, then the cortex, and eventually can result in parenchymal replacement 
(Iochim and Ratech 2009). Thus although isolated metastatic cells may be found near to 
the outer surface of the node large macrometastases are more likely to be found in the 
centre of the node.   
 
Thus a dataset was created that included the spectra from the macrometastases positive 
nodes (that had been acquired from both the inner and the outer surface of the node) and 
the spectra obtained from the inner surface of the N0 negative nodes. When the mean 
spectra of the macrometastases samples acquired from the inner surface were plotted 
with the mean spectra of the macrometastases samples acquired from the outer surfaces 
clear differences are evident. If the mean spectra acquired from the inner surface of the 
N0 negative nodes were plotted on the same graph it is clear that the mean spectra from 
the outer surface of the macrometastases nodes has shifted towards the mean spectra 
from the true negative nodes (Figure 96). 
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Figure 96 – Mean spectra collected from the outer (orange dash, n=31) and inner (red, n=32) surface of 
the lymph nodes with metastatic spread and the inner surface of normal nodes (green, n=160). 
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This is further demonstrated when the contributions of the 34 key peaks described at the 
start of Chapter 4 are assessed.  There were statistically significant differences in the 
contribution of protein, DNA and lipid. The results demonstrate a shift away from the 
N0 nodes but not quite to the level achieved when sampling from the inner cut surface 
(Figure 97) (Table 27). 
 
Figure 97 –Mean intensity scores (with 95% confidence intervals) for peaks related to protein, DNA and 
lipid and a combined score for N0 inner surface (n=160,green), macrometastases outer surface 
(n=31,orange) and macrometastases inner surface (n=32,  red.)  
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 Mean Lipid 
Score 
(SD, SEM) 
Mean Protein 
Score 
(SD, SEM) 
Mean DNA 
Score 
(SD, SEM) 
Mean Combined 
Score 
(SD, SEM) 
 
Macrometastases Inner 
(n=32) 
 
0.32 
(0.03, 0.005) 
 
0.40 
(0.04,0.007) 
 
0.24 
(0.02, 0.004) 
 
0.82 
(0.06, 0.01) 
 
N0 Negative   
(n=160) 
 
0.40 
(0.05, 0.004) 
 
0.30 
(0.06,0.005) 
 
0.19 
(0.04, 0.003) 
 
0.59 
(0.04, 0.003) 
 
Macrometastases Outer 
(n=31) 
 
0.35 
(0.03,0.005) 
 
0.368 
(0.03, 0.005) 
 
0.2185 
(0.02,0.004) 
 
0.73 
(0.05, 0.01) 
 
1.Unpaired t-test 
Inner v. Outer 
2.Unpaired t-test 
N0 v. Outer 
 
p=0.004 
t=3.74 
 
p=0.007 
t=3.6 
 
p<0.001 
t=4.3 
 
P<0.001 
t=6.5 
 
p<0.001 
t=4.9 
 
p<0.001 
t=6.3 
 
p<0.001 
t=4.3 
 
p<0.001 
t=17 
  
Table 27: The combined intensity of peaks attributable to lipid, protein and DNA in the macrometastases 
(inner and outer spectral collections) and N0 (inner spectral collection) groups. Results of unpaired t-tests 
confirm the statistical significance of these differences and are also shown. 
 
This effect was further interrogated by using the data to differentiate between the 
positive and negative samples. PCA fed LDA and leave one node out cross validation 
was again used as discussed earlier in the chapter.  
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Using leave one node out cross validation testing the test achieved a specificity of 
97.7% (129/132) and a sensitivity of 81% (25/31) at differentiating between N0 negative 
nodes (spectra from the inner surface) and macrometastases samples (spectra from the 
outer surface) (Table 28). This was then compared to the results of the leave one node 
out cross validation testing of the samples acquired from the inner surface of the 
macrometastases samples which in this dataset achieved a sensitivity of 93.6% (29/31) 
and a specificity of 99.2% (131/132).  
 
 Pathology 
Positive Negative 
Raman Positive 25 3 
Negative 6 129 
 Sensitivity =81% Specificity=98% 
 
Table 28- The sensitivity and specificity table with spectra from the outer surface. 
 
An explanation for the compositional analysis results is that there is greater contribution 
to the spectra from normal areas of the node when they are acquired from the outer 
surface. Therefore in the 6 false negatives it could be argued that the spectral features of 
the metastases were either masked by the normal areas of the node or the probe simply 
did not collect information from a deep enough volume to detect them. This will have 
also affected the overall model and may explain the slightly worse specificity. The 
histopathology reports for these nodes demonstrate that the 6 false negative samples 
have a mean diameter of 9.33mm which is beyond the sampling depth of the probe, and 
that there is no evidence of extra nodal spread in any of them. Neither of the false 
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negatives from the inner surface analysis were correctly placed by assessment of the 
outer surface. This suggests that currently lymph node assessment from the outer 
surface of the node is not only, not as sensitive as assessment from the inner surface, but 
that it may not be complimentary to the inner surface testing either. It should however 
be noted that the sensitivity remains higher than that reported for frozen section and 
touch imprint cytology. It therefore appears that whilst not as good as inner surface 
testing then this might be worth pursuing following the establishment of an effective 
testing model if the benefits of in situ testing were clear. 
 
The dataset was then used to examine the spectra for micrometastases and ITCs 
Potentially because ITCs are found in the outer capsule of the node it is possible that 
spectra acquired from the outer surface of the node would be better able to detect these 
small deposits than those obtained from the inner surface. This however proved not to 
be the case. Using chemometric analysis a specificity of 99% (159/160) but a sensitivity 
of only 33% (3/9) was achieved when differentiating ITCs from. When differentiating 
between micrometastases and N0 nodes with a specificity of 99.2% the sensitivity was 
37.5% (3/8). These are broadly consistent with the results of the spectral analysis of 
those collected from the inner surface. Again none of the false negatives, from analysis 
of the inner surface, were correctly placed using the outer surface spectra. 
 
Based on these results nodal analysis based on spectra obtained from the outer surface 
of the node as opposed to those obtained from the inner surface of the node could not be 
supported. The results are poorer both for the identification of macrometastases but also 
micro metastasis and ITCs. Complimentary assessment of both the inner and outer 
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surface would have not improved the correct classification of the node as the false 
negatives were present in both groups. If spectral analysis from the outer surface is to be 
improved then either the benefits of in-situ testing need to be significant enough to 
overcome the poorer sensitivity or probes with a greater sample depth will be required 
to overcome the effects of normal tissue which surrounds the metastatic deposits. 
 
4.6. Intraoperative Work - Conclusions  
 
The results in this chapter for the first time demonstrate the efficacy of a portable 
Raman spectroscopic device at differentiating between positive and negative nodes for 
patients undergoing axillary surgery for breast cancer, in real time. They are also some 
of the first results that use Raman spectroscopy at the patient “bed side” to assess tissue.  
 
 The results of dataset 1 comparing N0 negative nodes to nodes positive for 
macrometastases are unsurprisingly, most promising. The best results achieved are 
easily comparable, if not better, than many of the currently available techniques. The 
demonstration of the molecular differences that underpin these results by both 
interpretation of peak positions and evaluation of the principal components generated 
using PCA adds further weight to these results. Differences in the protein, DNA and 
lipid concentrations within nodal tissue are consistent with the anticipated changes that 
would be expected when a colony of metastatic cells invades an axillary lymph node.   
The results achieved when including the negative samples from non-N0 patients and 
those with micrometastases and isolated tumour cells were less encouraging. They are 
however important findings as it demonstrates that future models should be built on data 
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from samples from N0 patients and samples positive for macrometastases only. 
Clinically the need to discover either micrometastases or especially ITCs is 
questionable. If it was felt clinically important then samples used in future studies may 
need to be multiply sectioned before spectra were acquired to help overcome the issue 
of sampling depth. The results in the final section suggest that until portable devices 
with greater sampling depth become available that spectral acquisition from the cut 
inner surface will remain the mainstay of assessment. 
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5. Reproducibility 
 
A key concern associated with the introduction of a new diagnostic technique is the 
reproducibility of the results that it produces. This chapter will examine this by altering 
key factors in the assessment of tissue using a portable Raman spectrometer. Discussion 
amongst the project investigators identified three modifiable factors which could 
influence the results obtained. The first of these is the time between tissue excision and 
assessment using the Raman device. This along with the second factor identified, the 
effect and implications of using different spectrometers, was investigated using the 
nodes collected as part of the series reviewed in Chapter 4. The final factor, the effect of 
different individuals using the equipment to assess the same tissue was assessed using 
animal tissue within the laboratory setting. In this chapter the methods and results of the 
experiments carried out to investigate the effects of altering these three factors will be 
introduced and discussed.   
5.1. Reproducibility Experiment 1 - The effect of alterations in the time from 
excision to the time of assessment.  
 
5.1.1. Reproducibility Experiment 1 - Methods 
 
The project protocol, discussed in Chapter 4, stipulated that following excision of the 
node, any fat would be dissected free from the node and the node would then be 
bisected and assessed using the Raman spectrometer. The tissue was then returned to 
theatre before the end of the case to reduce the risk of samples being mislabelled. As a 
result the maximum time that tissue could be assessed post excision was estimated to be 
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40 minutes. As often more than one sample was collected from each patient the exact 
time at which the sample was assessed post excision varied. To assess the effect of this 
time delay on the diagnostic ability of the system an experiment was set up such that 
nodes were assessed immediately post excision, and then at time delays of 10, 30 and 60 
minutes.  
 
8 of the node samples collected from 8 different patients and on 6 different days were 
included in this study. Following the techniques described in the methods section of 
Chapter 4, 5 spectral measurements were made immediately after excision and then 
again 60 minutes later. For 7 of the eight samples intermediate measurements were also 
made at 10 and 30 minutes after the initial spectrum had been acquired. In between 
sample acquisitions the tissue was placed on a clean Petri dish.  Acquisition of spectra 
from other samples continued during the intervening time and the node was orientated 
on the probe in as close to the same orientation as possible for each assessment. Spectra 
were then interrogated using Matlab® software on a desktop PC. Prior to interrogation a 
mean spectra (n=5) was created for each sample at each collection time. A mean spectra 
containing all the spectral information from each time point (n= 40 (time 0), n=35 (+ 10 
minutes), n=35 (+30 minutes), n=40 (+60 minutes)). Statistical analysis using a paired t-
test and PCA fed LDA was then performed.  
 
5.1.2. Reproducibility Experiment 1- Results. 
 
Histopathologically three of the nodes in this dataset were negative samples from N0 
patients, 2 were non N0 negative nodes, one was positive for isolated tumour cells, one 
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for macrometastases and one contained no lymphoid material.  The mean spectra for all 
the spectra collected from all eight samples at each separate time interval were plotted 
and demonstrated very few obvious differences on initial inspection (Figure 98). To 
statistically demonstrate this, paired t-tests were performed to compare the mean 
intensity of each wavenumber at time +10 minutes, +30 minutes and +60 minutes to the 
intensity at time 0. The null hypothesis was that there was no difference between the 
intensity of each wavenumber. With 6 and 7 degrees of freedom (in the 10 and 30 
minute groups and 60 minute groups respectively) this would be rejected if the t value 
was greater than 3.14 or 3. In the 10 minute group two wavenumbers at 930 and 
1648cm
-1 
recorded t values above 3.14 and in the 30minute group two different 
wavenumbers at 1074 and 1248cm
-1 
recorded t values above 3.14. In the 60 minute 
group the greatest t value that was achieved was 2.9 and therefore the null hypothesis 
was accepted for all wavenumbers.  These results supported the conclusion that there 
were only very minimal changes in the spectra when recorded from the same fresh 
tissue sample up to 60 minutes apart. However it did not look at individual samples but 
instead focused on the change in time.  
 
As the critical end point was the diagnostic output of the system further analysis was 
performed to determine whether the difference in time altered the diagnostic result 
achieved for each sample. To do this an analytical experiment was designed using the 
spectra collected from all the 339 lymph node samples in the series described in Chapter 
4. Using PCA fed LDA and leave one node out cross validation we were able to 
calculate both a score for each node at the four different time intervals and a diagnostic 
result (Figure 99). 
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Figure 98 – Mean spectra (n=40 at time 0, n=35 at time +10, n=35 at time +30 and n=40 at time +60) 
from all nodes taken at different times following excision. 
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Figure 99 –Diagrammatic representation of the diagnostic assessment of data collected at different time 
intervals following excision. 
 
To achieve this a dataset termed “negative” that included 289 non positive samples and 
a dataset termed “positive” that included 50 samples that were positive for 
macrometastases, micrometastases or isolated tumour cells was created . PCA fed LDA 
was then performed and a score was generated for each sample at each time point. A 
paired t-test was then used to determine the statistical significance of the differences in 
these scores for each sample with changing time. The null hypothesis was that there was 
no difference in the scores obtained over the different time ranges. With 6 and 7 degrees 
of freedom we were unable to reject the null hypothesis at the 99% confidence level in 
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any setting.  There were thus no statistically significant differences in the scores 
recorded for each sample at the three different time points.  It was interesting to note the 
rise in the t value as the time from the first spectral acquisition increased (Table 29).  It 
is questionable, although this hasn’t been confirmed in this study, whether beyond 60 
minutes the score achieved for each sample may demonstrate significant differences.  
This needs to be given careful consideration as further trials and experiments are 
planned and set up. 
 
The negligible affect of time, up to 60 minutes, from first spectral acquisition was 
further emphasised by the results achieved when projecting the data onto the LDA 
model (Figure 99). In all of the 8 samples the same pathological classification was made 
in comparison to time point 0 at time points +10 minutes, +30 minutes and +60 minutes 
(Table 30). 
 
Time 
Point 
 
Sample 
Numbers 
 
Mean difference in sample LDA 
score between time 0 and time point 
 
 
Standard error of 
the difference 
 
t-value 
 
p value 
10 7 -0.0004 0.002 0.17 0.87 
30 7 -0.003 0.003 1.0 0.3554 
60 8 -0.004 0.002 1.96 0.09 
 
 
Table29: Difference between the mean LDA score achieved at time 0 and at time points +10 (n=7), +30 
(n=7) and +60 (n=8) minutes. Statistical significance of this difference is given by the t value and p 
values following a paired t-test. None of the time points have statistically significant differences but they 
are approaching significance at 60 minutes. 
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Sample Time 0 Time 10 Time 30 Time 60 
1 Neg Neg Neg Neg 
2 Neg x x Neg 
3 Neg Neg Neg Neg 
4 Neg Neg Neg Neg 
5 Neg Neg Neg Neg 
6 Pos Pos Pos Pos 
7 Neg Neg Neg Neg 
8 Neg Neg Neg Neg 
 
Table 30 - LDA based classification at time point 0, +10, +30 and +60 minutes. There is no difference in 
any of the 8 node samples at all time points (neg=negative, pos=positive). 
 
5.1.3 Reproducibility Experiment 1- Conclusions. 
 
As real time clinical use of Raman spectroscopy becomes closer the results of this study 
are pivotal. The vast majority of published Raman based studies to date are based on 
snap frozen samples assessed within the laboratory setting. These results support the 
acquisition of spectra from fresh tissue up to 60 minutes after excision. In the context of 
this project this time is well beyond the time available for intra-operative analysis. As 
has already been discussed this time period is approximately 40 minutes and thus these 
results support the validity of results that are achieved within this time.  
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5.2. Reproducibility Experiment 2 -Use of different spectrometers. 
 
If Raman spectroscopy driven diagnostic models are to be used clinically then it is 
apparent that more than one spectrometer will need to be used. Indeed it may be that 
many spectrometers are used at different sites based on a classification model derived 
from one or more spectrometers.  To examine the effects of using different 
spectrometers a MiniRam I, a similar but earlier model of the MiniRam II was obtained 
from Pacer UK, the UK distributor of B&W-Tek Raman spectrometers. This 
spectrometer was then used to acquire spectra alongside the MiniRam II during 6 days 
of intra-operative theatre based testing. 
 
5.2.1. Reproducibility Experiment 2 – Methods. 
 
To investigate the effect of using two different spectrometers an experiment protocol 
was set up such that each sample could be assessed using the two systems. 5 spectra 
were acquired from 14 node samples, from 9 different patients over 6 separate days in 
the series described in Chapter 4. Each sample was placed on the probe and 5 spectra 
were recorded using one spectrometer as described in the methods section of Chapter 4. 
The collection and excitation ends of the probe were then transferred to the other 
spectrometer and a further 5 spectra were obtained without moving or touching the 
node. 8 nodes were assessed first with the MiniRam I and 6 with the MiniRam II to 
avoid the confounding error of time. A total of 140 spectra were included in the data 
analysis. All data was assessed using Matlab® software.  Initial interpretation of the 
results was made difficult as the computational method by which data was recorded and 
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saved by each system was slightly different and resulted in a peak shift when the raw 
data was plotted. Subsequently this experiment also investigated whether the correction 
methods that have previously been described (Chapter 4) would help overcome this.  
 PCA fed LDA was used to try and split the data based on the type of spectrometer used. 
A paired t-test was then performed and finally leave one node out cross validation 
testing was used to determine any differences in the classification of samples by the two 
systems.  
 
5.2.2. Reproducibility Experiment 2 – Results.  
 
Following histopathological analysis 10 of the nodes included in this dataset were 
negative; one was positive for isolated tumour cells, one for micrometastases and one 
for macrometastases. As described in Chapter 4 initial spectra correction was based on 
the position of the cyclohexane peaks. This helped to overcome the obvious shift that 
was evident in the two groups (Figure 100, 101, 102). Despite this correction the two 
groups could easily be differentiated by chemometric analysis. However the 
Mahalanobis distance, which is a measure of the variability between the two groups, fell 
from 4090 to 104 after this initial corrective procedure. 
 
The second step in correcting the spectra was based on the green glass standard. The 
mean green glass spectra obtained from the two spectrometers were markedly different 
(Figure 103).  This difference was corrected for all of the spectra acquired (Figure 104). 
When PCA fed LDA was performed on this corrected dataset the Mahalanobis distance 
fell further to 74. 
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Figure 100– Mean spectra of nodal tissue collected with two different portable Raman spectroscopy 
devices (MiniRam I, n=70 (blue), MiniRam II, n=70(red)). 
222 
 
0
2
0
0
4
0
0
6
0
0
8
0
0
1
0
0
0
1
2
0
0
1
4
0
0
1
6
0
0
0
0
.0
2
0
.0
4
0
.0
6
0
.0
8
0
.1
0
.1
2
0
.1
4
0
.1
6
0
.1
8
0
.2
R
a
m
a
n
 S
h
if
t 
(c
m
-1
)
Intensity
 
 
M
in
iR
a
m
 I
I
M
in
iR
a
m
 I
 
Figure 101 – Mean spectra of cyclohexane standards recorded with two different Raman spectroscopy 
devices (MiniRam I, n=6 (blue), MiniRam II, n=6(red)). 
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Figure 102 – Mean Spectra of nodal tissue recorded with the two different Raman spectroscopy devices 
after shift correction (MiniRam I, n=70 (blue), MiniRam II, n=70(red)).Labels included for clarity and to 
demonstrate the position of prominent peaks.  
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Figure 103 – Mean Spectra of green glass standards recorded with two different Raman spectroscopy 
devices (MiniRam I, n=6(blue), MiniRam II, n=6(red)). 
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Figure 104– Mean spectra of nodal tissue collected with two different Raman spectroscopy devices after 
shift correction and green glass correction (MiniRam I, n=70 (blue), MiniRam II, n=70(red)). 
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Following the protocol in the previous chapter the next step involved baseline 
correction the data of the data, followed by smoothing and then normalising it. After 
each of these steps the Mahalanobis distance was calculated and continued to fall to 73, 
64 and 26 respectively.  
 
Following all stages of correction the mean spectra of the 14 node samples and the 
cyclohexane standards collected from each spectrometer were plotted (Figure 105, 106). 
The similarity of the two mean spectra was now more visible. This was supported by 
the Mahalanobis distance which had fallen from 4090 to 26. Differences still remained 
evident and these were highlighted when a paired t test was performed on the data. 
 
The null hypothesis of the t-test was that there was no difference between the spectra 
obtained using each spectrometer following correction. With 13 degrees of freedom the 
null hypothesis would be rejected if the t value was greater than 2.65. The null 
hypothesis was rejected for 35 wavenumbers suggesting that even after correcting the 
data there are areas of significant difference between the spectra obtained from the two 
spectrometers (Figure 107).  
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Figure 105 – Mean Spectra of nodal tissue recorded with two different Raman spectroscopy devices after 
correction. (MiniRam I, n=70 (blue), MiniRam II, n=70(red)). 
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Figure 106 – Mean Spectra of cyclohexane standards recorded with the two different Raman 
spectroscopy devices after correction (MiniRam I, n=70 (blue), MiniRam II, n=70(red)). 
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Figure 107 – Statistical significance of the residual spectral differences after correction to overcome the 
use of two different Raman spectrometers (x axis = Raman Shift (cm-
1
), y axis = t value). 
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When these results were plotted it was clear that a significant number (24/35) of these 
differences occurred in the region between 1747 and 1771 cm
-1
. As detailed in Chapter 
4 there were very few significant peak differences above 1747cm
-1
. If the dataset was 
cropped at 1748cm
-1
 the Mahalanobis number was further reduced to 18. Whilst 
recognition of the differences was important the effect on the diagnostic outcome was 
the key factor that the study hoped to demonstrate.  Previous experiments, discussed in 
Chapter 4, differentiating between negative v macrometastases nodes achieved a 
Mahalanobis distance of 31. 
Thus the differences in spectra obtained by the two spectrometers were less than the 
spectral differences between the two groups. It was thus felt likely that the results from 
either spectrometer could still be used to differentiate between the pathological groups. 
To test this PCA fed LDA and leave one node out cross validation was used to calculate 
a classification score for each sample based on the spectra collected with each 
spectrometer (in a similar way to the previous experiment looking at the effects of 
time). In the cross validation test the spectra from all the intra-operative node series 
(n=339) that were collected with the Mini Ram II were used. The classification scores 
for each sample in the series were then used to perform a paired t-test. The null 
hypothesis was that there was no difference between the scores achieved using the two 
systems. The null hypothesis would be rejected if the t value was greater than 2.65. The 
calculated t value was 1.1281 and thus the null hypothesis was accepted.  The cross 
validation analysis classified each node based on the results achieved and 13/14 node 
samples were placed in the same pathological category. Only one sample, a node that 
had micrometastases on histopathology, was changed from a positive classification to a 
negative one. 
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5.2.3. Reproducibility Experiment 2 - Conclusions 
 
Drawing conclusions from this experiment is important for the long term viability of 
Raman spectroscopy as a diagnostic tool. Although these results are drawn from a 
relatively small dataset they are one of the first that directly compare spectra acquired 
from human tissue in a real time clinical setting using two spectrometers. The correction 
protocol, described in Chapter 4, appears to give good if not perfect spectral correction. 
Although 35 of the wavenumbers show statistically significant differences only 10 of 
these were between 400- 1747cm
-1 
which equates to 0.7% of the spectra in this region. 
Data analysis in Chapter 4 did not highlight any significant peak differences between 
positive and negative nodes above 1747cm
-1
. Importantly there was no statistical 
difference between the classification scores obtained for each node using either 
spectrometer. Only one node was re-classified using the Mini Ram I. This node was in 
the micrometastases group and had a classification score that placed it on the border 
between the positive and negative groups. These results are therefore encouraging and 
suggest that applying diagnostic models recorded with one spectrometer to prospective 
data collected from multiple spectrometers could be possible. Further testing with larger 
datasets and multiple spectrometers will be required prior to the clinical use of any 
Raman based diagnostic model. 
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5.3. Reproducibility Experiment 3 - Multiple Users. 
 
One of the key elements of reproducibility is that multiple users should be able to use 
the equipment and still achieve the same diagnostic results. This is vital if the 
spectrometer is to be used in a clinical environment by multiple users often with varying 
levels of experience.  An experiment was thus designed whereby three samples were 
measured using the same spectrometer by 6 individuals. 1 user had extensive experience 
of using the equipment, 2 had previously used the equipment on a limited basis and 3 
were naïve to the system.  
 
5.3.1. Reproducibility Experiment 3 – Methods. 
 
In the experiment each user was given a standard instruction sheet and acquired spectra 
from the three samples in the same order. They were blinded to the composition of the 
samples they were measuring.  5 spectra were acquired from each sample and saved 
automatically using a standard function that was built into the spectrometer. The data 
was then transferred to Matlab® for further assessment. Following spectral correction 
(as detailed in Chapter 4), all the spectra from each sample were plotted. PCA fed LDA 
as outlined previously was employed to separate the 3 sample groups. 
 
5.3.2. Reproducibility Experiment 3 – Results. 
 
The spectra collected by each individual appeared broadly similar with only minimal 
differences on initial inspection of each sample group (Figure 108-110). 
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PCA fed LDA was then performed to test whether the spectra recorded by each 
individual could be used to differentiate the tissue into separate groups.  A sensitivity 
and specificity of 100% was recorded for each of the 3 groups. As can be appreciated 
from reviewing the mean spectra for each sample it was much easier to differentiate the 
spectra from sample c from the samples a and b (Figure 108-110). There was a degree 
of variation in the spectra collected by each user but this was not significant enough to 
prevent each sample being correctly grouped using PCA fed LDA (Figure 111) (Table 
31). One possible explanation for these differences was a slight difference in the 
position of the sample when it was placed on the probe tip.  However despite this, these 
results demonstrate that the equipment and technique can be used to differentiate 
between different samples independent of who measured the sample. 
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Figure 108 – All spectra collected by all 6 individual users from sample A (n=30). 
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Figure 109 – Spectra collected by all 6 individual users from sample B (n=30). 
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Figure 110 – Spectra collected by all 6 individual users from sample C (n=30). 
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0 
 
0 
 
Sample B 
 
0 
 
30 
 
0 
 
Sample C 
 
0 
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Table 31- Results demonstrating 100% sensitivity and specificity independent of the assessor  
 
 
Figure 111 – Separation of the three groups based on PCA fed LDA scores for all the spectra collected 
by 6 different users 
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5.4 Reproducibility Experiment 3 – Conclusions.  
 
The results presented in this chapter touch on what will in turn become a much wider 
area of research. Proving that results obtained using different spectrometers by different 
individuals at different times after removing the tissue from the body will be vital if this 
technique is to be used as part of main stream diagnostics in breast cancer.  
Much more thorough testing will of course be required to satisfy the appropriate 
regulatory bodies than presented here. However these results for the first time start to 
explore these concepts and as a provisional set of results they appear very promising. 
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6. Discussion 
 
Breast cancer is a disease which attracts a great deal of clinical research, of which this 
Raman based study, is one such example. There is a strong base of knowledge that 
supports the use of Raman spectroscopy as a method of differentiating between normal 
and malignant tissue. As systems have developed researchers have become increasingly 
excited about moving the research from the laboratory to the patient’s bedside. This is 
one of the first studies to take this move. By moving to the patient the study is 
conducted in real time, on fresh tissue. By coupling smaller spectrometers to 
mathematically based diagnostic algorithms this study supports the use of Raman 
spectroscopy as a rapid, accurate, non destructive and potentially affordable diagnostic 
test.   
 
At the start of this study there were two key questions which needed to be answered. 
Could a portable Raman spectrometer be used within the theatre environment and could 
it achieve results at differentiating between normal and metastatic nodes that were 
comparable to other modalities? If both were answered positively then the final question 
would be how can the results achieved be used to take the study forward? 
 
6.1. Could a portable Raman spectrometer be used within theatre? 
 
Much of the clinical Raman spectroscopy work to date has been performed within the 
laboratory within very stable and regulated environments. Overcoming factors 
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associated with both the operating theatre environment and the methods employed as 
part of surgical technique was thus a crucial first step in this process. 
 
Anticipated variations in temperature have been demonstrated to have a limited effect 
on the spectra collected. The operating lights and ambient room lighting has been 
overcome with the use of light eliminator. As it turned out, because of safety 
precautions, this was not as vital as anticipated as all of the intra-operative work was 
performed within a small room adjacent to theatres. None the less this work was an 
important step which will allow the spectrometer to be used within theatre in the future.  
 
One of the key concerns about any new diagnostic modality, particularly within surgical 
oncology, is the importance of avoiding cross contamination. The devastating effects of 
one patient undergoing, ultimately unnecessary, treatment based on the results of 
another patient must be avoided. This study utilised two different mechanisms to avoid 
this. The first and most important of these was ensuring that all node assessment was 
performed before the patient left the operating theatre. The second technique was the 
use of a sterile sheath. Early testing demonstrated that this had minimal effect on the 
spectra collected and was thus used throughout the clinical phase of this study. 
 
The time taken to collect spectra and thus “assess” the node is not only critical to avoid 
clinical errors but is also important when considering the ultimate aim of guiding a 
clinical decision as to the need for an axillary clearance. An intra-operative test needs to 
provide results in a time frame that avoids any delays that would disrupt an operating 
list and mean that the patient is anaesthetised for a longer period of time than necessary. 
239 
 
Current techniques are performed on the excised node whilst the operating surgeon 
continues with the excision of the breast tumour. If an axillary clearance is deemed to be 
required then this is performed as the final part of the operation. Within this study no 
patient underwent further axillary surgery based on the results of either the Raman 
spectrometer or any other intra-operative method. Ensuring that all assessment took 
place before the patient left theatre, initially to prevent cross-contamination of samples, 
also demonstrated that the results could be delivered without undue delay if an axillary 
dissection was deemed necessary. It can be argued that the “assessment” carried out in 
this study was not complete as there was no diagnostic output, but it is anticipated that 
algorithms used to provide this answer will be rapid and measured in seconds.  
 
The time frame of assessment took on further importance when the effects of time post 
excision of tissue were investigated. The results of the reproducibility study looking at 
the effects of time post excision suggest that there are no statistically significant 
differences up to 60 minutes after tissue removal. The trend in the t-value does however 
suggest that this may not be the case much beyond this time frame, and will need to be 
considered when planning future studies.  
 
Introducing a new step in the management of a particular condition requires that the 
additional step is compatible with the established techniques. One of the concerns at the 
outset of the study was the effect of Patent V blue dye on the spectra obtained from the 
lymph nodes. Within the UK this dye is widely used to help identify the lymph node 
and any new test will need to be compatible with it. Although initial studies suggested 
that this was likely to be problematic, further studies on nodes in the Dudley series 
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disproved this. The identification of the principal component of blue dye and its 
subsequent removal from reconstituted spectra had little effect on the diagnostic 
potential of the results achieved. One potential problem as this project moves forward is 
that, although blue dye is widely used in the UK, other markers such as Indomethacin 
Green are used elsewhere and this will need to be accounted for. 
 
6.2. Could a portable Raman probe achieve results at differentiating between 
normal and metastatic nodes that were comparable to other modalities?  
 
In any clinically based study the “buy-in” of the clinicians whose patients you hope to 
recruit is vital. Before embarking on real time clinical work it was important to 
demonstrate to them why a diagnostic test based on Raman spectroscopy might work. 
This involves both a study of the previously published literature and early feasibility 
studies using the equipment that we had selected.  
 
Previous work, as discussed in Chapter 2, has consistently shown, within breast tissue, 
that the key differences in the spectra obtained are an increased contribution of lipid in 
the normal tissue relative to an increased contribution of protein and DNA in the 
malignant tissue. These results are supported by FTIR studies in axillary, oesophageal 
and head and neck cancers, and by mapping Raman studies on axillary lymph nodes 
performed within our own unit (Smith 2005). The mapping studies and subsequent 
probe modelling of the data produced were carried out on tissue with a depth of several 
μm. To replicate this tissue depth in this study would have involved a significant 
preparatory step. This would have extended the time frame beyond clinical relevance 
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and potentially damaged tissue that remained important for the staging and thus 
management planning of the patients who agreed to take part in the study. A number of 
experiments were set up to estimate the depth from which spectral information could be 
collected using the MiniRam II spectrometer and probe.  Whilst it is recognised that 
there are a number of limitations to these studies and that interpretation should therefore 
be performed with caution the results suggest that spectral information could be 
detected at depths up to 3mm. This was crucial as the vast majority of lymph nodes 
have been shown to be less than 9mm in diameter and metastatic deposits are initially 
found within the medulla of the node before spreading to the cortex. By collecting 
spectra from the inner surface there was confidence that spectral information 
particularly related to macrometastases would be detected if they were present. 
 
Prior to commencing studies within theatre a feasibility study was performed on node 
samples that had been collected by collaborators at Russell’s Hall Hospital, Dudley, 
UK. The feasibility study, discussed in Chapter 3, included 38 node samples from 17 
different patients and revealed very encouraging results. A sensitivity of up to 90% and 
a specificity of up to 96% were achieved using unsupervised leave one node out testing. 
The results achieved were broadly similar even when only 5 spectra were assessed per 
node and enabled the “assessment” of each node to be performed in a clinically relevant 
time frame.  There were a number of drawbacks to this study however. The samples 
were snap frozen, it was often difficult to determine the orientation of the node and thus 
definitively collect spectra from the inner half, and the “gold standard” 
histopathological assessment was based on a single slice with immuno-histochemistry 
staining. Therefore spectra may have been collected from the outer half of the node and 
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samples may have been mis-classified. It was however an important step in establishing 
the potential of the equipment we were using and it was hoped that even better results 
could be achieved in the real time study. 
 
Building on both the feasibility study and the preparatory experimentation the clinically 
based part of this study was established. With local ethical approval a total of 66 
patients undergoing 72 operative procedures were recruited and from these patients 339 
samples from 176 lymph nodes were assessed. The results achieved when trying to 
distinguish between the two most distinct groups, the macrometastases and the N0 
patients were most promising, as discussed in Chapter 4. The unsupervised test result 
achieved specificity of 99.4% and a sensitivity of 93.8%, which is easily comparable if 
not far better than currently available intra-operative tests. Evidence that these results 
are based on differences in lipid, protein and DNA contributions is also consistent with 
previous work on breast cancer and normal breast tissue and is vital in helping explain 
the application of the test to clinicians. On an individual level 44/48 patients would have 
benefited from intraoperative testing had the results been used to guide clinical decision 
making. In particular 38 patients would have been spared the wait for their 
histopathological nodal assessment, and 6 would have avoided the need for a second 
operation to clear the axilla. There would have been two false positives and this will 
need to be addressed as the use of Raman spectroscopy moves forward. It is vital that 
the specificity should be maintained as close to 100% as possible, as the result of a false 
positive would be a recommendation for an axillary clearance that ultimately was not 
needed.  
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The subsequent inclusion of negative nodes from non-N0 patients into the negative 
group had a deleterious effect on the specificity (96%) and sensitivity (84%). This is 
suggestive that there are some differences within nodes that although not metastatic 
themselves are part of a chain of nodes at least one of which is metastatic. Peak analysis 
demonstrated significant differences in the contribution of proteins to the spectra of 
non-N0 nodes. This may have affected the overall classification model and could 
account for the increase in both false negatives and false positives. For the individual 
patient involved this would not have had any deleterious effects as they would, by 
definition, have had another node that was positive. They would therefore already have 
been defined as having a positive axilla. 
 
The effect of these non-N0 negative nodes is important in helping to design a 
mathematical algorithm as this project progresses forward. This data suggest that any 
such algorithm will need to be based on spectra from N0 patients only and not negative 
nodes from non-N0 patients.  
 
In comparison to the results achieved with the macrometastases the results from the 
nodes with either micrometastases, 50% sensitivity, or isolated tumour cells, 40% 
sensitivity, were disappointing. It was interesting to note that those that were 
successfully identified and those that were not, appeared to be in two distinct groups 
based on the contribution of lipid, protein and DNA to the spectra. It could be argued 
therefore that within the samples which were correctly identified the foci of metastases 
did significantly contribute to the spectra but in the other samples it either did not at all 
(i.e. it was not “seen”) or the greater amount of normal tissue eclipsed it. This may be a 
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reflection on the small size of the deposits within the tissue and the difficulty detecting 
them using the methodology that was employed. If it was clinically felt that the 
identification of micrometastases and isolated tumour cells remained important then 
samples used in future studies may need to be multiply sectioned before spectra were 
acquired to help overcome this problem. The emerging data, especially from Z-0011 
suggests that this is unlikely to be the case. It is likely that patients with ITCs will 
continue to be classified as node negative and that those with micrometastases will 
increasingly not be recommended to undergo further axillary surgery. If further surgery 
is recommended then this should be following MDT discussion and would not, given 
the current evidence, be following intra-operative assessment.  
 
In situ testing from the outer surface of the node was suggested as a possible next step 
forward for this project. However the results presented, a fall in sensitivity to 81% for 
the identification of macrometastases, do not support this. The difference can be 
explained by the initial presence of metastatic deposits within the medulla before spread 
towards the cortex occurs. Therefore by placing the probe on the outer surface, light will 
be scattered first by a normal cortex before it reaches a metastatic medulla. No 
improvements in the results for the micrometastases or isolated tumour cells were 
reported. Thus future testing should continue to collect spectra from the cut inner half of 
the node.  
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6.3. Future Studies 
 
The results presented within this thesis really do open the door to real time “bed side” 
tissue testing using Raman spectroscopy. This technique which is quick, non destructive 
(thus facilitating gold standard cross checking) and affordable has many advantages 
over the other currently available methodologies that were outlined in Chapter 1. Before 
it can guide clinical management a number of future studies need to be completed.  
 
The first and most important next step should be the production of a classification 
algorithm or model that can then be prospectively tested. It is envisaged that this model 
would be based on dataset 1 that was discussed in Chapter 4. Prospectively testing this 
with independent specimens could then directly compare Raman spectroscopy and its 
algorithmic model to the current gold standard. Particular care will be need to be paid to 
any false positive results as these are the cases that need to be avoided. Further 
sectioning of the axillary node by the pathologists may be required to ensure that the 
gold standard technique hasn’t missed any small deposits that the Raman device is 
“seeing”. Initially this testing would be take place at one hospital site but then latterly 
this could be extended to multiple units, with multiple spectrometers. The use of 
multiple instruments and users would build on the reproducibility experiments outline in 
Chapter 5. The results from these independent samples could then be added to the 
algorithm to further increase its size and robusticity. It is hoped that with increasing 
sample numbers the classification model will become more powerful resulting in further 
improvements in sensitivity and specificity. This work is ongoing currently and the 
results are awaited eagerly. It is hoped that these results will provide a catalyst for 
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further studies that move Raman spectroscopy away from the laboratory to the patient’s 
bed side. Within breast cancer the demonstration that this equipment can differentiate 
between normal and metastatic tissue opens it up to use in the immediate assessment of 
core biopsy samples, within a “one-stop” breast clinic or the interrogation of margin 
status during a wide local excision. Outside of breast cancer the potential for Raman 
spectroscopy to be used in a wide range of clinical scenarios is very real. It could, for 
example, be used in place of frozen section analysis in parathyroid or anal surgery by 
giving an immediate assessment of tissue type.  
 
6.4 Conclusions 
 
This study has taken a very important step toward the clinical use of Raman 
spectroscopy to improve patient care. After many years of offering great potential its 
use within a real-time clinical situation has been demonstrated. At the start of Chapter 2 
a table demonstrating the key features of a diagnostic tool for use in intra-operative 
axillary node testing was shown. The ideal technology needed to be sensitive and 
specific, usable within the theatre environment, fast, cost effective and non destructive. 
No currently available method of node assessment offers all of these features. This 
study has shown that Raman spectroscopy can and does meet all these criteria. Further 
work to develop and test a diagnostic algorithm and to enhance on the reproducibility 
studies described in Chapter 5 will be required, but the use of Raman spectroscopy to 
improve the lives of patients with breast cancer is now within touching distance.  
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